1
Quality of Life in Menopausal Women With Polycystic Ovarian Syndrome
Chapter 1: Introduction to the Study
Introduction
The National Institutes of Health (NIH, 2017) identified polycystic ovarian
syndrome (PCOS) as a severe public health issue that puts a strain on medical resources
and adversely affects women’s lives. The Centers for Disease Control and Prevention
(CDC, 2016) defined the syndrome as a lifelong endocrine condition with adverse
reproductive and metabolic features. PCOS is linked to infertility, heart disease, cancer,
diabetes, and psychological problems. The reproductive and metabolic features of PCOS
present a serious economic burden to health care. Four billion dollars is spent annually to
manage fertility-related treatments for reproductive age women, ages 14 to 44, (NIH,
2017). Research studies have revealed a poor quality of life (QoL) among reproductive
age women (Acmaz et al., 2013; Hung et al., 2014; Panico et al., 2017; Rzonca, et al.,
2018; Scaruffi, et al., 2014). However, less in known about the QoL of menopausal PCOS
women, ages 48 to 65. No research has been conducted to investigate the QoL among
menopausal women within this age range who were diagnosed with PCOS during the
reproductive age of 18–45. Results of this study may provide insight into the QoL of
menopausal women with PCOS. This research could contribute to positive social change
when shared with organizations that develop educational interventions for women with
the diagnosis.
2
In this chapter, I provide a general backdrop for understanding the effects of
PCOS on women’s physical and mental QoL. I describe the conceptual support for this
study, leading to a discussion of the chosen methodology. I also consider the specific
scope of this project alongside its inherent delimitations and limitations. Finally, the
potential significance of the study is discussed.
Background
The existing research on this topic has largely been focused on PCOS among
reproductive age women. However, PCOS is a complex lifelong endocrine condition.
During their reproductive years, PCOS women from their mid-teens to mid 40s have a
poorer QoL compared to same age women (Acmaz et al., 2013; Hung et al., 2014; Naz et
al., 2019; Panico et al., 2017; Scaruffi, et al., 2014). Although PCOS is diagnosed in the
reproductive years, many of the physical and psychological symptoms follow patients
into menopause (Helvaci & Bulent, 2020; Sanchez, 2016). Less in known about the QoL
and psychological well-being of these women as they transition to menopause. These
women face a unique challenge because the metabolic features of PCOS and the
transition to menopause have similar health risks that may further erode their QoL
(Comim et al., 2017; Kakoly et al., 2019; Lenart-Liprnska et al., 2014; Sirmans et al.,
2014).
Developing a more comprehensive understanding of the lives of PCOS
menopausal women has significant academic and practical implications. This study
contributes to the understanding of menopausal women diagnosed with PCOS in their
reproductive years to enhance advocacy for the health and well-being of women at this
3
phase of life. As a result, practitioners can be better prepared to identify psychological
needs among this patient population.
Problem Statement
PCOS spans the lives of women from in utero before they are born until they die,
leading to several health risks that can impair QoL (Bellever et al, 2018). Furthermore,
menstrual and fertility problems evolve into metabolic complications as age advances.
Nonetheless, little is known about QoL of menopausal PCOS women, ages 48–65. No
researchers have investigated the QoL of menopausal women within the age range of 48–
65 years who were diagnosed with PCOS during reproductive ages 18 to 45. A review of
the literature indicates that menopausal PCOS women face life altering biological,
physical, and psychological challenges (Bromberger et al., 2015; Helvaci & Yildiz, 2020;
Winkler et al., 2015; Zheng et al., 2015). More serious chronic conditions such as cancer,
cardiovascular disease, and diabetes among menopausal age PCOS women have been
well-documented (Comijs et al., 2015; Kakoly et al., 2019). Furthermore, the
psychological changes linked to menopause such as weight gain, disturbed sleep, and
depression may exacerbate the condition of PCOS (Chau et al., 2019; Chen et al., 2013).
These factors indicate that researching how PCOS menopausal women perceive their
QoL is relevant and warranted.
Purpose
The purpose of this qualitative phenomenological study was to explore the QoL in
women ages 48–65 previously diagnosed with PCOS during their reproductive years and
4
how they experience and manage the disorder during menopause. Findings from this
study may provide a basis for researchers and psychology intervention planners to gain
an understanding of the effects of PCOS during menopause. The results of this study
could be used to inform health care workers targeting this population.
Research Question
RQ: What are the lived experiences of QoL among menopausal PCOS women,
ages 48 to 65?
Theoretical Framework
The World Health Organization created a worldwide research group to provide a
framework for understanding QoL (Bonomi et al., 2000). This framework constitutes the
basis for this study. The World Health Organization Quality of Life (WHOQoL) group
defined QoL as individuals’ assessment of their standing in life according to their culture,
values, goals, expectations, standards, and concerns (Suárez et al., 2018; WHOQoL,
1995). According to the WHOQoL group, QoL includes consideration of physical,
psychological, and environmental factors and social relationships (Bonomi et al., 2000).
Such a framework for QoL encompasses a person’s physical health, psychological
condition, personal beliefs, social relationships, and relationships with the environment
(Monteleone et al., 2018; Ozkan et al., 2005).
This conceptualization of QoL was used to understand the experiences of
menopausal PCOS women. A diagnosis of PCOS causes life-altering biological, physical,
social, and psychological challenges (Bromberger et al., 2015; Dokras et al., 2018;
Winkler et al., 2015; Zheng et al., 2015). Furthermore, the transition to menopause can
5
adversely affect women’s QoL (Jenabi et al., 2015; Nazarpour et al., 2018). Menopausal
women may experience somatic, vasomotor, sexual, and psychological symptoms related
to the decline in ovarian hormones. PCOS menopausal women are at greater risk for
cancer, diabetes, and cardiovascular disease (Brand et al., 2019; Comijs et al., 2015;
Ganapathy, 2018). A QoL framework including consideration of physical, psychological,
and environmental factors, as well as social relationships, was used to help to better
understand and explore the issues PCOS menopausal women face (Jenabi et al., 2015;
Nazarpour et al., 2018). I used this conceptualization of QoL to understand the
experiences of menopausal PCOS women. The different domains of QoL, including
physical, psychological, social relationships, and environment, are used to better
understand and explore issues PCOS menopausal women face (Jenabi et al., 2015).
Nature of the Study
In this study, I used a qualitative interpretative phenomenological analysis (IPA)
to answer the research questions (Smith et al., 2009). This project aligned with an IPA
methodology given that the goal of the project was to understand the lived experiences of
this phenomenon (Smith, 2011; Vicary et al., 2017). Women ages 48–65 diagnosed with
PCOS were interviewed regarding their experiences of managing and living with this
diagnosis at this stage in life. Women also reported on their QoL and psychological
wellbeing.
The main source of data for this study were interviews with a small sample of
menopausal PCOS women ages 48 to 65, diagnosed with PCOS in the reproductive age
range of 18–45. Face-to-face interviews with open-ended questions took place virtually
6
with the use of video conference through the Zoom, Facebook, or a similar platform. I
collected qualitative observation field notes on the perceptions, concerns, attitudes, and
behaviors of participants at the research location. Participants were encouraged to freely
express their opinions. Thematic analysis was used to investigate data generated in the
interviews (Braun & Clarke, 2006; Clarke & Braun, 2018).
Operational Definitions
The following terms were considered to be operational definitions and were
implemented throughout the scope of this research:
Anovulation: Occurs when the ovaries do not release an oocyte during a menstrual
cycle and ovulation does not take place. A woman who does not ovulate at each
menstrual cycle is not necessarily going through menopause. Chronic anovulation is a
common cause of infertility (Bellever et al., 2018; Palombo et al., 2015).
Hyperandrogenism: A medical condition characterized by high levels of
androgens in women. Symptoms may include acne, seborrhea (hair loss on scalp),
hirsutism (increased body and facial hair and infrequent or absent menstruation (Avery et
al., 2020; Hadjiconstantinou et al., 2017).
Menopause: The condition of an absent menstrual cycle for at least l2 months
(Basirat et al., 2019; Masood et al., 2016).
Metabolic syndrome: A combination of abnormal glucose metabolism, elevated
blood pressure, abnormal lipid profile, and abnormal obesity (Kakoly et al., 2019;
Mahalingaiah & Diamanti-Kandarakis, 2016).
7
Polycystic ovarian syndrome (PCOS): A heterogeneous and complex disorder
with adverse reproductive and metabolic features linked to infertility, heart disease,
cancer, diabetes, and psychological problems (CDC, 2016). Two of the following three
criteria must be met to diagnose PCOS: (a) clinical or biochemical hyperandrogenism,
(b) oligo-anovulation, and (c) polycystic ovaries (Dumesic et al., 2015; Lim et al., 2019).
Polycystic ovaries: Presence of 12 or more follicles in each ovary measuring 2 to
9 millimeters in diameter and/or increased ovary volume (Lizneva et al., 2017; Palomba
et al., 2015; Rosenfield & Ehrmann, 2016). The presence of polycystic ovaries is
indicated via ultrasound.
Assumptions
I assumed the participants in the study would share their experiences in a sincere
and authentic way and would answer the semistructured questions honestly. Second, I
assumed that, as the main researcher, I would act only as a facilitator for the research,
allowing participants to share their experiences. Lastly, I assumed that participants
diagnosed with PCOS in their reproductive years would evoke similar themes as they
talked about their personal experiences of transitioning to menopause.
Scope and Delimitations
A narrow focus was intentionally adopted in this study to answer the research
questions and contribute to an empirical understanding of the lived experiences of women
diagnosed with PCOS during their reproductive years as they transition to menopause.
The precise population investigated was suggested by the existing literature that states
8
PCOS reproductive age women have a poorer QoL than other women of the same age
(Acmaz et al., 2013; Hung et al., 2014; Panico et al., 2017; Scaruffi et al., 2014).
According to the conceptual lens applied to this project, the lived experiences of PCOS
menopausal women must be understood from a standpoint of the QoL of these women as
they cope with the metabolic features of PCOS and menopause. The four domains of the
WHOQol were used to understand the physical health, psychological condition, beliefs,
social relationships, and environmental relationships of these women (Gupta & Kumari,
2021; Ozkan et al., 2005). Although the narrow focus of this project was called for based
on the state of the literature, conceptual background, and methodological choices, the
transferability of this study’s findings is limited based on a necessarily low sample size.
However, the themes that emerge from this investigation speak to the real-life
experiences of PCOS menopausal women and thereby can inform advocacy on a larger
scale.
Limitations
The study was limited to PCOS menopausal women who volunteered to
participate following my solicitation within an online support group. This was a one-time
study with no longitudinal follow up. Therefore, I was unable to assess the presence or
absence of changes in perceptions over time. The findings of the study are limited to the
women in the study and may not be transferable to other populations or women from
outside the geographical area of those interviewed.
9
Significance
The study is significant because the findings provide insight into how menopausal
women with PCOS experience QoL. Themes emerged from data collected during
semistructured interviews, which were then analyzed. This research could contribute to
positive social change when shared with organizations that develop interventions for
women with this diagnosis. These interventions could include educational programs
dedicated to improving mental and physical wellness through the development of
selfmanagement skills. Society would ultimately benefit from the improved QoL of
menopausal PCOS women by increasing public health and productivity.
Summary
This chapter provided a general description of the phenomenon of women
diagnosed with PCOS during their reproductive years. The theoretical, conceptual, and
empirical support for the research questions and purpose were described. Key words were
defined in preparation for further discussion of these concepts in Chapter 2. The scope
and limitations of this study were also identified. I further discussed this project’s
potential to bring about positive social change. Chapter 2 includes a deeper discussion of
the discourse surrounding PCOS within the existing literature.
Chapter 2: Literature Review
Introduction
PCOS is the most common endocrine syndrome affecting reproductive-age
women and the syndrome has reproductive and metabolic features (Naz et al., 2018;
10
Rzonca et al., 2019). A diagnosis of PCOS results in comorbid conditions and lifelong
health complications (Gilbert et al., 2018). However, the primary focus of existing
research has been on fertility and diminishing the cosmetic features of the syndrome
(Avery et al., 2020; Enjezab et al., 2017; Hadjiconstantinou et al., 2017). Approximately
$4 billion is spent annually in the United States to manage fertility-related treatments for
reproductive-age women, ages 14 to 44 (NIH, 2017). Excluded from this amount are
obstetrical complications or morbidities in women who are experiencing menopause or
who are postmenopausal (Brakata et al., 2017). Furthermore, more serious chronic
conditions such as cancer, cardiovascular disease, obesity, and diabetes among women
with PCOS who are menopausal have been well documented (Comijs et al., 2015; de
Medeiros, 2020). Transitioning to menopause alone is associated with similar metabolic
health risks found in women with PCOS, including psychological distress and poor QoL
(Appian et al., 2016; Ratnayake et al., 2019). The reproductive features of PCOS
contribute to poor QoL and psychological distress in reproductive-age women (Sanchez,
2020; Sanchez & Jones, 2016). However, less is known about the psychological
wellbeing and QoL of these women during menopause.
The literature provides evidence that the QoL and psychological well-being of
women with PCOS who are menopausal is compromised due to comorbidities related to
both the reproductive and metabolic features of the syndrome. As these women transition
to menopause, they face unique challenges because the health risks associated with
menopause are similar to those associated with the metabolic features of PCOS. These
factors may contribute to worsening physical and psychological health, resulting in
11
poorer QoL. The QoL of women with PCOS who are menopausal who transition to
menopause has been underresearched. Therefore, my objective in this study was to fill a
gap in the literature by exploring the lived experiences of women with PCOS who are
menopausal. I conducted the study to better understand the experiences of women in this
population to improve their lives and promote future research.
In this chapter, I explain my search strategy for a comprehensive literature review,
discuss the conceptual framework, and review the literature on the concepts of interest in
the study. In the review of literature, I provide information from studies organized by
categories as follows: defining PCOS; ramifications of PCOS; links between PCOS and
QoL (reproductive features, metabolic features); defining menopause; and similarities
between the health risk of menopause and metabolic features of PCOS, type 2 diabetes,
cardiovascular disease, obesity, and psychological distress. Finally, the chapter ends by
highlighting the gaps in literature on this topic, affirming the need for the study.
Literature Search Strategy
I searched many different sources and topics to yield an inclusive and thorough
review of the literature that supports the topic. I accessed search tools, databases, and
articles through Walden University Library’s online portal. Many different databases were
used to complete this search, including PubMed, PsyArticles, Google Scholar, PsyInfo,
Medline, and Walden dissertation databases. I filtered my search to pay special attention
to peer-reviewed documents capable of suggesting future studies. I also considered
several different textbooks focusing on PCOS and menopause. I reviewed the sources
used in these works to ensure I was familiar with all authors who have contributed to this
12
topic. The following key terms were used in various combinations throughout these
searches: polycystic ovary syndrome, aging women, reproductive age women, menopause,
and menopausal PCOS women. I focused particularly on how women incorporate the
meaning of PCOS into their daily activities and identify common factors that may support
or interfere with self-management of PCOS.
Conceptual Framework
The WHOQoL provided a framework for understanding the lived experiences of
PCOS menopausal women (Bonomi et al., 2000). The WHOQoL-BREF has been tested
for validity and reliability across different populations and countries, has been used in
health research, and can help to evaluate various treatments (WHO, 1997b). The
WHOQoL-BREF instrument is a shortened version of the WHOQoL and was developed
to capture many subjective aspects of QoL (WHOQoL Group, 1993). Furthermore, it is
the best known instrument developed for cross-cultural comparisons and is available in
more than 40 languages. The WHOQoL group (1995) defines QoL as an individual’s
perceptions of where they live within their culture and value judgment and their goals
expectations, standards, and concerns.
According to the WHOQoL, QoL contains four main domains: (a) physical,
(b) psychological, (c) social relationships, and (d) environment (Bonomi et al., 2000).
QoL also refers to a person’s physical health, psychological condition, beliefs, social
relationships, and relationships with the environment (Ozkan et al., 2005; Utian et al.,
2018). I used this conceptualization of QoL to understand the experiences of women with
PCOS who are menopausal. A diagnosis of PCOS causes life-altering biological,
13
physical, and psychological challenges (Bromberger et al., 2015; Maki et al., 2018;
Winkler et al., 2015; Zheng et al., 2015). Furthermore, the transition to menopause affects
QoL (Ganapathy, 2018; Jenabi et al., 2015). Women who are menopausal may experience
somatic, vasomotor, sexual, and psychological symptoms related to the decline in ovarian
hormones (Monteleone et al., 2018; Ozkan et al., 2005).
In addition, women with PCOS who are menopausal are at greater risk for cancer,
diabetes, and cardiovascular disease (Brand et al., 2019; Comijs et al., 2015). Therefore,
the different domains of the WHOQoL-BREF, including physical, psychological, social
relationships, and environment, were used to better understand the QoL of women with
PCOS who are menopausal (Jenabi et al., 2015; Monteleone, 2018).
Literature Review Related to Key Variables and Concepts
My research was supported by disciplines that highlight a range of health and
social issues that need to be explored further. These issues relate to the lived experiences
of women with PCOS who are menopausal. The key terms I describe in the next section
explore central areas of focus across the literature on women with PCOS, including
reproductive features, metabolic features, and QoL. In addition, I review the literature on
menopause and QoL because this stage of life alone poses similar metabolic health risks
found in women with PCOS who are menopausal.
Defining PCOS
PCOS is a severe public and clinical health issue that puts a strain on health care
resources and adversely affects the health of women throughout their life span (Mohsin et
al., 2018; Patel, 2018; Rosenfield et al., 2016). The CDC (2016) defined the syndrome as
14
a lifelong endocrine condition with adverse reproductive and metabolic features linked to
infertility, heart disease, cancer, diabetes, and psychological problems. PCOS is
diagnosed during the reproductive age of women using the 2003 Rotterdam diagnostic
criteria (Mohsin et al., 2018). Two of the following three criteria must be met to diagnose
PCOS: (a) clinical or biochemical hyperandrogenism, (b) oligo-anovulation, and (c)
polycystic ovaries. However, there is no criteria to identify prevalent phenotypes in
PCOS menopausal women or to diagnose PCOS in menopausal women.
Phenotypes of PCOS
Dapas et al. (2020) found the phenotypes of PCOS were developed by the NIH
beginning in 1990. In the classic form (Phenotype A and Phenotype B), two of three
criteria were used to diagnosis PCOS as follows: hirsutism, ovulatory dysfunction, and
polycystic ovaries. Researchers explained that in 2003, at a meeting of European and
U.S. reproductive societies and conferences, two additional phenotypes were introduced
(Lizneva et al., 2016). These were Phenotype C, or ovulatory PCOS, and Phenotype D, or
non-hyperandrogenic, which increased the number of patients diagnosed with PCOS
(AlJefout et al., 2017). The phenotypes are linked to reproductive, dermatological, and
metabolic features and continue to affect women with PCOS who are menopausal. For
instance, Phenotypes A and C represent a greater lifelong risk for a metabolic condition,
and Phenotypes A and B are linked to greater insulin resistance regardless of body mass
index (BMI; Cooney et al., 2017; Helvacia & Bulent, 2020).
Lizneva et al. (2017) identified a medical bias in diagnoses of PCOS in a
metaanalysis of 13,796 patients with PCOS from 43 populations. The findings indicated
15
that the prevalence of PCOS in referral versus unselected populations was higher for
Phenotype A (50% vs. 19%) and lower for Phenotype B (13% vs. 25%) with little
difference between Phenotypes C (14% vs. 34%) and D (17 vs. 19%). In addition, a
20year longitudinal follow-up study found that, by age 40 years, the more severe
phenotypes were reduced with improved ovulation and a lessening in the degree of
hyperandrogenism (Helvacia & Bulent, 2020). Furthermore, referral status had greater
BMI than local controls, a difference not apparent in unselected PCOS subjects (Lim et
al., 2012). Lizneva et al. concluded that the phenotype, effects of referral status, and age
must be considered in understanding the PCOS condition and plan effective interventions.
Aziz (2018) suggested therapeutic decisions in PCOS depend on the patients’
phenotype, concerns, and goals and should focus on improving fertility, improving
metabolic status, and suppressing and counteracting androgen secretion and actions.
Further, the evaluation of patients suspected of having PCOS includes a thorough history
and physical examination, assessment for the presence of hirsutism, ovarian
ultrasonography, and hormonal testing to confirm hyperandrogenism and
oligoanovulation as needed and to exclude similar mimicking disorders (Aziz, 2018).
Zore et al. (2017) noted phenotypes play an important role in determining metabolic and
other risks of PCOS. Furthermore, Fauser et al. (2012) and Rzonca et al. (2018)
suggested that phenotypes should not be aggregated into one disorder because a critical
understanding of PCOS phenotypes is needed to determine patients at risk of long-term
complication. For instance, hirsutism is associated with Phenotype A and affects 70% of
women with PCOS (Escobar-Morreale et al., 2012; Escobar-Morreale, 2018). The authors
16
further noted that acne affects 15% to 25% of women with PCOS and contributes to
androgenic alopecia (AGA), permanent hair loss.
In addition, patients with PCOS as defined by the NIH criteria consisting of
Phenotypes A and B have higher rates of insulin resistance than the general population,
regardless of BMI (Bienenfeld et al., 2019 Diamanti-Kandarakis & Pinidis, 2007).
Authors noted that other phenotypes did not, implying that hyperandrogenism contributes
to insulin resistance (Bienenfeld et al., 2019 Diamanti-Kandarakis & Pinidis, 2007). For
instance, Phenotype D was not associated with increased risk of metabolic syndrome;
however, women exhibiting hyperandrogenism have increased prevalence of metabolic
syndrome compared with those with oligo-ovulation and PCOS ovaries alone
(BehboudiGandevani et al., 2018; Shroff et al., 2007). Additionally, González et al.
(2020) and Zhoa et al. (2010) found that hyperandrogenism is independently connected to
Type 2 diabetes mellitus, which supports that Phenotypes A and C are associated with
greater risk for metabolic syndrome. Furthermore, a 35-day menstrual cycle within the
anovulatory phenotypes has been found to predict insulin resistance (Cower et al., 2013).
PCOS Diagnosis and QoL Among Reproductive-Age Women
Despite significant progress in understanding the pathophysiology and diagnosis
of the disorder over the past 20 years, the disorder remains undiagnosed and
misunderstood (Aziz, 2018). Studies have identified a poor QoL among reproductive-age
women with PCOS 14 to 44 years of age (Amiri et al., 2014; Sanchez, 2020; Taghavi et
al., 2015). Similar themes related to poor QoL have been found in qualitative studies of
the lived experience of reproductive-age women with PCOS. The themes were sexual
17
problems: an unsexualized self; physical problems such as pain, invasion,
rejection/invasion by the social world; and avoiding public scrutiny (Sanchez, 2020;
Taghavi et al., 2015). PCOS challenges women’s perceptions of themselves due to
reproductive and cosmetic features such as lack of fertility, a hairy appearance, and
irregular menses (Amiri et al., 2014; Moghadam et al., 2018). Reproductive-age women
with PCOS (ages 14 to 44 years) have been found to have a poorer QoL and increased
psychological problems compared with healthy women of the same age (Acmaz et al.,
2013; Basirat et al., 2019; Hung et al., 2014; Panico et al., 2017). Researchers have found
a considerable amount of depression in the population related to QoL and disease
manifestation such as obesity, hirsutism, hair loss, acne, and menstrual disorder (Enjezab
et al., 2017; Hadjiconstantinon et al., 2017; Sanchez, 2020). The clinical features of
PCOS diagnosed during reproductive years follow patients into menopause.
Lived Experiences of Reproductive-Age Women With PCOS
Dermatologic manifestations hyperandrogenism are clinical features that result in
hirsutism, acne, and AGA in 70% of women with PCOS affected by hirsutism or
excessive male-like hair (Escobar-Morreale et al., 2020). Acne affects 15% to 25% of
women with PCOS and contributes to AGA, androgenic alopecia, or hair loss with no
racial difference in women’s complaints of hirsutism and acne (Bienenfeld et al., 2018;
Quinn et al., 2014). In a study of 70 reproductive-age women, 18–45, Chaudhari et al.
(2018) found prevalence of anxiety was 38.6% and depression was 25.7%. Infertility and
alopecia are associated with anxiety, while acne is associated with depression (Chaudhari
et al., 2018). Hirsutism is associated with a lower psychological QoL (Chaudhari et al.,
18
2018). Belever et al. (2018) conducted a study of postmenopausal women with PCOS,
ages 41 to 55, and found they frequently reported hirsutism or excessive hairiness on
face, hands, arms, legs, and overall body. Comim et al. (2017) identified the presence of
hirsutism and oligo-amenorrhea during female reproductive years predicts susceptibility
to diseases such as stroke, angina, cancer, and cardiovascular disease. Other researchers
have highlighted the need for more and better tests to determine the association between
infertility, cosmetic features, and psychological problems in women with PCOS based on
phenotype, age, and ethnicity (Chaudhari et al., 2018; Quinn et al., 2014).
Measurements of QoL in Reproductive-Age Women With PCOS
PCOS causes a reduction in health-related quality of life (HRQoL) due to
complaints of irregular menstrual periods and/or heavy menstrual bleeding and infertility.
In addition, symptoms include excessive growth of coarse facial and body hair, obesity,
oiliness of the skin, seborrhoea (dandruff patches), and cystic acne. Therefore, Cronin et
al. (1998) developed a quality-of-life questionnaire to promote interventions to reduce or
eliminate the symptoms of the disorder. The self-administered questionnaire includes a
total of 26 items and takes 10 to 15 minutes to complete. The content validity of the
questionnaire was ensured by the comprehensive approach to item selection and the
involvement of 100 women with PCOS in item reduction (Cronin et al., 1998). Currently,
researchers have used the Modified Polycystic Ovary Syndrome QoL Questionnaire to
determine health-related QoL in women with PCOS. However, study samples have
differed in the degree of impairment in each domain of the Modified Polycystic Ovary
Syndrome QoL Questionnaire. Therefore, Bottcher et al. (2018) conducted a study to
19
validate the PCOSQ-G (German) to validate the questionnaire’s ability to assess the
impact of PCOS on patients’ lives. The research consisted of 199 patients aged between
18 and 45 years who were diagnosed with PCOS . They were recruited from the
outpatient department of the University Clinic of Gynecologic Endocrinology and
Reproductive Medicine Innsbruck, Austria, between 2012 and 2014. The analyses
showed satisfying psychometric properties and good internal consistency and retest
reliability values. The patients reported significantly higher impairment on the emotion,
body hair, infertility, menstrual problems, and weight domains than the healthy controls.
The findings indicate a need for a disease-specific questionnaire, and that the
nowvalidated German version of the PCOSQ-G may help select patients with an impaired
HRQoL and consequently a possible higher risk for psychological disorders.
In a similar study to Bazarganipour et al. systematically reviewed specific
domains of PCOS in the questionnaire. For their systematic review, Bazarganipour et al.
used the following search engines to locate articles published between 1998 to 2013:
PubMed, Psych Info, CINAHL, CENTRAL, and Scopus. The search yielded six relevant
publications, and Bazarganipour et al. found that the studies included two questionnaires:
the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Modified Polycystic
Ovary Syndrome Questionnaire (MPCOSQ). The PCOSQ contained questions related to
emotions, obesity, irregular menses, and infertility. The MPCOSQ, a modified version of
the PCOSQ, included four additional questions to address concerns about acne. According
to Bazarganipour et al., the two instruments were used to gather appropriate information to
assess the QoL of reproductive-age women with PCOS. Thus, the six relevant publications
20
and scores of each domain of the PCOSQ or the MPCOSQ of 1140 participants with PCOS
were collected to create the meta-analysis.
The findings of the meta-analysis showed that the most affected domains in
specific HRQoL were hirsutism and menstruation (Bazarganipour et al., 2015).
Bazarganipour et al. elaborated by explaining the features and distress associated with
each. For instance, the loss of menstruation (amenorrhea) was described as a nonvisible
characteristic of PCOS. The condition also causes emotional distress due to feminine role
expectations, religious practices, and sociocultural norms (Bazarganipour et al., 2015).
Furthermore, menstruation is a major component of role expectation, whereby women are
to become mothers. Religion can be a source of distress in some groups such as Islam,
where menstruating women are not allowed to pray. In addition, the family and social
group of a woman who misses more than 5 days of prayer monthly would be aware of her
menstrual irregularities (Bazarganipour et al., 2015).
Last, social and cultural generalizations also contribute to distress for women with
PCOS who are not menstruating due to the expectation that women become pregnant in
the first year of marriage. According to Bazarganipour et al. (2015), these factors
highlight the need for future research to emphasize both the importance of hirsutism and
menstruation as a contributor to impaired HRQoL in PCOS.
Various generic and specific questionnaires have been used for assessing different
dimensions of HRQoL in PCOS women. Therefore, Behboddi et al. (2018) examined the
general and specific instruments used to determine factors that affect HRQoL in women
with PCOS. Behboddi et al. reviewed studies published between 1945 and 2017 and were
21
indexed in MEDLINE, ISI Web of Science, and Scopus. Behboddi et al.’s (2018) search
yielded 52 studies (nine qualitative and 43 quantitative). In addition, the forms used most
frequently in the studies were the 36-item Short Form Health Survey-SF-3 and the
Polycystic Ovary Syndrome Questionnaire Health-related QoL Questionnaire. Overall,
five general measures and three specific measures used to assess the QoL in PCOS
women. The five general measurements were as follows: Short Form -36, Symptom
Checklist-90-Revised, World Health Organization Quality of-Life-BREF
(WHOQoLBREF, Child Health Questionnaire-Child Form, and the General Health
Questionnaire28. The three specific instruments were the Short Form Health Survey- 36
(SF-36), the
Polycystic Ovary Syndrome Questionnaire Health-related QoL Questionnaire and the
Modified Polycystic Ovary Syndrome Questionnaire Health-related QoL Questionnaire.
Behboddi et al. found that the Polycystic Syndrome Health-related QoL Questionnaire
(PCOSQ), a disease-specific instrument, was used more frequently to determine QoL in
women diagnosed with PCOS. Behboddi et al. further noted that the questionnaire
contains 50 items representing six areas, namely emotions, obesity and menstrual
disorders, fertility, sexual function, hirsutism, and coping. Each item is answered by
selecting from options on a 5-point Likert scale with higher scores meaning better
condition. Behboddi et al. found the Short Form Health Survey-SF-36 was used to
determine QoL those diagnosed with PCOS. The form consists of 36 items tapping into
eight subscales, namely physical functioning, role physical, bodily pain, general health,
22
vitality, social functioning, role emotional, and mental health. The scores on each domain
range from 0 to 100, with higher scores indicating better conditions.
Lastly, Behboddi et al. (2018) found the SF-36 instrument has proven to be
reliable, widely validated, and employed in the assessment of HRQoL for various medical
conditions, as well as soliciting general information about health conditions and
emotional responses to PCOS. However, an important feature of the PCOSQ was
providing more specific information related to health conditions such as obesity,
infertility, and hirsutism (Behboddi et al., 2018). Both or either instrument with a generic
measure would be appropriate when measuring QoL in PCOS women and identifying
areas to help improve QoL in these women. Behboddi et al. concluded that all the
instruments assessed different aspects of QoL in PCOS women and found that PCOS had
negative effects on QoL in this population. Researchers have used all instruments to
identify the issues facing reproductive age women, including adverse clinical
complications, reproductive issues (menstrual irregularity and infertility), metabolic
issues (insulin resistance, diabetes, and cardiovascular risk), and psychological
disabilities (anxiety and depression). Bazarganipour et al. (2015) noted treatment of
hyperandrogenism and menstrual irregularities can improve psychological functions in
PCOS reproductive age women.
In sum, the most widely used instrument used to measure PCOS are the Short
Form-36 (Sf-36), (PCOSQ) and (MPCOSQ). The SF-36 consists of 36 items tapping into
8 subscales, namely physical functioning, role physical, bodily pain, general health,
vitality, social functioning, role emotional, and mental health.
23
The PCOSQ contains the following domains: emotions (8 items), hirsutism (5
items), weight (5 items), infertility (4 items), and menstrual disorders (4 items). Lastly,
the MPCOSQ includes 30 questions from 6 HRQoL domains: emotional disturbance (8
items), weight concerns (5 items), infertility (4 items), acne (4 items), menstrual
symptoms and predictability (4 items), and hirsutism (5 items). Each item was rated on a
7-point Likert scale where higher scores represent better function for both instruments
(PCOSQ and MPCOSQ).
Each of the above- mentioned instruments identified the poor QoL in PCOS
reproductive age women. However, PCOS is a lifelong condition with continuing
metabolic features and health risks (Gurka, et al., 2018; Hildreth et al., 2018; Wang et al.,
2018) similar to those of women transitioning to menopause due to the natural change in
the reproductive hormones, progesterone, and estrogen (Ganapathy et al., 2018; Masood
et al., 2016). The transition to menopause alone is associated with metabolic issues such
as type 2 diabetes, obesity, cardiovascular disease, and certain cancers (Brand et al.,
2013; Lenart-Liprnska et al., 2014; Monteleone et al., 2018). For instance, Chedraui and
Pérez-López (2019) found after menopause women exhibit higher prevalence of
metabolic syndromes and higher risk of heart disease. In addition, chronic physical
diseases such as polycystic ovary disease are associated with risk for depressive
symptoms (Gurka et al., 2016; Park et al., 2017). These factors highlight the need to
better understand the lived experience of women diagnosed with PCOS in their
reproductive years as they transition to menopause.
24
Economic Burden of PCOS
The reproductive and metabolic features of PCOS presents a serious economic
burden to health care. Four billion dollars is spent annually in the United States to
manage fertility-related treatments for reproductive age women 14-44 (NIH, 2017).
Approximately 40% of the economic burden is a result of the increased prevalence of
diabetes associated with PCOS; 30% arises from the treatment of the associated
menstrual dysfunction/AUB, 14% from the treatment of hirsutism and 12% provision for
infertility services (Albahar, 2015; Rosenfield, 2020). This breakdown does not include
the cost of obstetrical complications or morbidities in menopause and postmenopausal
women (Brakata, et al., 2017).
Metabolic Features of PCOS
PCOS reproductive age women are at increased risk of hypertension, insulin
resistance, diabetes, central obesity and myocardial infarction compared to age-related
referents (Chedraui, P., & Pérez-López, 2019; Mahalingaiah et al., 2015). Further noting
the risk of metabolic syndrome was found in 45% prevalence in women aged 20-29 years
and 53% in women ages 30-39. In addition, the more serious chronic conditions such as
cancer, cardiovascular disease and diabetes become more pronounced with age among
PCOS women (Comijs, et al., 2015; de Medeiros, 2020).
Ezeh et al. (2020) found visceral adiposity has been reported to negatively affect
metabolic function to a greater degree than non-visceral adiposity. Further noting, in
PCOS women both visceral and subcutaneous adipose mass independently and negatively
predict insulin insensitivity. Previous studied noted adipose tissue is the largest endocrine
25
organ and the insulin resistance of PCOS may also result from altered production in
adipocyte by products regardless of obesity (Chazenbalk et al., 2010; Ezeh et al., 2012:
Ezeh et al., 2020). Furthermore, reduced levels of adiponectin or production of by
adipocytes may contribute to insulin resistance in addition to endothelial dysfunction and
cardiovascular risk of PCOS (Carmina et al., 2008: Dunaif & Finegood, 1996; Ezeh et al.
2020).
Obesity
Zore et al. (2017) suggest obesity represents a more severe phenotype with greater
degree of insulin resistance, hyperinsulinemia, metabolic dysfunction and
hyperandrogenism. Further noting, obesity exacerbates or fosters other long-term
morbidities including metabolic complications, risk for certain types of cancers due to
chronic unopposed estrogen. Concluding that obesity leads to a poor QoL and low
selfesteem, which can cause a variety of mood disturbance.
In the United States obesity affects 30 to 75% of women with PCOS (Carmina et
al., 2013), a prevalence higher than Europe (Ehrmann, 2005; Mohsin, 2018). Multiple
studies have concluded that there is a greater degree of insulin resistance in obese
compared to lean women with PCOS (Gonzales et al., 2020; Morales et al., 1996:
Vrbikiva et al., 2014). PCOS women have higher rates of hyperinsulinemia, and insulin
resistance, independent of obesity (Lugue-Ramirez et al., 2015; Toosy et al., 2018). The
concomitant presence of obesity is associated with further increase in the long-term risk
for metabolic dysfunction (Zore et al., 2017).
26
Zore et al. (2017) found the long-term effects of PCOS are at a greater risk for
insulin resistance and hyperinsulinemia than matched controls resulting a greater risk of
developing long-term complications associated with metabolic syndrome. Further noting,
this includes higher lifetime risk of type 2 diabetes mellitus (T2DM), non-fatty alcoholic
liver (NAFLD), metabolic syndrome, hypertension and potential vascular complications.
In addition, the risk of cardiovascular is elevated in individuals with metabolic syndrome,
based on a retrospective analysis of women with PCOS, the prevalence of metabolic
syndrome as defined by NIH criteria may be higher than 33 to 43% approximately twice
that of the general population. Concluding that the study was based on estimates using the
National Health and Nutrition Examination Survey and even higher in age-matched
study.
Cancers
PCOS women are at increased risk of developing endometrial, ovarian and breast
cancer (Zore et al., 2017). Further noting, the risk is associated with unopposed estrogen
exposure from persistent hyperandrogenemia with subsequent aromatization, chronic
anovulation, hyperinsulinemia and hyperglycemia. The researchers identified obesity as a
factor in endometrial, breast cancer and possibly ovarian cancer with the malignancy of
PCOS increased by the prevalence of obesity. Furthermore, the presence of the
circulating sex steroids and insulin characteristic of PCOS put the hormonally sensitive
cancers such as endometrial cancer at risk. Most studies have demonstrated an increased
risk of endometrial cancer in women with a PCOS (Azizia & Hardiman, 2014; Bellver et
al., 2018; Gottschau et al., 2015). For instance, a large cohort study from the Danish
27
Cancer Registry consisting of 12,000 women with PCOS found they were four times
more likely to develop endometrial cancer compared general Danish female population
(Gottschau et al., 2015; Neven et al., 2020). Further noting, the women were diagnosed
with type1endometrial cancer. These findings were consistent with a systematic review
and meta-analysis exploring the risk of endometrial cancer among PCOS women and
found an increased risk of neoplasia in the syndrome (Azizia & Hardiman, 2014; Bellver
et al., 2018).
Lundberg (2019) found in a population-based cohort of 2,882,847 women, cox
regression analysis was used to investigate cancer incidence among infertile women.
Overall, infertility was associated with a higher incidence rate of ovarian endometrial
cancer, but not of breast cancer. Previous studies found PCOS women are not at
increased risk for breast cancer (Azizia & Hardiman, 2014; Gottschau et al., 2015; Neven
et al., 2020; Shobeiri & Jenabi, 2016). For example, a large cohort study of 45,000
patients failed to find an increased risk of breast cancer among PCOS women (Shobeiri &
Jenabi, 2016). Another systematic review and meta-analysis also failed to find increased
risk of breast cancer with no change in results when the analysis excluded women older
than 54 years (Azizia & Hardiman, 2014; Bellver et al., 2018. Kim et al. (2016)
conducted a similar study of more than 1500 women with newly diagnosed or in suti or
invasive breast cancer and compared to age-matched controls. The investigators found
breast cancer incidence of threefold increase in premenopausal women which contrasted
to post-menopausal PCOS women in whom breast cancer incidence decreased by 33%.
28
The results were hypothesized as due to the abnormal hormones associated with a PCOS
diagnosis which impacts the pre-menopausal breast and ameliorates over time.
There have been mixed results regarding PCOS and ovarian cancer (Zore et al.,
2017). The increase in ovarian cancer in PCOS women significantly increases when
women over the age of 54 are excluded from studies. For instance, a large cohort Danish
Cancer Registry study of 12,000 PCOS women did not find an association between
ovarian cancer and PCOS (Barry et al. 2014; Gottshau et al., 2015; Neven et al., 2019;
Shobeiri & Jenabi, 2016). However, a case-controlled Cancer and Steroid Hormone
consisting of 4000 controls and 476 women diagnosed with epithelial cancer found 7
women with ovarian cancer and 24 control reported a diagnosis of PCOS. The risk for
ovarian cancer was 2.5 times higher for PCOS patients (Shobeiri et al., 2016; Carvalho et
al., 2019)
PCOS women are at risk of leiomyomata or uterine cancer due to elevated sex
steroids and insulin anabolic hormones (Zore et al., 2017). Furthermore, the luteinizing
hormones levels of PCOS women may also be responsible for the development of uterine
fibroids. For instance, a 6 year retrospective study of women from the Black Women’s
Health study found increased risk of fibroids. Wise et al. (2007) noted the association
between hyperandrogenism or leiomyomata was supported by a diverse Study of
Women’s Health Across Nations (SWAN). The study consisted of 3240 women age 4552
of diverse backgrounds and ethnicity. Women with higher testosterone were at greater
risk but not for recurring fibroids (Wong et al., 2016). The findings indicated high
testosterone and estradiol were associated with greater risk, whereas higher estradiol and
29
testosterone resulted in lower risk for recurrent fibroids. However, in a study of 1,070
women, age 18-40 with gynecological problems or infertility found fewer patients with
polycystic ovaries (not necessarily PCOS) had fibroids (Abdel-Gadir et al., 2009). The
findings were compared to women with normal ovaries and the negative correlation was
sustained regardless of age, parity or ethnic origin. Therefore, the connection between
uterine leiomyomata and PCOS remains unclear.
Defining Menopause
Menopause is defined as the condition of an absent menstrual cycle for at least l2
months (Masood et al., 2016). The transition to menopause is associated with risk for
chronic diseases such as type 2 diabetes, cardiovascular disease, and bone disease (Brand
et al., 2019, Wellons et al., 2012). In addition, menopausal women have a poor QoL
compared to non-menopausal women (Ratynayake et al., 2019). Factors influencing
depressive symptoms in menopausal women were, frequency of hot flashes, and
sweating, educational level and diabetes (Zheng et al., 2017).
Menopause and Psychological Distress
Psychological distress and poor QoL related to infertility, obesity, hirsutism, acne
have been identified and addressed in PCOS reproductive age women (Enjezab et al.,
2017; Martin et al.,2017; Sanchez, 2020). For instance, reproductive age women with a
PCOS diagnosis are challenged in the perception of themselves as feminine due to their
lack of fertility, obesity and a hairy appearance (Amir et al., 2014; Sanchez, 2020).
Previous studies found that as these women transition to menopause they experience
psychological distress due in part due to aging ovaries, leading to the deterioration in the
30
fabrication of the ovarian gonadotropins such as progesterone and estrogen (Masood et
al., 2016; Zheng et al., 2017).
Winnie et al. (2020) conducted a study aimed to explore the menopausal-specific
QoL and assess its relationship with the sociodemographic characteristics in menopausal
and post-menopausal women in Hong Kong. A cross-sectional survey was conducted
with 218 women aged between 45 and 80 or over. The QoL was assessed by
MenopauseSpecific QoL Questionnaire (MENQoLTM). Results showed high scores in
vasomotor, psychosocial, physical and sexual domains in menopausal and post-
menopausal domain.
With younger and less educated working post-menopausal women perceive lower QoL.
The findings suggest that menopausal-related symptoms affect the QoL.
In a previous study Masood et al. (2016) conducted research to investigate the
relationship between depression, anxiety, psychological distress, QoL in menopausal
women. Their objective was to discover whether the QoL for menopausal women is
affected by psychological distress and relative levels of anxiety and depression. They
designed a cross-sectional study consisting of 100 women (50 menopausal/50
nonmenopausal) in 2 hospitals located in Lahore, Pakistan. The researchers used the
following tools to assess the women; Kessler Pathological Distress Scale K10, (Kessler &
Mroczek, 1992) and the Utian Quality of Life Scale (UQoL) was developed by Uitan,
Janata, Kingsberg, Schluchter and Hamilton (2002).
Menopause consists of three phases as follows, pre-menopause, peri-menopause
and post-menopause (Masood, et al., 2016; Winne et al., 2020). The phases were
31
explained as follows: pre-menopause, the first phase of menopause is the time around
menopause and denotes peri-menopausal stage; the time period that comes after the last
menstrual period is the post-menopause period. Further noting, menopause is a
psychological and biological event in the lives of all women. According to the
researchers, these biological changes to these hormones can cause profound biological
and psychological reactions that affect the quality of a menopausal woman’s life. This is
consistent with a review of the literature that suggest reproductive hormones are often
considered to be involved in the susceptibility to depression, especially during periods of
alterations in ovarian function such as postpartum and the menopause transition (Freeman
et al., 2014; Gordon et al., 2016; Marsh et al.,2017).
The longitudinal research of (Bromberger, Schott, & Kravitz, 2015; Bromberger,
& Epperson, 2018) found in pre- to post-menopause stage of reproductive life, some
women demonstrate a greater sensitivity to gonadal steroid shifts resulting in the risk for
negative mood symptoms. Bromberger, & Epperson (2018) reviewed two well-designed
longitudinal studies of clinical depression, the Study of Women’s Health Across the
Nation (SWAN) and the Penn Ovarian Aging Study (POAS) that identified an increased
risk of Major Depressive Disorder (MDD) in peri-versus late pre-menopause. Based on
their review of three similar studies, the Harvard study of Mid-life Mood and Cycles, the
Australian Longitudinal Study of Women’s Health (ASWH), and the Seattle Midlife
Women’s Health Study, the researchers concluded that depressive disorders or symptoms
during the menopause transition and early post-menopause affect a subset of vulnerable
women (Bromberger, & Epperson, 2018). The researchers found evidence that
32
reproductive aging is associated with increased risk for depression as well as the varied
endocrine, genetic, behavioral and social factors.
Masood et al. (2016) noted in previous studies found 85% of menopausal women
experienced sleep disturbances, hot flushes, fatigue, night sweats, forgetfulness, vaginal
dryness headaches, poor concentration, palpitations and reduced libido. The studies also
found menopausal women experience psychological distress such as mood disturbances,
tension, depression, anxiety, and irritability. For instance, Hickey et al. (2016) identified
fluctuating and unpredictable reproductive hormone concentrations, particularly
estrogens (estradiol), the principal estrogen, modulates the synthesis, availability, and
metabolism of serotonin, a key neurotransmitter in depression.
A review of the literature found a correlation between psychological distress and
QoL for menopausal women (Bromberger, & Epperson, 2018; Gordon et al., 2016; Marsh
et al.,2017). With anxiety, depression and psychological distress as strong predictors of
QoL of menopausal women (Masood et al., 2016). Further noting, menopausal women
spend approximately three decades of their life in the postmenopausal phase with a life
expectancy of 78 years. Concluding, a major global health concern has been raised for the
overall health and well-being of middle-aged women.
Similarities of Health Risks of Menopause and Metabolic Features of PCOS
PCOS is defined as the most common endocrine disorder affecting reproductive
age women with reproductive and metabolic features. The metabolic conditions that
plague PCOS menopausal women has been well-documented (Baldani et al., 2015;
Comijs, et al., 2015, Comim et al., 2017). Furthermore, the metabolic features become
33
more pronounced with age and associated with increased risk for insulin resistance,
dyslipidemia, cardiovascular disease and abdominal obesity (Mahalingaiah et al., 2015;
Torres Fenandez, 2019). The following metabolic features of PCOS are similar to the
health risk for menopausal women.
Type 2 Diabetes
Several factors are linked to menopausal women and the onset of type 2 diabetes
such as shortest reproductive period, age 30-45 and the longest reproductive period age
45 plus (Leblanc et al., 2018; Muka et al., 2017). Early age of natural menopause (age 45
or younger) was also a risk for type 2 diabetes based on a study of 3639 post- menopausal
women (Muka, et al., 2017). With PCOS women five to seven times more likely to
develop T2DM than age-matched women. PCOS women are at increased risk of insulin
resistance, abdominal obesity and dyslipidemia and cardiovascular disease (Gonzalez et
al., 2020; Mahalingaiah et al., 2015). While, glucose tolerance and T2DM seem to
increase independent of the degree of obesity (Bazarganipur et al., 2015; Jin & Xie,
2018)). The findings indicate glucose tolerance and T2DM are at a lower rate in nonobese
PCOS women.
Cardiovascular Disease and Menopause
Previous research identified the early age of natural menopause (before age 45) as
associated with a greater risk of heart failure in women (Appian et al., 2016; Murka et al.,
2017; Wellons et al., 2012). In a study of 5629 postmenopausal women with a mean age
56 years, 26% with bilateral oophorectomy (hysterectomy) without a history of heart
failure found early age of menopause (before age 45) was associated with greater risk of
34
heart failure. (Murka et al., 2017). Furthermore, Gurka et al. (2016) discovered in a
longitudinal study of 1140 women who transitioned to menopause over a 10 year period
that the women had a rate of cardiovascular disease equal or greater than those of men.
Additionally, inflammation caused by the biological changes in the circulating hormones
for women transitioning to menopause puts them at greater risk of cardiovascular disease
due (Wang et al., 2018). While, Comim et al. (2017) found post-menopausal women who
self-report hirsutism and oligo-menorrhea had a higher prevalence of cardiovascular
disease. Furthermore, women with the clinical features of PCOS defined by menopausal
history of irregular menses and current evidence of hyperandrogenemia were at higher
risk for cardiovascular disease (Glintborg et al., 2018; Meaz et al., 2016). The findings
indicate the reproductive features of PCOS continue to affect these women as they
transition to menopause and during post-menopause.
Obesity
Post-menopausal women have higher central and intra-abdominal fat
accumulation (Rathanayake et al, 2019). The findings indicate higher BMI has shown a
negative impact on physical domain of QoL among postmenopausal women. In addition,
among PCOS women obesity may be a contributing factor in the pathogenesis of the
syndrome (Panico, et al.,2017). Additionally, glucose tolerance and T2DM are found at a
lower rate in non-obese PCOS women. Furthermore, PCOS women are five to seven
times more likely to develop T2DM than age-matched women (Zore et al., 2017).
Brennan et al. (2017) found that obesity exacerbates the condition of PCOS,
further noting that excessive weight gain negatively effects reproductive lifespan and is
35
associated with pregnancy complications, including gestational diabetes, preeclampsia,
and large gestational-age babies. In addition, longitudinal research revealed that women
18-23 years of age diagnosed with PCOS gained 6.32 kg/ 14 pounds over 8 to 10-year
period compared to mid age (7 pounds) and old age (3 pounds) controls (Brennan et al.,
2017). Therefore, the purpose of Brennan et al.’s narrative review was to provide
evidence supporting the use of behavioral strategies in weight management interventions
for reproductive-aged women to apply to PCOS. Brennan et al. suggested most weight
management strategies for PCOS women has focused primarily on physical activity
interventions and diet without considering the value of counseling, behavioral therapies,
and education in weight loss strategies. However, high attrition and drop-out rates of up
to 46% were associated with programs that focused on only diet and exercise, and
successful programs included behavioral and psychological components, such as regular
exercise, flexible eating, monitoring of weight/shape, and social support (Brennan et al.,
2017).
Brennan et al. (2017) cited the findings of the National Weight Control Registry,
which identified behavioral and psychosocial correlates associated with at least 30
pounds of weight loss among 3000 registrants who were able to keep the weight off for
12 months by eating less than 1500 calories daily and daily exercise. Brennan et al.
attributed the long-term weight loss success to self-regulation, process change, decisional
balance, self-efficacy, and autonomous motivation. Brennan et al. recommended
behavioral strategies including goal setting, cognitive restructuring, problem-solving, and
relapse prevention to help improve the weight loss outcomes among PCOS women.
36
Psychological Distress and PCOS
Studies have shown that women with PCOS have an increased prevalence of mild
depressive and anxiety symptoms, as well as increased depression and anxiety scores in
reproductive age women (Blay et al.,2016; Enjezab et al., 2017; Tan et al., 2017, Scaruffi,
et al.,2019). Studies have identified hyperandrogenism as factor that manifest into
hirsutism, acne and alopecia, all of contribute to anxiety and psychological distress.
Scaruffi et al. (2019) found PCOS affects women’s physical well-being and leads
to great psychological distress. In a study to assess personality characteristics, body
image and alexithymia among 59 women with PCOS and 38 healthy controls, The
researchers used the Toronto Alexithymia Scale (TAS), the Body Uneasiness Test (BUT)
and the Minnesota Multiphasic Personality Inventory-2 (MMPI-2). The study identified a
compromised QoL as well as impaired emotional well-being. In a previous study, Scaruffi
et al. (2014) found anxiety and depression were independent of obesity and infertility in a
study of 60 PCOS women age 25-29.
Cooney et al. (2017) sought to determine if women diagnosed with PCOS have
increased prevalence of moderate to severe depression and anxiety symptoms compared
to control women (same age women not diagnosed with PCOS). Also, Cooney et al.
sought to determine if the symptoms are associated with age, BMI, testosterone, hirsutism
or insulin resistance. Cooney et al. conducted a comprehensive systematic review (SR) of
30 cross-sectional studies published between January 2011 to January 2016 representing
3050 participants with PCOS and 3858 controls (ages 18 -31) from 10 countries. In the
cross-sectional studies reviewed, 18 were meta-analyses and showed women with PCOS
37
have over three times the odds of depressive symptoms and over five times the odds of
anxiety symptoms than controls, supporting prior research on the topic (Cooney et al.,
2017).
Cooney et al.’s (2017) SR analysis also revealed a significant increase worldwide
for risk of depressive and anxiety symptoms in young PCOS populations. For instance,
PCOS women are three times more likely to have depressive symptoms and five times
more likely to experience anxiety compared to the controls, who do not have PCOS
(Cooney et al., 2017). In addition, anxiety was significant in PCOS women with diabetes,
while depression and anxiety were associated with obesity, hirsutism, free testosterone,
and infertility (Cooney et al., 2017). The odds of depressive symptoms increased by 53%
in women with hirsutism, increased BMI, and who were older (Cooney et al., 2017).
Further noting, anxiety and depression in persons with chronic conditions such as PCOS
persist and may worsen over time.
Cooney et al.’s research (2017) highlighted the importance of screening PCOS
women for depression and anxiety with appropriate follow-ups beyond their reproductive
years because serious chronic conditions such as cancer, cardiovascular disease, and
diabetes among menopausal age PCOS women have been well-documented. (Bromberger
et al., 2014; Bromberger et al, 2018; Chen et al., 2013; Comijs, et al., 2015). However,
less is known about the QoL and psychological wellbeing of the reproductive age PCOS
women as they transition to menopause. Furthermore, the transition to menopause has
been linked to depression (Bromberger et al., 2015; Bromberger et al., 2018) and health
risks similar to the metabolic features of PCOS, such as type 2 diabetes, cardiovascular
38
disease, and obesity (Appian et al., 2016; Gurka et al., 2016; Torres Fernandez et al.,
2018).
The prevalence of depression and anxiety appears increased in PCOS which in
turn negatively affects health-related QoL of PCOS (Brutocao et al., 2018; Dokas et al.,
2016; Dokas et al., 2018). A systematic review and meta-analysis of 2384 PCOS women
and 2705 control found higher emotional distress in PCOS women than controls (Ezeh et
al., 2013; Ezeh et al., 2020). Additionally, a subgroup analysis identified the development
of anxiety and depression in PCOS women as associated with hirsutism, infertility, and
obesity. However, the strong link between PCOS and emotional distress was not
explained by the findings (Zore et al., 2017).
Previous studies suggest the link between PCOS and mental issues may be caused
by the physical features of the syndrome such as hirsutism, acne, obesity and patient’s
concern related to long-term health risk (Dokras et al., 2018; Dokras, 2016; Torres
Fernandez et al., 2018; Elsenbruch, 2007; Hollinrake, 2007). These factors may in turn
lead to decreased self-esteem and QoL and manifest in a risk for mood disorders and
social anxiety (Zore et al., 2017). For instance, a vast number of studies showed that
women with PCOS are more prone to suffer from psychological disorders such
depression (Brutocao et al., 2018), anxiety (Chau et al., 2019; Cooney et al., 2017),
recreational drug-related incidents (Anagnostis, et al. 2018; Hart and Doherty, 2015),
disordered eating, and psychosexual dysfunction ( Doretto et al., 2020; Teede et al., 2011)
in comparison to healthy female controls. In addition, females with PCOS have a lower
self-esteem and body satisfaction (Basirat, 2019: Bottcher et al., 2018; Bottcher et al.,
39
2018) and subsequently tend to have more psychiatric hospital admissions than controls
(Hart and Doherty, 2015). As a result, they display a low QoL (Jones et al., 2008; Li et
al.,2011; Fauser et al.,2012) and are prone to a high degree of emotional distress
(Brutocao et al., 2018). It is worth noting that obesity (Elsenbruch et al., 2003; Hahn et
al., 2005; Barnard et al., 2007), acne, hirsutism (Weiner et al., 2004; Himelein and
Thatcher, 2006) and irregular menstrual cycles (Elsenbruch et al., 2003), all associated
with PCOS, are major contributors to the psychological stress that the patients experience
due to the challenging of the female identity and her body image (Legro et al., 2013;
Sanchez, 2020; Teede et al., 2011; Teede et al.,2018).
Major depressive disorder affects nearly 17.3 million American adults and is more
prevalent among women 8.5 compared to men at 5.3 %. (National Institute of Mental
Health, 2017). Cooney et al. (2017) conducted a comprehensive systematic review (SR)
was performed up to January 2016 and included 30 cross-sectional studies, representing
3050 subjects with PCOS and 3858 controls, from 10 different countries. According to
the researchers, the meta-analysis (MA) on depressive symptoms included 18 studies and
the MA on anxiety symptoms included 9 studies. Further noting, the findings of a
separate SR identified 15 studies for the meta-regression examining the associations with
PCOS-related symptoms or comorbidities. In a previous cohort study of 103 women with
PCOS reported higher instances of major depressive disorder compared to controls
independent of obesity (Hollinrake et al., 2007). The study was based on the Beck
Depression Scale but the correlation was not strong enough to account for the increase. A
subsequent systematic review and meta-analysis found the incidence of depression was
40
well-defined and 4 times more likely to occur in those diagnosed with PCOS than in that
of controls (Dokras, 2018). Therefore, Dorreto et al. (2020) conducted a study to
facilitate accurate diagnosis and timely treatment, clinicians who see female patients need
to be familiar with the diversity of PCOS phenotypes. The findings indicate PCOS and
psychosis, treatment with antipsychotic drugs can worsen PCOS symptomatology and
lead to negative consequences for a woman’s reproductive potential and her QoL.
Emeksiz et al. (2018) conducted across-sectional study to determine anxiety rates
among teenage girls diagnosed with PCOS compared to controls. The study was done
during the period from May 2013 to July 2014 and included 80 adolescent girls with the
diagnosis of PCOS (17.23 ± 1.15 years, range: 16–19 years). The findings indicate
adolescents with PCOS experience significantly more emotional distress compared to
adolescents without PCOS. This emotional distress may be related, at least in part, to
certain clinical features of PCOS including obesity and hirsutism. Mood disorders in
women are 35 to 50 % associated with GAD General Anxiety Disorder. Less studies are
available reporting the association between anxiety and PCOS, however those that have
reported increased compared to controls (Zore et al., 2017; Asp et al., 2020). For instance,
Emersiz et al. (2018) identified correlation between excess weight and anxiety in a study
of 80 adolescents with PCOS and 50 age- and BMI-matched controls. Higher BMI was
found to be associated with higher levels of depression and generalized anxiety, and
higher modified Ferriman–Gallwey score with higher level of panic disorder in
adolescents affected by PCOS.
41
A review of meta-analysis studies found PCOS women 6.7 % higher OR of
having GAD compared to controls with most of the PCOS patients and the controls were
overweight or obese (Dokras, 2018). Most studies found no difference in terms of age and
BMI between the two groups. Among PCOS women the association with anxiety is the
same for depression including, feelings of social stigma, low self-esteem, poor body
image and concerns for future health (Barry et al., 2012; Chau et al., 2019; Cinar, 2011;
Dokras, 2018). Furthermore, in depressed patients, coexisting GAD may increase the risk
of suicide, functional disability and decreased response to treatment (Zore et al., 2017).
Dokras (2018) suggest PCOS women undergo routine screening for mental health
disorder using valid screening tools and refer these women to health care professionals
for treatment as indicated.
Psychosexual Dysfunction
The health-related QoL PCOS has shown to be lower on all domains compared to
controls and is linked to the presence of obesity, hirsutism, mental dysfunction and
infertility. PCOS women scored higher in dimensions relating to OCS (obsessive
compulsive disorder, interpersonal sensitivity, depression, aggression and psychoticism
than health controls (Li et al., 2011; Castello-Branco, & Naumova, 2020).). To evaluate
Qol, psychosocial well-being and sexual satisfaction, 50 PCOS women and 50 controls
were provided with three validated questionnaire (Elenbruch et al., 2003). The findings
indicate PCOS women were less satisfied with their sex life, and their partners were also
less satisfied. Furthermore, the women found themselves less sexually attractive which
was associated with feelings of sexual dissatisfaction. Another study assessed 49 women
42
with PCOS and age-matched women, the women with PCOS reported decreased
satisfaction with their sex life (Dokras, 2011; Dokras, 2018). Therefore, disease-specific
screening tools were recommended because when used aspects of QoL are improved
through effective interventions (Mansoon et al., 2011). The Polycystic Ovarian Syndrome
Questionnaire (PCOSQ) has been identified as a valid instrument for measuring the QoL
in PCOS women (Cronin et al., 1998; Guyatt et al., 2004). Zore et al. (2017) suggest the
findings indicate mental health problems are higher in women with greater degrees of
hyperandrogenism resulting in a greater risk of metabolic dysfunction. Further noting,
this risk is more prevalent in “classic PCOS” which affects phenotypes “A” and “B” as
PCOS criteria defined in 1990 by NIH. Concluding, that limited data exists concerning
the relationship between phenotypes and mental health in PCOS.
Strategies for Prevention of Long-Term Health Consequence of PCOS
Several strategies were recommended for the prevention of the long-term
consequences of PCOS (Zore et al, 2017). Since the exact etiology of PCOS is unclear,
and the impact of early life intervention on the disease progression is unclear, it is not
possible to recommend a specific plan for those at risk developing PCOS (Azziz et al.,
2016). The researchers noted exercise has proven effective in preventing the progression
or severity of the disorder. For instance, a study of the letrozole PCOS rat model found
levels of testosterone, luteinizing hormones, fasting insulin and leptin were lower
following high intensity exercise. Another strategy was routine screening for adult
women diagnosed with PCOS and exhibiting metabolic abnormalities. A 2- hour fasting
43
oral glucose tolerance test was suggested for those who have insulin glucose tolerance
(IGT; Coa et al., 2017). In addition, a combination of metformin and lifestyle changes in
PCOS was suggested as more effective than lifestyle change alone (Salpeter et al., 2018).
Furthermore, reductase inhibitors were found to be more effective than placebos for
PCOS women with altered lipid profile statins (Goa et al., 2012).
Summary and Conclusion
PCOS is defined as a lifelong endocrine condition affecting reproductive-age
women with adverse reproductive and metabolic features and is linked to infertility, heart
disease, cancer, diabetes, and psychological problems (CDC, 2016). Given the
compromised health and poor QoL experienced by PCOS reproductive age women, it is
necessary to determine their QoL during menopause. These women face a unique
challenge because the metabolic features of PCOS and transitioning to menopause have
similar health risks that may further erode their QoL as they age (Comim et al., 2017;
Lenart-Liprnska et al., 2014; Sirmans et al., 2014).
This study contributes to the academic understanding of women diagnosed with
PCOS in their reproductive years and transitioning to menopause to enhance advocacy
for the health and well-being of these women at this phase of life. Both social issues are
promoted while also yielding potentially significant implications for future research and
programming. Beyond the systematic and academic impact, this research can affect
PCOS menopausal women at the individual level. In understanding, the QoL of PCOS
menopausal women interventions can be designed to assist them in living more
productive lifestyles (Barthelemess et al., 2014; Maki et al., 2018 Palomba et al., 2015).
44
Educational and intervention materials could be created to better serve the needs of these
women. The health of PCOS menopausal women may be improved through effective
self-management strategies and ultimately lead to better health outcomes.
Finally, an in-depth study of the lived experience of PCOS menopausal women
diagnosed during reproductive years as they transition to menopause. This provided an
empirical understanding of the quality of their lives to identify and create effective
interventions and treatments. Chapter 3 described the research methodology I used to
reach the goals of this study.
Chapter 3: Research Method
Introduction
The purpose of this research was to explore QoL in menopausal women diagnosed
with PCOS during their reproductive ages, 18 to 45. I also explored how women living
with PCOS experience and manage the disorder during menopause. A review of
qualitative studies of PCOS reproductive age women were similar in findings and
indicate a poor QoL (Enjezab et al., 2017; Hadjiconstantinou et al., 2017; Martin et al.,
2017). Less in known about the QoL and psychological well-being of these women as
they transition to menopause. Although PCOS is diagnosed in the reproductive years,
many of the symptoms follow the women into menopause, such as hirsutism, which is
linked to psychological distress (Sanchez, 2020). In addition, hyperandrogenism has been
linked to Type 2 diabetes, some cancers, and cardiovascular disease (Baldani et al., 2015;
Gonzales et al., 2020). In this chapter, I discuss the rationale of the research design for
45
this study. I also discuss the sampling strategy and data collection, data recording, and the
analysis process. Trustworthiness and ethical procedures are also presented.
Research Design and Rationale
In this study, I used a qualitative IPA to answer the research question (Smith et al.,
2009). This project aligns with an IPA methodology given that the goal of the project was
to understand the lived experience of this phenomenon (Smith, 2011). Women in the age
range of 48–65 diagnosed with PCOS were interviewed on their experiences of managing
and living with this diagnosis at this stage in life. The women also reported on their QoL
and psychological well-being.
Interpretative Phenomenological Approach
The qualitative method was chosen as the best fit for the goals of this study.
Qualitative research is defined as a means for exploring and understanding the meaning
individuals or groups ascribe to a social or human problem (Pietkiewicz & Smith, 2014).
The flexible design along with the open-ended questions show the strengths of using
qualitative design for this particular topic of study. I used IPA because it provides insights
into how a given person, in a given context, makes sense of a given phenomenon (Smith
et al., 2009).
IPA research is distinct from other approaches, in part, because of its combination
of psychological, interpretative, and idiographic components (Pietkiewicz & Smith,
2014). Participants in an IPA study are expected to have certain experiences in common
with one another. Analysis consists of a researcher generating codes from the data, rather
than using a pre-existing theory to identify codes that might be applied to the data. IPA
46
studies do not test theories, but they are often relevant to the development of existing
theories. The small-scale nature of a basic IPA study shows how something is understood
in a given context and from a shared perspective (Smith et al., 2009). For example, my
study of the lived experience of women diagnosed with PCOS during their reproductive
years as they transition to menopause may generate theoretically relevant information to
build on existing literature and promote further research and interventions to improve the
lives of these women.
Role of the Researcher
In phenomenological research, the purpose is to understand the subjective
experiences of the participants (Larkin & Thompson, 2012). However, a researcher must
remain unbiased in gathering and analyzing data. This is best accomplished through
bracketing (Larkin & Thompson, 2012). Bracketing, which was originally a mathematical
principle, is one of the primary concepts of Husserlian phenomenology. Within this
method of phenomenology, the preconceived notions held by a researcher must be set
aside, or bracketed, to ensure they do not allow their personal expectations to influence
the data collection or shape their comprehension or analysis of the data (Polit & Beck,
2008).
Women with PCOS are frequently socially isolated (Kitzinger & Willmott, 2002);
therefore, the mode of data collection needed careful consideration. Seymour (2001)
suggested that online data collection methods enable a researcher to access inaccessible
domains, such as hard to reach populations or socially isolated groups. Kraut et al. (2004)
47
also noted that online research could make apparent psychological phenomena that do not
exist in traditional settings. Therefore, I conducted the interviews online using Skype,
Zoom, or Google Hangouts.
Methodology
Participant Selection
Participants were solicited from PCOS online supports groups via Facebook using
flyers to reach this socially isolated group (Williams et al., 2015). Sullivan (2012)
proposed there is potential for data collection in social research using technology such as
Skype and Google Hangouts. Accordingly, online research may enable access to a
socially isolated population such as women with PCOS. Deakin and Wakefield (2013)
suggested that online synchronous interviews using, for example, Skype are a useful
replacement of traditional face-to-face interviews. The researchers described several
advantages of using Skype to conduct interviews, including allowing more flexibility for
researcher and participant and being more cost and time efficient (Deakin & Wakefield,
2013). Janghorban et al. (2014) argued that Skype offers a useful alternative to face-
toface interviews and is suitable for conducting individual interviews. Previous research
using Skype has explored online health forums (Fan et al., 2013) and online psychiatric
consultations (Williams et al., 2014). Williams et al. (2014) found high acceptability of
online consultations via Skype among participants, further noting that Skype is a viable
way to conduct online research. The specific criteria for participating in the study were:
Participants must 48–65 years old and previously diagnosed with PCOS during their
reproductive years.
48
Number of Participants and Rationale
A qualitative study typically requires between five and 25 participants
(Moustakas, 1994). A variety of factors can influence sample size, but the most
significant in qualitative research using interviews is saturation (Mason, 2010). The more
limited the population sample is, the easier it is to reach saturation. The goal of the
research project was to identify a sample of between seven and 10 PCOS menopausal
women through online support groups or Craigslist.
Two major sources to recruit participants were used. I posted an announcement
about the study on Craigslist, and I also sought permission from online support group
leaders to submit flyers to their online environment to recruit participants. I used
snowball or chain sampling as a second sampling strategy. In this strategy, participants
who complete the interview are encouraged to inform others who meet the criteria and
ask them to contact the researcher (Patton, 2002). The leaders of the PCOS online support
group were asked to post the flyer online, and I posted information about the study on
Craigslist. Interested participants were asked to contact me by email or text message.
Participants were selected as candidates based on the following criteria: ages 48–65,
diagnosis of PCOS during their reproductive years, and English speaking. Selected
candidates were sent an informed consent form by email. Once participants consented to
participate in the study, an online interview via Zoom was scheduled at a convenient time
for the participant.
Guest et al. (2006) recommend that saturation is obtained with a sample size of 12
because the majority of changes in the codes occur between the first and 12th interviews.
49
However, Smith (2004) stated that most IPA studies are of a smaller sample size (five to
10) because it is only possible to conduct the detailed analysis associated with IPA on a
small sample. Similarly, Creswell (2013) stated that participants for a phenomenological
study range from three to 10 individuals. In reviewing the information provided by
Creswell (2013), Guest et al. (2006), and Smith (2004), I sought 10 participants. If there
had been too few participants, I would have contacted the PCOS online support group
leader. I would have repeated the process to obtain participants who met the criteria and
conducted interviews online or by phone until saturation was reached.
Instrumentation
I screened participants using the criteria to identify eligible participants. I used an
audiotape recorder while conducting semistructured interviews with participants. A
second audio-recording device was used simultaneously in case the first device
malfunctioned. I also took physical notes with pencil and paper. I used a semistructured
interview to explain what it means to participate in the study.
Smith (2004) stated that the best way to collect data for an IPA study is through
semistructured interviews (Appendix A). Semistructured interviews allow a researcher
and participant to engage in dialogue where initial questions are modified depending on
the participant’s responses and the researcher can probe for additional information
(Smith, 2004). The interview questions were developed based on the literature review and
the theoretical framework. At the beginning of the interview, I collected demographic
information to understand participants’ context.
50
Procedures for Participation, and Data Collection
Interviews were conducted using Skype or Zoom over the internet utilizing voice
or face-time calls depending on the participants’ preference (see Williams et al., 2015).
Skype is an online application for making video or telephone calls and allows individuals
to send text-based messages to one another. Interview questions were developed based on
a review of the literature and included questions such as the following: Could you
describe a typical day living with PCOS? Have your PCOS symptoms changed over
time? Have you changed the way you deal with your PCOS symptoms over time? (see
Williams et al., 2015).
The interviews were transcribed and then transcripts were analyzed using an
inductive thematic analysis process (see Braun & Clarke, 2006). Thematic analysis is a
method for identifying and reporting themes within the data, which organizes and
describes the data in detail (Braun & Clarke, 2006). To analyze the data according to the
six steps recommended by Braun and Clarke, I read and re-read the transcripts and then
generated initial codes. Next, I sorted the initial codes into potential themes. Then I
reviewed the themes and defined and named them. Finally, I wrote the thematic analysis.
Data Analysis Plan
To analyze data extracted from interviews, I used thematic analysis (Braun &
Clarke, 2006). Thematic analysis differs from other descriptive analytic methods as it is
not wedded to any pre-existing theoretical framework (Braun & Clarke 2006). It
qualitatively synthesizes data through the extraction of themes and sub-themes.
According to Braun and Clark, thematic analysis comprises six phases:
51
I familiarized myself with your data. Phase 1 consisted of becoming immersed in
the content of data through repeated reading and rereading, actively searching for
meanings and patterns that assisted in transcribing a thematic analysis.
Generating initial codes: The second phase involved using familiarity with the
data to develop initial codes based on the similarities and difference found to assess the
information in a meaningful way.
Searching for themes: The third phase involved refocus of the analysis on a
broader level by analyzing the codes to develop broader potential themes of the data. The
key features identified in the data were outlined in the first thematic map.
Reviewing themes. The fourth phase involved selecting permanent themes from
the chosen codes. The thematic map was adjusted and the themes were written up to
present a clear coherent explanation of the information.
Defining and naming themes. In the fifth phase the data was refined by
identifying the core of each theme. Themes were named and a consistent, coherent
accompanying narrative provided for each.
Producing a Report- The task of the six phase was to develop a write-up of the
themes to provide a valid academic document. The fully developed themes illuminated
the phenomenon as expressed through the voice of the participants and reflected the
research question.
The following steps were used to analyze the data obtained from the interviews to
create a concise, logical report. Discrepant or negative information may contradict the
52
themes (Creswell, 2014). However, the contradictory information was discussed because
it could build a case for the theme with the account becoming more valid and realistic.
Issues of Trustworthiness
Trustworthiness is an essential element of the qualitive study used to produce
methodological integrity (Merriam & Tisdell, 2015). Credibility, transferability,
dependability, and confirmability are criteria recommended to ensure the issue of
trustworthiness is addressed in qualitative studies (Morrow, 2005). I followed Lincoln
and Guba’s (1985) guidelines and recommendations in ensuring quality in my study. A
few of these guidelines used to address trustworthiness of this study were as follows.
Credibility
Credibility refers to the congruency of the findings with describing reality
(Connelly & Pittman, 2016). Triangulation, rich descriptions, member checking, and peer
debriefing are the strategies that were used to analyze the data and draw conclusions to
support credibility. I used triangulation to build coherent justification for themes of the
research with use of multiple journal research sources to add to the credibility of the
information (Connelly & Pitman, 2016). I acquired thick, rich, well-developed
descriptions from the participants that not only included the phenomenon, but the context
and culture as well was used to contribute to credibility (Morrow, 2005). I used peer
debriefing to enhance the accuracy of the research by locating a person (peer debriefer) to
ask questions about the qualitative study so the account would resonate with people other
than the researcher (Connelly & Pitman, 2016).
53
Transferability
Transferability refers to the extent to which results of a study can be transferred or
applied to similar contexts (Lincoln & Guba, 1985). Transferability is achieved with the
researcher providing rich, thick description of the information as conveyed by the
participants with detailed accounts of their individual experience (Creswell, 2014). I
provided details regarding the instrument being used -the semi-structured interviews
along with context, processes, participants, and relationships, which demonstrated how
these findings may be transferred to a general population (Morrow, 2005). Lastly, my
research choice investigating the QoL of menopausal PCOS women who are members of
a national online support group may increase transferability.
Dependability
Dependability refers to the stability and consistency of research procedures
(Connelly & Pitman, 2016). Dependability was accomplished by conducting an external
trail, by having a researcher not involved in the research process examine both the
process and product of the research study (Lincoln, & Guba, 1985). The purpose was to
evaluate the accuracy and evaluate whether or not the findings, interpretations and
conclusions were supported by the data. Dependability was determined as the
researcher’s review of my log that consisted of my detailed records of activities,
processes, influences, emerging themes, categories, and analysis of the research process.
Including a review of my notebook that documented the dates and thoughts on the
research and the steps taken. This contributed to dependability, which allowed others to
54
fully understand this research and enables them to repeat this study if they should choose
to do so.
Confirmability
Confirmability refers to comparable concepts of objectivity in quantitative
research. Confirmability is attained by demonstrating that the study’s findings represent
the responses of the participants; and it does not reflect the researcher’s subjective
predilections and interpretations (Lincoln, & Guba, 1985). Confirmability was
accomplished by overlapping or triangulating the data, conducting audit trials, using
reflexivity, and the researcher documenting the process, from the designs to data
collection to analysis (Connelly & Pitman, 2016); Morrow, 2005). It is through these four
areas that this research maintained high standards. Reflexivity was used, to disclose my
biases and experiences during the procedures. Additionally, Patton (2002) indicated that a
way to mitigate bias and inaccuracy is by triangulating data sources to increase
credibility. Ensuring confirmability was an ongoing process of keeping detailed records
and constantly being aware of personal biases at all stages of the research.
Summary
This chapter explained the step-by-step process of the study. The central focus of
the study was to gain an understanding of the lived experience women diagnosed to with
PCOS as a reproductive age women as they transition to menopause. The research
indicates PCOS reproductive age women experience a poor QoL compared to same age
women. The qualitative tradition used in this study was IPA. Data were collected from
interviews with PCOS menopausal women recruited from an online support group. I used
55
snowball sampling, as it is the most appropriate method to ensure that participants meet
the criteria and to ensure that the research questions are answered. Having described the
methodological framework for this project, the following chapter focused on the study’s
findings and outcomes.
Chapter 4: Results
Introduction
The purpose of this qualitative phenomenological study was to explore the QoL in
women 48–65 previously diagnosed with PCOS during their reproductive years.
Participants of this study were asked to report on their QoL and psychological well-being.
For this study, data were collected through interviews with 10 women who met the
study’s criteria for participation to answer the research question: What are the lived
experiences of QoL in menopausal PCOS women, ages 48 to 65? This chapter is divided
into several sections. In the first sections, I present information regarding the setting,
demographics, and data collection. Finally, I discuss study results, evidence of
trustworthiness, and a summary.
Setting
Participants were recruited from PCOS online supports groups via Facebook and
via Craigslist. Once a potential participant showed interest to participate, I confirmed
they met the participation criteria. Then, I sent them an email containing the informed
consent form to participate. Once participants reviewed the form and consented to
participate in the study, I sent a follow-up email for them to schedule their interview
session. I arranged a secure Zoom link for each interview according to the participant’s
56
availability. All interviews were recorded via Zoom, saved, and then transcribed.
Interviews were recorded and lasted from 30 to 45 minutes. Once each interview was
completed, I emailed a digital gift certificate for $20 to each participant.
Demographics
All participants involved in the study were women. The total number of
participants for the study was 10, and at the time of the interviews, all women resided in
the United States and their demographics were diverse. Participants were African
American (n = 7), Caucasian (n = 2), Asian (n=1), and Latina (n = 1). Participants were
between ages 48 and 57 years (M = 49.8, SD = 2.8). Participants’ relationship status was
also diverse: married (n = 7), single (n = 1), and divorced (n = 2).
One characteristic of PCOS is the increased production of androgens (male
hormones) in women diagnosed with the disorder, causing infertility. Some of the women
reported that infertility was a problem. However, the majority of the participants had
children, either naturally or with the assistance of reproductive technology. Participants
reported children (n = 7) and no children (n = 3). Participants also differed regarding the
age of PCOS diagnosis, physical health, and mental health status. Participants reported
being diagnosed with PCOS between ages 12 and 34. Participants also reported assorted
physical health issues, including joint pain (n = 5), abdominal pain (n = 1), obesity (n =
1), and diabetes (n = 3). Furthermore, mental health status varied among participants as
they reported depression (n = 2), mood disorders (n = 4), or being emotionally stable
(n = 4). Table 1 depicts participants’ demographic information.
Table 1
57
Participants’ Demographics
Participant
Ethnicity
Age
Relationship
Children
Diagnosis
age
Physical
health
Mental
health
Belma
Asian
48
Single
0
34
Obesity
Depression
Gealan
African
American
48
Married
0
20
Diabetes
Stable
Amila
African
American
48
Married
1
28
Joint pain
Stable
Cluy
African
American
48
Married
2
27
Joint pain
Stable
Riama
African
American
50
Divorced
1
27
Ab. Pain
Depression
Lynadaum
African
American
51
Married
2
21
Diabetes
Mood
disorder
Rasha
African
American
50
Married
1
22
Joint pain
Mood
disorder
Tesybe
Caucasian
57
Married
2
12
Joint pain
Mood
disorder
Lenerma
Latina
48
Married
2
22
Diabetes
Stable
Fenjier
Caucasian
50
Married
0
33
Joint pain
Mood
disorder
Data Collection
A total of 10 participants who responded to my flyer seeking participants from
online PCOS support groups or Craigslist met the search criteria for participating in the
study. After each potential participant contacted me, I verified they met the research
criteria for participating. Each participant was emailed an informed consent form to read
and if willing to participate reply with “I consent” in an email. Participants were informed
the interview would last 30–40 minutes via Zoom and they would be compensated with a
$20 gift card.
58
On the date of the interview, after formal introduction, I reviewed the purpose of
the study and informed the interviewee the meeting would be recorded. Once the
participant agreed, the interview began. I used a prepared semistructured interview with
open-ended questions, as noted earlier (see Appendix A). The interview questions were
formulated to guide the participants in describing their lived experiences of being
diagnosed with PCOS in their reproductive years with regards to their physical health and
psychological well-being as they transition to menopause. The interview emphasized the
participants’ entire PCOS experience with the following topics: (a) initial PCOS
diagnosis, (b) transition to menopause, (c) health and psychological well-being during
reproductive years, and (d) health and psychological well-being during the transition to
menopause.
Data Analysis
The analysis consisted of generating codes from the data, rather than using a
preexisting theory to identify codes that might be applied to the data. Throughout the
process of interviewing, I kept a reflective journal to take notes of my thoughts and
feelings for each participant during the interview. Thematic analysis was conducted to
determine the themes (Braun & Clarke, 2006). Interpretations and descriptions of the
findings evolved as the themes were generated from the analysis, and the reflexive notes
and shared feelings derived from the participants’ responses.
Once all interviews were completed, all interviews were transcribed, and
participants were provided a pseudonym. Next, transcripts were uploaded using
59
Microsoft Word. I reviewed all transcripts again and highlighted text, expressions, and
opinions that gave meaning to the phenomenon of study. Lastly, I read the transcripts
line-by-line again, this time concentrating on the implications hidden in the text. To
understand the expressions of the participants, the interviews were coded.
The data were arranged by creating a Word file containing a large matrix of 12
columns. The matrix was used to code and cross code the common themes identified
within each participant and across participants. The first column contained the following
items: (a) PCOS diagnosis, (b) transition to menopause, (c) typical day, (d) physical
health, (e) mood and psychological health, (f) social relationships, (g) surroundings or
environment, (h) symptoms today, (i) symptoms over time, (j) cope with PCOS, and
(k) recommendations. These topics reflected the content of the interview guide. The next
10 columns contained the first name pseudonym of each participant with interview
transcriptions below of their thoughts pertaining to each of the 12 items. The 12th column
provided a cross code summary interpretation.
The process of data analysis began with reviewing each transcript and reading
carefully to immerse myself in the original data. I explored the transcripts by
documenting notes regarding the content while reviewing each transcript. During this
stage in the analysis, I extracted significant statements from the transcripts and assigned
codes to them to reduce the data to latent meaning. I categorized the themes based on
questions developed for the interview guide and common themes brought up by the
participants during the interviews to best explore the lived experiences of women
60
diagnosed with PCOS in reproductive years as they transition to menopause. The codes
offered an approach to break down the interviews for interpretation.
After this first step, I began organizing merging codes together based on
conceptual meaning. Coded passages determined to be conceptually similar were
combined into one code to develop emergent themes. For example, codes identified in the
first phase, like symptoms–balding or symptoms–excessive or unwanted hair, were both
conceptually related to feeling self-conscious. These two codes and all their associated
significant statements were compiled into a larger code.
This coding process continued for each participant until all significant statements
were extracted and coded. Four major trends resulted from interviews with the 10
participants in the research study. The patterns or themes that developed from the
thematic analysis were combined or categorized together to give further meaning. The
following four patterns emerged: (a) concern over condition worsening, (b) satisfied with
life despite health challenges, (c) symptom management – physical activity, and (d)
feeling self-conscious. Examples of the codes are provided using the participants’ quotes
to illustrate the conceptually related content that the codes represented in Table 2.
Table 2
Examples of Coded Excerpts
Code
Excerpt
Concern over
condition worsening
“I don’t feel safe because my PCOS condition is bad. I am
overweight and my health could get worse if I don’t lose the
weight.”
Satisfied with life
despite health
challenges
“I am satisfied with my life, even though I have health
problems and I am overweight, but I am doing something to get
61
health. I also have the love and support of my husband,
children, family, and friends.”
Symptom
management –
physical activity
“My health is poor because of the PCOS. But I have been trying
to follow the doctor’s suggestions to take better care of myself
by exercising and changing my diet, eating more fruits and
vegetables.”
Feeling selfconscious
“Well, the main issue is the hairs, the unwanted hairs. It’s so
embarrassing as a young lady then, I was too embarrassed. I
didn’t want short skirts.
Next, I searched for connections across the emergent patterns and refined the
trends into final themes. To do this, I explored patterns or shared qualities across
participant experiences. This resulted in combining themes that were related to others by
some conceptual, textual, or structural thread, and those initial codes were brought
together again. For example, the initial codes emotionally painful/difficult, symptoms–
mood swings, and dissatisfied with life due to health were all connected by the thread of
mental health challenges that women experience, and so brought together under the
umbrella of a new theme, which was given a descriptive title. From this analysis, three
major final themes were generated: (a) women cope with depressive symptoms and mood
swings, (b) women feel helpless to the physical changes and challenges associated with
co-occurring PCOS and menopause, and (c) healthy lifestyle modifications are used to
manage co-occurring PCOS and menopause. Theme 2 had a related subtheme that
women experience pain during routine activities. These themes are described in the
results section.
62
Evidence of Trustworthiness
In this study, I used a qualitative phenomenological research approach to meet the
purpose of the research. Data were collected using a semistructured interview process that
allowed participants to share their lived experiences of being diagnosed with PCOS in
their reproductive years as they transition to menopause. The validity of the data was
established by the participants’ perceptions of their confirmed existence of the
phenomenon in their lived experiences. The guidelines and recommendations of Lincoln
and Guba (1985) were used in ensuring quality in my study. Several techniques may be
necessary to build consistency or trustworthiness in research. The research dictates
several techniques to support credibility as follows: dependability, confirmability,
transferability, member checking, and triangulation (Morrow, 2005).
Credibility
Internal validity is one of the critical criteria addressed by researchers to ensure
that their study measures what it is intended to measure (Lincoln & Guba, 1985). To
ensure credibility I used triangulation to build coherent justification for themes of the
research with use of multiple journal research sources to add to the credibility of the
information (Connelly & Pitman, 2016). I obtained thick, rich, well-developed
descriptions from the participants that not only included the phenomenon, but the context
and culture (Morrow, 2005). Lastly, peer debriefing was used to enhance the accuracy of
the research by locating a person (peer debriefer) to ask questions about the qualitative
study so the account would resonate with people other than the researcher (Connelly &
Pitman, 2016).
63
Transferability
Transferability enables the replication of a research study. One of the ways I
achieved transferability was providing rich, thick description of the information as
conveyed by the participants with detailed accounts of their individual experience
(Creswell, 2014). I provided details regarding the instrument being used: semistructured
interviews along with context, processes, participants, and relationships, which
demonstrated how these findings may be transferred to a general population (Morrow,
2005). My research choice investigating the QoL of menopausal PCOS women who are
members of a national online support group may increase transferability.
Dependability
Dependability is based on clear and accurate documentation of the researcher
throughout the research process and refers to the stability and consistency of research
procedures (Connelly & Pitman, 2016). The actions required to support credibility were
taken by maintaining and review a log consisting of my detailed records of activities,
reflexive journals, processes, influences, emerging themes, categories, and analysis of the
research process. To confirm that the sources were authentic or to establish confirmability
the data was verified through peer review for accuracy and observations of the data
collected to detect and correct discrepancies. This contributed to dependability of the
study and allow others to fully understand this research and enable them to repeat this
study if they should choose to do so.
64
Confirmability
Confirmability was used to prove the research is neutral and not influenced by the
assumptions or biases of the researcher. Confirmability was accomplished in this research
by overlapping or triangulating the data, conducting audit trials, using reflexivity, and the
researcher documenting the process, from the designs to data collection to analysis
(Connelly & Pitman, 2016; Morrow, 2005). It was through these four areas that this
research maintained high standards. Reflexivity was used to disclose my biases and
experiences during the procedures. Additionally, Patton (2002) indicated that a way to
mitigate bias and inaccuracy is by triangulating data sources to increase credibility.
Ensuring confirmability was an ongoing process of keeping detailed records and
constantly being aware of personal biases at all stages of the research.
Results
Three major themes represented the results of this study. The first theme was
women cope with depressive symptoms and mood swings, the second theme, women feel
helpless to the physical changes and challenges associated with co-occurring PCOS and
menopause, and the final theme was healthy lifestyle modifications are used to manage
co-occurring PCOS and menopause.
Theme 1: Women Cope With Depressive Symptom and Mood Swings
Women aged 48-65 described a complex set of challenging lived experiences
related to their QoL in menopausal PCOS that contributed to depressive symptoms and
mood swings. The first theme is about the way that women conceptualize their depressive
65
symptoms and mood swings. This theme also discusses the strategies that women use to
cope with these symptoms.
Women widely reported experiencing depressive symptoms and mood swings.
Culy said, “My mood has been very bad. Most times. I have this mood swing, and I could
be fine this minute and the next minute I’m off.” Belma, reflected on the ways in which
her mental health symptoms affected those around her. She indicated that at times her
feelings resulted in her snapping at those around her. She also shed light on the
debilitating nature of these symptoms, indicating that they sometimes prevented her from
routine activities, namely work. Of this she said,
I think I am a little more irritable. A lot of things that I didn’t notice before or
didn’t complain about before, I’m more snappy. Just snapping at people around
me. Some days, it makes me like wanna stay home. I’m having a bad day, bad
feeling day and I don’t wanna leave my house sometimes that happens. I don’t
wanna talk to nobody.
Some participants reported using medication to mitigate the mood-related
symptoms that they were experiencing. For example, Lynadaum explained her doctor’s
recommendation to cope with the symptoms,
At first, I was upset with the bleeding for a month when the menopause started,
and the mood swings because I already had to deal with the abdominal pain and
the hairy problem with PCOS. So, I talked to my doctor, and he told me to stop
worrying about it and put me on mood medication and told me try to be happy.
66
Amila shared that her mood swings typically occurred around the time of her period.
They shared, “Sometimes I just have like crazy mood swings. And before, it’s mostly my
period that causes the whole mood swing but now it’s just any little thing could make me
happy; a little thing could make me sad.”
One participant, Rasha, felt particularly troubled by her PCOS because she
believed that it caused her to age more rapidly than her peers who did not have PCOS.
This comparison contributed to feelings of negative self-worth. She said, “I feel
depressed. I feel life is not worth living because I’ve suffered for so many ailments and I
see myself looking like I’m older than my age mates. Sometimes I feel bad.” Participant
Riama was also aware of the severity of her mood swings, she shared that the progression
of her PCOS symptoms was causing significant interpersonal challenges for her, “I am
not coping well. I get depressed and have more mood swings because the menopause
seems to make the PCOS symptoms worse.” Riama seemed to vocalize what many
women were feeling, likening PCOS to feeling trapped. Riama said, “My feelings are
more negative than positive because of the PCOS. I feel like I am in bondage to this
PCOS.”
Although most women shared their experiences with negative mental health
symptoms resulting from their PCOS and menopause, symptom management strategies
were more often cited regarding physical symptoms. There seemed to be less of an
emphasis on specific strategies focused on mental health. The chief strategy for
addressing mental health symptoms was relaxation, as reported by Culy and Amila. Lucy
shared, “I’m getting positive. I’ve been told by my doctor, and he said my mood swing in
67
a symptom of menopause. So, when I feel that I’m overreacting, I just calm myself
down.” This idea of calming down in response to negative mental health symptoms was
echoed by Amila who described practicing self-care by prioritizing herself, I would say
the first step in taking care of myself is to stop thinking, because there’s a saying that fear
kills faster. I think relaxation is what I’ve got to remind myself to do every day, find time
for relaxation. Like it’s not even much of a bigger disease. It’s just like, I would call it
imbalance in your system. But some people will be like, “Oh, I have PCOS, and oh my
God, what’s that?” I feel the first step is to be calm and then not to try so hard to give
birth. Because if you keep pushing it, you literally don’t know if you’re pushing yourself
into danger or stuff like that. So put yourself first, take care of yourself. Children will
come later.
Yeah. That’s what I feel, children will come later.
One participant, Lynadaum shared that her doctor had prescribed antidepressants to
address her mental health symptoms, “I take mood medications twice daily for the
depression and mood swings I been experiencing since the menopause.”
Theme 2: Challenges Associated With Co-occurring PCOS and Menopause
This theme mainly focused on physical symptoms and challenges related to
physical health. The theme has a subtheme related to how women described their
experience of pain during daily life and routine activities. Co-occurring PCOS and
menopause symptoms caused women to feel helpless or out of control, this was
particularly true regarding physical changes and challenges with fertility. The women
were initially challenged by infertility, resulting in the diagnosis of PCOS as young
68
married women trying to become pregnant. Although, other health issues were present
during this time period such as excessive weight, insulin resistance, diabetes hirsutism,
and acne, achieving reproduction was the primary focus. However, as the women
transitioned to menopause the metabolic features to PCOS seems to dominate. The
women reported worsening health conditions related to excessive weight gain, diabetes,
joint pain, balding and hirsutism.
In the transition to menopause women experienced physical symptoms that were
out of their control. The most widely reported physical symptoms included balding,
excessive hair in unwanted places, weight gain, and joint pain. Balding and excessive hair
in unwanted places seemed to be particularly emotionally taxing for women. Women
often used the phrase “like a man” when referring to their hair-related symptoms. Riama
said,
What stands out for me is losing my hair and looking old because of the PCOS.
My friends are menopausal, but they look younger than me. I don’t like looking
old, balding and with hair growing on my face like a man.
Lynadaum and Sebety also likened these symptoms to a man, saying, “I am
growing more hair all over my body, more like a man and I am losing the hair on my
head. I am going bald, and growing hair on my face and body.” And “I still grow hair like
a man” respectively. For most women, these hair related symptoms elicited feelings of
embarrassment. Belma shared that she did not feel comfortable discussing these
symptoms with others, “Actually I started noticing other things like excess hair on my
face and certain areas. I don’t wanna tell people, but it they were noticing” Nilada also
69
felt embarrassed by these symptoms because she felt they were not in alignment with her
feminine identity. Of this, she said,
The main issue is the hairs, the unwanted hairs. It’s so embarrassing as a young
lady them, I was too embarrassed, I didn’t want short skirts. I’m too embarrassed
going out and people would say, “Is she a man or is she a lady?” I was also losing
my hair on my head.
The effect of hair loss on self-esteem was detailed by Belma,
The scalp hair loss that as a woman you don’t wanna see bald spots. It like
diminished your self-esteem, and also with the irregular periods…I sometimes…I
don’t know when or if I’m gonna get my menses the next month…will it be
heavy
or light flow.
In addition to symptoms related to excessive hair or balding. Participants reported
excessive weight gain and retention. At times, weight was also reported as a contributing
factor of feelings of low self-esteem. Belma shared that her weight made her feel
selfconscious, she said, “I’m very self-conscious about my weight.” Being overweight
increased concerns among participants that they make experience obesity related chronic
diseases or general disability. Lynadaum her perception of how her weight was affecting
her mobility. She said,
My mobility is not great because I am overweight, I can do basic things like my
chores and go to the market, but I am overweight, so I get tired easily and it takes
me longer to complete certain chores.
70
She also shared that because of her weight she did not feel safe, saying, “I am
overweight, so I don’t feel safe because it takes me longer to move around. I move slower
because of the extra weight so that could be a problem if I need to move faster for my
safety.” Rasha spoke of the comorbid conditions that she was living with because of her
PCOS further emphasizing the far-reaching health implications of PCOS. She said, “Well,
because of so many things, when I developed the PCOS, so many things were going on. I
was putting a lot of weight also and I was diagnosed with diabetes.” Sebety also
discussed the ways in which negative health outcomes were exacerbated, although she
seemed to think that these health outcomes were normal and not related to her PCOS
“I’m overweight and have high blood pressure, but that’s being a person in America, in
their middle age, most of us are overweight and have high blood pressure.” Conversely
some women shared concern over their weight or condition worsening over time. Rasha
feared her condition becoming debilitating, “Sometimes I feel that maybe I might die. I’m
scared of being bedridden. I’m scared of so many things. It makes me to feel insecure.”
Amila shared similar feelings of not being able to keep up with potential future weight
gain, “Are you seeing me? If I get pregnant now, I am gonna be like on a much bigger
size. Look at me. I am not even 50 yet and I’m already looking like a ball. I can’t keep up
with that.” Amila further explained that despite their best efforts maintaining a healthy
weight had not been attainable due to their PCOS. She reflected on her weight gain by
saying,
Honestly, concerning PCOS, I feel safe, but what I don’t feel safe is with the
weight adding, because I don’t really eat much, I try my possible best to eat
71
healthy. I don’t even eat the pastries I bake with my own hands, or the cakes I
bake with my own hands, but it keeps adding. So, for the weight aspects, I don’t
feel safe.
Lastly, women reported symptoms of physical pain, most commonly join pain.
These symptoms were commonly reported in the context of inhibiting routine activities.
Pain-like symptoms that affected women’s daily routine are reported in Theme 3.
Subtheme: Women Experience Pain During Routine Activities
This subtheme is part of the major theme on challenges associated with
cooccurring PCOS and menopause’s physical symptoms. It refers to physical pain and
associated obstacles, but it specifically it highlights how daily and routine activities are
affected. The sample of women under study described the challenges that they faced due
to physical pain related to excessive weight gain, joint pain and physical weakness. All of
the women complained about daily joint and body pain affecting their ability to perform
activities daily. However, only two of the women were disabled and receiving
government assistance. A third woman stopped working in the physically demanding jobs
available to her due to fatigue, physical weakness, and joint and body pain. Chronic pain
impacted the QoL of participants.
Culy shared that her pain made it difficult for her to get out of bed. She said, “I
work but I’m having aches on my joints, on my nails, and sometimes I wake up, I don’t
feel like standing up from my bed and most time I’m weak.” Culy felt that the pain was
causing mental weakness in addition to physical weakness, “I am now beginning to
72
notice the weakness, not just in the body, but in my mental reasoning.” Amila also
described the impact of pain on her ability to engage in physical activity.
As I said I do exercise at the gym sometimes, but the exercise causes my bones to
ache all over my body. Sometimes I try to go up to the gym to kick up some fights, but
then like, without even getting 20 minutes into it, I’m already feeling so dizzy or tired.
Like I could…I can’t physically keep up with gym activities. Nilada also noticed that her
ability to complete normal activities was diminishing due to greater physical weakness,
I’m having this challenge of not going things I know I ought to have done or
things I ought to be doing. Like of recent, the doctor said I am supposed to be
more engaged in physical exercise, but I’m not physically exercising like I ought
to have been doing. Because most of the time I don’t really have the strength to
do them, and then when I try to do it, I find myself breaking down.
For Nilada the pain was so strong that she ultimately resigned from her job,
This thing has been, I think it was when the menopause started. I started having
the pains, I think so, and that was one of the reasons I resigned from my work.
The job was very demanding, and I wasn’t meeting up with the demands of the
job.
Similarly, Rasha noticed a progression of her physical symptoms and felt weaker because
of these symptoms, “These days, I tend to be easily weak, and I don’t have strength. I’m
not as fit as I used to be.”
Theme 4: Healthy Lifestyle Modifications used to Manage Co-Occurring PCOS and
73
Menopause
Women varied in their management of PCOS during menopause. They employed
methods such as taking medication, practicing self-care, communicating with their
physician, and using cannabis oil. One symptom management strategy that all
participants engaged in or strived to engage in was healthy lifestyle behaviors as
recommended by their physicians such as increased physical activity and high-quality
nutrition. Although physical activity was reported as a salient strategy to mitigate PCOS
symptoms, some women did not feel that they could meet the demand of physical activity
due to symptoms of physical pain, as noted in Theme 3. For some women, decreased
mobility contributed to feeling unsafe, making it difficult to engage in physical activity.
For at least one participant, concern about crime in the area was also reported as a barrier
to engaging in physical activity, Belma explained,
There’s so many concepts, stories I hear in the news every day about high crime,
especially to women, like New York crime rate has gone up so far. And also,
because to Asians, and recent Asian hate crime[s]. I think somebody’s gonna
attack me or something.
Despite physical pain and fear of crime impeding physical activity engagement,
most participants shared that they regularly engaged in physical activity or had intentions
to, some participants modified the type of physical activity that they engaged in to meet
their personal abilities. Culy shared her decision to walk instead of jog, “I actually
exercise during the weekends when I’m off work so I take a walk because I can’t really
jog. So, I mostly I just take a walk”
74
The women varied in the type of physical activity that they preferred. While some
women like Riama shared that she enjoyed walking, others like Belma opted a variety of
options including yoga, meditation, biking, and swimming. Both Riama and Belma
expressed that their lifestyle changes provided relief to their symptoms. For Riama
regular physical activity improved her perception of her QoL, “My doctor told me to
exercise, so I walk on the street and stop when I get tired, walk, and stop. I feel better
now that I do it more regularly.” Belma observed weight loss because of her diet and
exercise. It is important to note that the lifestyle changes were not always sustainable as
indicated by Belma’s testimony, “I am eating more healthy, cleaner lifestyle, more
plantbased, more vegetables. No more soda, more water. I’ve actually lost weight, but at
the same time I’ve lost weight and then gained it, gained weight back.” Despite
challenges in maintaining the lifestyle changes, Belma and others were firm in their
intentions to continue engaging in these behavioral changes. Amila shared, “I try to cope
as best I can by doing what the doctor recommends by eating healthy, stay positive and
trying to exercise more.” Belma expressed a positive outlook of her diagnosis when
considering the ways in which healthy lifestyle behaviors could impact her symptoms.
I would say to other women like me, it’s a condition that affects a lot of women.
It’s very similar to menopause, but not 100% similar, but it’s not life threatening.
You can get through it, control it, over time, with proper diet, exercise and
counseling or take medication to help if the doctor recommends it.
75
Addressing the Research Question
The purpose of this study was to gain an understanding of the lived experience of
women diagnosed with PCOS in the reproductive years as they transition to menopause.
There was one foundational research questions to address this phenomenon What is the
lived experience of QoL in menopausal PCOS women, ages 48 to 65? The first theme
that emerged revealed the women experience depressive symptoms and mood swings
related to the PCOS diagnosis and transitioning to menopause and how the women cope
with these psychological disorders. The second theme to emerge was challenges the
women experienced associated with co-occurring PCOS and menopause. As part of this
theme, women revealed the experience of pain during routine activities such as working,
household duties and physical exercise. Lastly, the third theme emerged as the women
complied with to the recommendations of their doctor’s and made healthy lifestyle
modifications to manage co-occurring PCOS and menopause.
The three themes specifically responded to the research question as they identified
the declining mental health, worsening physical health, challenges associated with
activities of daily living, and healthy lifestyle change used to cope with PCOS and
menopause. For instance, theme one emerged as several of the women reported
depressive symptoms and mood swings related to the PCOS diagnosis or as a result of
transitioning to menopause. The symptoms varied among the women with five of them
reporting a psychiatric diagnosis and are currently prescribed medications to treat the
symptoms. Whereas other participants reported using cannabis oil to cope with occasional
mood swings, anxiety, and depression.
76
Theme two addressed the research question as participants described worsening
health conditions associated the PCOS diagnosis and the transition to menopause such as
joint pain, body aches, loss of strength, physical weakness and fatigue. Along with
diabetic conditions and obesity that occurred during their reproductive years further
eroding their health in the transition to menopause. Additionally, the reported the loss of
scalp hair, and balding increased with menopause as did excessive hair growth on the face
and body that began in their reproductive years. In this theme, women described
worsening health conditions causing difficulty accomplishing activities of daily living.
With two of the women reported being disabled and receiving government assistance due
to joint and body pain that was so severe and constant it prevented gainful employment. A
third woman decided to stop working due to joint and body pain that prevented her from
performing adequately in a physically demanding job and relied on her partner to provide
financial stability.
Finally, the third theme also addressed the research question and the women
reported they followed their doctor’s recommendation to use diet and exercise to cope
with the symptoms of PCOS and menopause. Most of the ten participants reported
sedentary lifestyles and were initially resistant to following the doctor’s
recommendations. However, as the majority of the women began to gradually make
healthier food choices and exercise regularly, mostly by walking. They reported a
lessening of the worst of the symptoms, such as joint pain, weight gain, fatigue, anxiety,
and mood swings.
77
Summary
This chapter detailed participant recruitment procedures, data collection, storage
of data, data analysis, evidence of trustworthiness, and the results of the study. The
process involved semi-structured interviews and analysis of audio-recordings,
transcriptions, and handwritten notes. All these procedures were used to gain an
understanding of the lived experience of 10 women diagnosed with PCOS during their
reproductive years as they transition to menopause. Findings from the study indicate the
women experienced infertility as a result of the PCOS diagnosis along with other health
issues such as diabetes, obesity, and depression. The transition to menopause seems to
have worsened these conditions and added mood swings, joint pain, fatigue, and body
weakness. A few of the women were disabled by the disorder and all reported challenges
in performing activities of daily living due to joint and body pain. Some of their doctors
prescribed medication to relieve the pain and all suggested a healthy lifestyle change
through diet and exercise to ease the symptoms of PCOS and menopause. In the next
chapter, the findings of the study are interpreted, limitations are noted, and implications
for future research are described.
Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this qualitative study was to explore the lived experiences of
women diagnosed with PCOS during their reproductive years as they transition to
menopause at ages 48–65. PCOS is associated with a variety of comorbidities, such as
cardiovascular diseases, the most significant and frequent cause of morbidity and
78
mortality in women; metabolic disorders; insulin resistance; chronic inflammation;
oxidative stress; and psychological disorders. Many of these comorbidities can be found
in PCOS patients even at early age and worsen in pre-menopause and post-menopause
stages (Moulana, 2020).
A large body of research has been focused on adverse reproductive and metabolic
comorbidity features of PCOS that present a serious economic burden to health care
(Bromberger et al., 2015; Dokras et al., 2018; Winkler et al., 2015; Zheng et al., 2015).
Although there is an expansive amount of literature on the complications of PCOS for
reproductive-age women, there is minimal information about the health and well-being of
these women as they transition to menopause (Moulana, 2020). Thus, the current IPA
study was conducted to explore the lived experiences of 10 participants diagnosed with
PCOS in their reproductive years as they transition to menopause. Three themes emerged
from the interview data: (a) depressive symptoms and mood swings related to the PCOS
diagnosis and transitioning to menopause and how the women cope with these
psychological distress/disorders, (b) the challenges and physical pain women experience
associated with co-occurring PCOS and menopause, and (c) how women comply with the
recommendations of their doctors and make healthy lifestyle modifications to manage
cooccurring PCOS and menopause. The following sections include an interpretation and
discussion of the findings, limitations of the study, recommendations for further research,
implications for positive social change, and a conclusion.
79
Interpretation of the Findings
The data were collected from semistructured interviews of each participant and
their reactions to being diagnosed with PCOS in their reproductive years and their
experiences as they transition to menopause. Three themes were identified through the
data analysis. The findings of this study helps to fill a gap and extend empirical
knowledge of the psychological health and well-being of PCOS menopausal women. All
themes that originated from this study are supported by findings in the existing literature.
By comparing the findings from this study to the foundational understanding of the lived
experiences of PCOS menopausal women, health care workers targeting this population
can be better informed as can future directions for research in this area.
Theme 1: Women Cope With Depressive Symptom and Mood Swings
Participants revealed feelings of depression and anxiety beginning in their
reproductive years due to features related to PCOS: hairiness, obesity, irregular and
painful menses prior to being officially diagnosed by a doctor as newly married women,
and inability to become pregnant. Depression, anxiety, and helplessness have been
associated with women who have PCOS (Moulana, 2020). As noted by Amir et al. (2014)
and Sanchez (2020), reproductive-age women with a PCOS diagnosis are challenged in
the perception of themselves as feminine due to their obesity, hairy appearance, and lack
of fertility. Depression and other mental health issues in women with PCOS are not only
due to the psychological effects of obesity, infertility, or hairiness (Dokras et al., 2018;
Dokras, 2016; Torres Fernandez et al., 2018; Elsenbruch, 2007; Hollinrake, 2007), but
PCOS is also seen as an inflammatory condition; excessive inflammation caused by
80
PCOS is an important inducer of depression (Joham et al., 2022; Kolhe et al., 2021).
Anxiety and depression are seen as two major PCOS-associated psychological
comorbidities, with high incidence; and they are considered as a substantial public health
burden (Moulana, 2020). Further noting, it has been found that women with PCOS are at
an increased risk of social phobia, painful emotional stress, suicidal ideation, bipolar
disorder, and attention-deficit/hyperactivity disorder.
Participants in this study reported increasing mood swings, depression, and
anxiety as they transitioned to menopause; some participants were diagnosed with mood
disorders and prescribed psychotropic medication to cope with the symptoms. According
to Masood et al. (2016) and Zheng et al. (2017), PCOS women who transition to
menopause experience psychological distress due in part to aging ovaries, leading to the
deterioration in the fabrication of the ovarian gonadotropins such as progesterone and
estrogen. Furthermore, Henson and Kulkarni (2022) expanded on this information noting
evidence that supports the notion that women with menopause-associated depression do
not suffer from a gonadal hormone abnormality as such but have a brain response to the
hormonal fluctuations, leading to depression associated with menopause transition.
Theme 2: Challenges Associated With Co-occurring PCOS and Menopause
Participants described feeling helpless and out of control due to co-occurring
PCOS that began in their reproductive years and menopause symptoms such as infertility,
irregular menses, diabetes, mood disorders, obesity, joint and body pain, and cosmetic
features of the disorder. The women reported struggling with obesity and being diagnosed
with diabetes in their reproductive years, and they found these symptoms worsened as
81
they transitioned to menopause due to increasing weight even when dieting or eating
smaller portions of food. According to Comijs (2015) and de Medeiros (2020), the more
serious chronic conditions, such as cancer, cardiovascular disease, and diabetes, become
more pronounced among PCOS women with age. Women diagnosed with PCOS at
reproductive age have increased risk and prevalence of prediabetes and diabetes and have
multiple risk factors for cardiometabolic disease. Other comorbidities include obstructive
sleep apnea, endometrial cancer, and mood disorders, which contribute to the overall
health burden of the syndrome (Deswal et al., 2022).
Balding and excessive hair growth in unwanted places such as the face, arms, and
body (hirsutism) are two of the cosmetic features of PCOS that participants identified as
emotionally taxing and threatening to their feminine identity. According to Sarfarti et al.
(2022), the clinical signs of PCOS appear around puberty and progress slowly in
adulthood; however, the clinical consequences of this pathology do not stop with
menopause. Symptoms of hyperandrogenism can worsen with menopause and present
with moderate clinical signs such as hirsutism, acne, and/or signs of virilization (alopecia,
hoarseness, clitoral hypertrophy).
Participants described the challenges they face due to physical pain. They
explained that, at times, pain makes it difficult for them to conduct routine activities.
Chronic pain impacts the QoL of individuals (Lu et al., 2022). The majority of the
participants reported a worsening of their health condition and difficulty completing
activities of daily living in the transition to menopause. Two of the participants were
disabled, and two reported being unemployed for several years due to poor health related
82
to the PCOS diagnosis and transitioning to menopause. PCOS is associated with several
diseases that contribute to physical pain and the interruption of activities of daily living.
For example, PCOS causes anovulation and hyperandrogenism, resulting in hormonal
imbalance, and is known to contribute to systemic autoimmune diseases such as
rheumatoid arthritis (Sharkeem et al., 2021).
Women with PCOS are at a higher risk of developing metabolic syndrome leading
to osteoarthritis development causing pain in the knees, hips, and hands (Kluzek et al.,
2021). The metabolic features of PCOS become more pronounced with age and are
associated with increased risk for insulin resistance, dyslipidemia, cardiovascular disease,
some cancers, and abdominal obesity (Mahalingaiah et al., 2015). Endometriosis and
PCOS are both associated with pelvic pain; they also have similar pathological causes
(e.g., obesity and oxidative stress) and contribute to the increased risk of cancer
development in the endometrium (Lu et al., 2022). Furthermore, several PCOS-related
pathologic factors may exacerbate pain perception, including low-grade inflammation,
oxidative stress, adipogenesis, and insulin resistance. In sum, pain expression may be
dynamic and diverse in patients with PCOS because several diseases that cause bodily
pain have been identified to be associated with PCOS. PCOS health-related debilitating
symptoms predict poorer participation in working life by increasing the risk of
disabilitybased absences and unemployment and disability retirement in middle age
(Kujanpää et al., 2022).
Theme 3: Healthy Lifestyle Modifications Used to Manage Co-occurring PCOS and
83
Menopause
Women varied in their management of PCOS during menopause. They employed
methods such as medication, practicing self-care, communicating with their physician,
and using cannabis oil. Healthy lifestyle behaviors such as increased physical activity and
high-quality nutrition were two symptom strategies recommended by their physicians.
Despite physical pain and fear for physical safety due to obesity most participants shared
that they regularly engaged in some form of physical activity. Lifestyle modifications
have been gradually acknowledged as the first-line management for PCOS, especially in
obese patients with PCOS (Gu et al., 2022: Shah & Rasool, 2021; Szczuko et al., 2021)
Further noting, lifestyle modifications, including diet modifications, exercise, and
behavioral modification, appear to alleviate the metabolic dysfunction and improve the
reproductive disorders of PCOS patients (particularly in obese women).
A review done on PCOS and metabolic syndrome highlights the unhealthy
association of the PCOS and obesity and emphasizes the importance of early diagnosis,
patient education, and long-term follow-up beyond the reproductive age into menopause
to prevent the long-term serious comorbidities (Shah & Rasool, 2022). Celik and Kose
(2021) recommended that patients with defined PCOS phenotypes should be observed
and monitored from the early reproductive period into the late postmenopausal period to
clarify morbidities and mortality in older women with PCOS. In addition, Lin et al.
(2022) and Shadid et al. (2022) suggest a focus on weight management practices based on
substantial evidence that obesity worsens reproductive and metabolic features of PCOS.
84
They further noted the important role of nutrition professionals to provide evidence-based
health care.
Conceptual Framework
The domains of the World Health Organization developed to determine QoL were
used as a framework for understanding the QoL of PCOS women diagnosed in their
reproductive years as they transition to menopause (Bonomi, et al, 2000). The QoL
domains are physical, psychological, social relationships and environment factors. In
addition, the framework for QoL encompasses a person’s physical health, psychological
condition, personal beliefs, social relationships, and relationships with the environment
(Monteleone et al., 2018; Ozkan, et al, 2005).
Considering the QoL dimensions, it is safe to conclude that participants in this
study were considerably affected in their physical health reporting low levels of QoL. The
results of the study found the most widely reported physical symptoms included weight
gain, joint pain, with balding and excessive hair in unwanted places seeming to be
particularly emotionally taxing for women. For instance, poor physical health was a
common complaint of all participants due to a history of obesity, diabetes and insulin
resistance that began in their reproductive years and worsened as they transitioned to
menopause. According to Deswal et al., (2022) noted women diagnosed with PCOS at
reproductive age have increased risk and prevalence of prediabetes and diabetes and have
multiple risk factors for cardiometabolic disease. In addition, the women all reported
varying degrees of joint and body pain, that affect their ability to perform activities of
daily living. Two of the participants were disabled and two stopped working during the
85
transition to menopause due to difficulty performing physically demanding jobs. Most of
the women reported feeling physically unsafe in their environments due to being obese
and experiencing frequent joint and body pain.
Similar to what was described regarding the physical QoL, the psychological
dimension was also affected. It can be concluded that participants reported a high level of
psychological suffering including issues of mood swings, depression, anxiety, and
selfesteem. For example, the cosmetic features, comorbidities associated with PCOS
affected the women self-perception, as they noticed same age friends were not having the
same experiences. The women struggled with poor psychological health beginning in
their reproductive years due to infertility, obesity, and the cosmetic features of PCOS. The
women reported feeling less than a woman due infertility and coping with masculine
features due to excessive facial and body hair. With the transition to menopause the
women experienced increased weight gain, mood swings, depression and anxiety. Four of
the women were diagnosed with mood disorders and prescribed psychotropic medication
to cope with the symptoms.
Limitations of the Study
The study is limited by using the online website, Craigslist, as the data collection
method to solicit volunteers. Initially, PCOS online supports groups were contacted as the
source of recruiting volunteers. However, there was no response from the members of the
four support groups that granted permission to post the flyer on their site. While the use
of Craigslist was mentioned as a limitation, it is relevant to notice that Craigslist can
provide an effective online method that allows social science researchers to recruit from a
86
wider range of people, especially with regards to stigmatized populations (Antoun et al.,
2016; Worthen, 2014).
Conducting the interviews online via Zoom can also be seen as a limitation of the
study. Face-to-face interviews would have allowed for more contact and observation of
the participants (Creswell, 2014). However, I was able to build rapport, and display
empathy during each session that seemed to ease participants’ anxiety in sharing very
personal information about their PCOS journey. It is relevant to mention that Archibald et
al. (2019), found that Zoom is a viable tool for collection of qualitative data because of its
relative ease of use and cost.
The study is limited by the participants’ perceptions of their experience as PCOS
menopausal women. In addition, the study is limited to the women in the study and may
not be transferable to other populations. Lastly, this is a one-time study with no
longitudinal follow-up. Therefore, I was not able to explore the presence or absence of
changes in perceptions over time.
Recommendations
Previous research found women with PCOS at reproductive age have increased
risk and prevalence of prediabetes, diabetes and multiple risk factors for cardiometabolic
disease and other comorbidities such as obstructive sleep apnea, endometrial cancer and
mood disorders, which contribute to the overall health burden of the syndrome (Bellever
et al, 2018; Deswal et al., 2022). The health risk for PCOS reproductive age women is
well-documented. However, little is known about the impact of PCOS on long-term
health in ageing women. This study explored the lived experienced of PCOS women
87
diagnosed in their reproductive years as they transition to menopause. The study revealed
that the women struggled with poor health related to obesity, diabetes, balding, excessive
hairiness (hirsutism), joint and body pain, and psychological distress. However, sparse
research for aging PCOS women makes it is difficult to determine how best to serve the
physical and psychological needs of aging PCOS women. Future research can
concentrate on how to support women suffering from physical and psychological issues
described in the study and how to encourage varied healthy lifestyles.
This study collected data from different online groups and Craigslist and relied on
participants’ self-report of PCOS diagnosis. Future studies may identify participants via
other sources and verify participants’ diagnosis with medical records. Additionally,
medical records could also serve as sources of data triangulation. Another
recommendation is the need for large, prospective studies on community-based and
wellphenotyped PCOS cohorts with extended follow-up into late menopause (Joham et
al.,
2022). Furthermore, future research should obtain clinical or biochemical confirmation of
PCOS status instead of relying on self-reports. Other data approaches are also needed to
determine the health risk associated with aging, transitioning to menopause and beyond.
Lastly, ethnic populations should be included in PCOS longitudinal studies to contribute
new knowledge to the natural history of PCOS.
Implications
PCOS is a lifelong endocrine condition with reproductive and metabolic
symptoms, and cosmetic features. The research literature indicates the primary focus of
88
PCOS research has been devoted to improving fertility in reproductive age women. The
fluctuating androgen levels that contribute to physical and psychological effects of the
disorder were thought to lessen as the women transition to menopause (Sharkeem et al.,
2021). Furthermore, the androgens do lessen with age but remain constant, causing
inflammation and worsens the health condition of PCOS menopausal women. This study
was conducted to gain an understanding of the physical and psychological well- being of
reproductive age women diagnosed with PCOS in their reproductive years as they
transition to menopause.
The women in this study struggled with diabetes, obesity, joint and body pain,
hairiness (hirsutism), balding and mood disorders. Thus, the findings of this study may
contribute to social change as health providers may use the results of this study to create
interventions and improve the lives of PCOS menopausal women. Health providers may
also use the results of this study to encourage healthy lifestyle habits for those identified
with PCOS at initial screening, which usually occurs during the reproductive years.
Furthermore, health providers’ encouragement of healthy lifestyle choices in the
reproductive years can foster social change by preventing the debilitating health
conditions associated with a PCOS diagnosis.
Counselors and clinicians who treat women presenting with psychological
symptoms associated with PCOS can use the results of this study to adjust treatment to
meet the women’s needs. Results of this study may also be used in recognizing and
addressing the challenges that women with PCOS experienced including stigma and
helplessness. Clinicians can become more aware of the long-lasting effects for women
89
with PCOS, an understanding of these effects is relevant in treating women with PCOS in
menopause. Additionally, clinicians working on psychoeducation and prevention can use
the information provided in this study as a basis to encourage the promotion of healthy
lifestyles for women with PCOS.
Conclusion
The purpose of this phenomenological study was to explore the perceptions and
lived experiences of women between the ages of 48–65 diagnosed with PCOS as they
transitioned to menopause. The women reported conditions such as irregular menses, or
no menstrual cycle for several months, acne and hairiness (hirsutism). Most of the women
were diagnosed with PCOS as newly married women seeking the advice of a physician
due to infertility while trying to become pregnant. The women struggled with obesity,
hairiness, and balding. Four women were diagnosed with mood disorders, two were
disabled and two were diagnosed with diabetes. They all reported a worsening of their
health conditions upon transitioning to menopause. Interventions by health providers to
address the health issues of PCOS menopausal women is needed. Future research should
focus on the health risks associated with menopausal women not addressed in this study
and the lived experience of a similar cohort of women post menopause.
References
Abdel-Gadier, A., Oyawoye, O. O., & Chander, B. P. (2009). Coexistence of polycystic
ovaries and uterine fibroids and their combined effect on the uterine artery blood
flow in relations to age and parity. Journal of Reproductive Medicine, 54 (6), 347
90
-352.
Acmaz, G. Albayrak, E. Acmaz, B., Baser, M., Soyak, M. A., Zararsiz, G., &
Ipekmuderis, I. (2013). Level of anxiety and, depression, self-esteem, social
anxiety and quality of life among the women with polycystic ovary syndrome.
Scientific World Journal, 2013, 1-v7. https://doi.org/10.1155/2013/851815
Anagnostis, P., Tarlatzis, B. C., & Kauffman, R. P. (2018). Polycystic ovarian syndrome:
Long-term metabolic consequences. Metabolism, 86, 33-43.
https://doi.org/10.1016/j.metabol.2017.09.016
Al-Jefout, M., Alnawaiseh, N., & Al-Qtaitat, A. (2017). Insulin resistance and obesity
among infertile women with different polycystic ovary syndrome phenotypes.
Scientific Reports, 7(1), 1-9. https://doi.org/10.1038/s4198-017-05717y
Akdoğan, M., Tamer, M. N., Cüre E, Cüre, M. C., Köroğlu, B. K., & Delibaş, N. (2007).
Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women
with hirsutism. Phytotherapy Research, 21(5), 444–451.
https://doi.org/10.1002/ptr.2074
Akilen, R., Tsiami, A., Devendraa, D., & Robinson, N. (2012). Cinnamon in glycemic
control: Systemic review and meta-analysis. Clinical Nutrition, 31 (5), 607 -615.
Albahar, A. (2015). A look at the epidemiology of PCOS and economic cost to healthcare
Polycystic Ovary Syndrome Conference. Endocrinology & Metabolic Syndrome,
4(4), pg.51. https://dx.doio.org//10.4172/2161-1017-c1.011
Anderson, S. A., Barry, J. A., Hardiman, P. J. (2014). Risk of coronary heart disease and
risk of stroke in women: A systematic review and meta-analysis. International
91
Journal of Cardiology, 176(2), 486 - 487
https://doi.org/10.1016/j.ijcard.2014.06.079
Amin, F. N., Tehrani, F. R., Simbar, M., Montazen, A., & Thamtan, R. A. M. (2014). The
experience of women affected by polycystic ovary syndrome: A qualitative study
from Iran. International Journal of Endocrinology and Metabolism, 12(2),
e13612. https://d01.org/10.5812/Item/13612.
Amiri, F. N., Tehrani, F. R., Simbar, M., Ali, R., Thamtan, M. & Shiva, N. (2014). Female
gender scheme is disturbed by polycystic ovary syndrome: A qualitative study
from Iran. Iran Red Crescent Medical Journal, 16 (2), e12423.
https://do1.org/10.52812/ircmj.1234.
Antoun, C., Zhang, C., Conrad, F. G., and Schober, M. F. (2016). Comparisons of online
recruitment strategies for convenience samples: Craiglist,Google AdWords,
Facebook and Amazon Mechanical Turk. Fields Methods, 28 (3), 231 – 246.
https://doi.10.11771525822X15603149
Appian, D., Schreiner, P. J., & Folsom, A. R. (2016). Association of age at menopause
with incident of heart failure: A prospective cohort study and meta-analysis.
Journal of American Heart Association, 5(8) e003709.
http://doi.org/10.61/jaka.116.003769.
Apridonidze, T., Essahm P., Iuorna, M. J., & Nestor, J. E. (2005). Prevalence and
characteristics of the metabolic syndrome in women with polycystic ovary
syndrome. Journal of Clinical Endocrinology & Metabolism, 90 (4), 1929 - 1935.
92
https://doi.org/10.1210/jc.2004-1045.
Archibald, M. M., Ambagtsheer, R. C. Casey, M. G., and Lawless, M. (2019). Using
Zoom videoconferencing for qualitative data collection: Perceptions and
experiences of researchers and participants. International Journal of Qualitative
Methods, 18, https://doi.org/10.1177/1609406919874596.
Arentz, S., Abbott, J. A., Smith, C. A., Bennsoussan, A. (2014). Herbal medicine for the
management of polycystic ovary syndrome (PCOS) and associated
oligo/amenorrhea and hyperandrogenism: A review of the laboratory evidence for
effects with corroborative clinical findings. BMC Complement Alternative
Medicine, 14, 511 (2014). https://doi.org/10.1186/1472-6882-14-511
Arm, N., & Abdel-Rahim, H. E. (2015). The effect of chromium supplementations on
polycystic ovary syndrome in adolescents. Journal of Pediatric Adolescent
Gynecology, 28(2), 112–118. https://doi.org/10j-pag.2014.05.005
Asp, M., Lindqvist, D., Fernström, J., Ambrus, L., Tuninger, E., Reis, M., & Westrin, Å.
(2020). Recognition of personality disorder and anxiety disorder comorbidity in
patients treated for depression in secondary psychiatric care. PloS One, 15(1),
e0227364. https://d01.org/10.1371/journal.pone.0227364
Ataabadi, M. S., Alaee S., Bagheri, M. J. & Bahmanpoor, S. (2017). Role of essential oil
of Mentha Spicata (spearmint) in addressing reverse hormonal and
folliculogenesis disturbances in a polycystic ovarian syndrome in a rat model.
Advanced Pharmacy Bulletin, 7(4), 651–654.
https://doi.org/10.15171/apb.2017.078.
93
Audette, J. F., Jin Y. S., Newcomer, R., Stein L., Duncan G. & Frontera, & W. R. (2006).
Tai Chi versus brisk walking in elderly women. Age & Ageing, 35, 388-393.
Avery, J., Ottey, S., Morman, R., Cree-Green, M., & Gibson-Helm, M. (2020). Polycystic
Ovary Syndrome support groups and their role in awareness, advocacy and peer-
support: a systematic search and narrative review. Current Opinion in
Endocrine and Metabolic Research, 12, 98 -104.
https://doi.org/10.1016/j.coemr.2020.04.008
Azizia, B. J., & Hardiman, P. J. (2014) Risk of endometrial, ovarian, and breast cancer in
women with polycystic ovary syndrome: A systematic review and meta-analysis.
Human Reproduction, 20 (5), 748-758.
Azziz, R., Carmina E, Dewailly D., Diamanti-Kandarakis, E., Escobar-Morreale H. F.,
Futterweit, W., Janssen, O. E., Legro R. S., Norman, R. J., Taylor, A. E., &
Witchel, S. F. (2006). Position statement criteria for defining polycystic ovary
syndrome as predominantly hyperandrogenic syndrome: An Androgen Excess
guideline. Clinical Endocrinology Metabolic, 91(11):4237-4245.
Azziz, R. (2018). Polycystic ovary syndrome. Obstetrics & Gynecology, 132(2), 321-336.
https://doi.org/10.1097/AOG.0000000000002698.
Bakken, K., Fournier, A., Lund, E., Wasaseth, M., Dumeaux, V., Clavel-Chapelon, F.,
Fabre, A., Hemon, B., Rinaldi, S., Chajes, V., Slimani, N., Allen, N. E., Reeves,
G. K., Bingham, S., Khaw, K. T., Olsen, A., Tjonneland, A., Rodriquez, L.,
Sanchez, M. J.,...& Berrino, F. (2010) Menopausal hormone therapy and breast
cancer risk: Impact of different treatment: The European prospective investigation
into cancer and nutrition. International Journal of Cancer, 128 (1), 144-156.
94
Baldani, D. P., Skrgatic, L., & Ougouag, R. (2015). Polycystic ovary syndrome:
Important underrecognized cardiometabolic risk factor in reproductive age
women. International Journal of Endocrinology, 2015 (2015), 1- 17.
Barnard L., Ferriday D., Guenther N., Strauss B., Balen, A. H., & Dye, L. (2007). Quality
of life and psychological well-being in polycystic ovary syndrome. Human
Reproduction, 22, 2279–2286. https://doi.org/10.1093/humrep/dem108.
Barry, J. A., Azzizia, M. M., & Hardiman, P. J. (2014). Risk of endometrial, ovarian and
breast cancer in women with polycystic ovary cancer: A systematic review and
meta-analysis. Human Reproduction Update, 20 (5), 748 – 758.
Barrea, L., Muscogiuri, G., Pugliese, G., de Alterius, G., Colao, A., and
Savastrano, S. (2021). Metabolically Healthy Obesity (MHO) vs. Metabolically
Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with
EndocrineMetabolic Profile, Adherence to the Mediterranean Diet, and Body
Composition.
Nutrients, 2;13(11):3925. https://doi.10.3390/nu13113925.
Barry, J. A., Kuczmierczyk, A. R., & Hardiman, P. J. (2011) Anxiety and depression in
Polycystic Ovary Syndrome: A systematic review and meta-analysis. Human
Reproduction, 26 (9), 2442 – 2451.
Barthelmess, E. K. & Naz, R. K. (2014). Polycystic ovary syndrome: Current and future
perspectives. Frontiers Bioscience (Elite Ed.),6,104 -119.
95
Basirat, Z., Faramarzi, M., Esmaelzadeh, S., Abedi, S., Firooziai, M., Mahouti, B., &
Geraili, Z. (2019). Stress, depression, sexual function, and alexithymia in infertile
females with and without polycystic ovary syndrome: a case-control study.”
International Journal of Fertility & Sterility,13 (3), 203 – 208. doi:
10.22074/ijfs.2019.5703
Basu, A., Du, M., Sanchez, K., Leyva M. J., Betts, N. M., & Blevins S., Wu, M., Aston,
A., & Vons, T. J. (2011). Green tea minimally affects biomarkers of inflammation
obese subjects with metabolic syndrome. Nutrition, 27(2), 206-213.
Bazarganipur, F., Taghavi, S., Montazeri, A., Fazollah, A., Reza, C., & Khosravi, A.
(2015). The impact of reproductive medicine on health-related quality of life: A
systematic review and meta-analysis. Iran Journal of Reproductive Medicine, 13
(2), 61-70.
Behboodi -Moghagam, Z., Fereidooni, B., Moghadana, S., Mohsen, S. & Montazeir, A.
(2018). Measures of health-related quality of life in pcos women: A systematic
review. International Journal of Women’s Health, 10, 397-408.
Behboudi‐Gandevani, S., Amiri, M., Bidhendi Yarandi, R., Noroozzadeh, M.,
Farahmand, M., Rostami Dovom, M., & Ramezani Tehrani, F. (2018). The risk of
metabolic syndrome in polycystic ovary syndrome: A systematic review and
meta‐analysis. Clinical endocrinology, 88(2), 169-184.
https://d01.org/10.1111/cen.13477.
Bellever, J., Reodriquez – Tabemer, L., Reobeles, A., Munoz, E., Martinez, F., Landeras,
J., Garcia-Velasco, J., Fontes, J., Alvarez, M., Alvarez, C., & Acevedo, B. (2018).
96
Polycystic ovary syndrome throughout a woman’s life. Journal of Assisted
Reproduction Genetics, 35, 25 – 39. https://doi.org/10.1007/s10815-017-1047-7.
Bienenfeld, A., Azarchi, S., Sicco, K. L., Marchbein, S., Shapiro, J., & Nagler, A. R.
(2019). Androgens in women: Androgen-mediated skin disease and patient
evaluation. Journal of the American Academy of Dermatology, 80(6), 1497-1506.
https://doi.org/10.1016/j.jaad.2018.08.06.2
Blay, S. L., Aguiar, J. V. A., & Passos, I. C. (2016). Polycystic ovary syndrome and
mental disorders: A systematic review and exploratory meta-analysis.
Neuropsychiatric Disease Treatment, 2016 (12), 2895 – 2903.
Bonadonna, R. (2003) Meditation’s impact on chronic illness. Holistic Nursing Practice,
17, 309-319.
Bonomi, A., Patrick, D., Bushnell, D., & Martin, M. (2000). Validation of the United
States’ version of the World Health Organization Quality of Life (WHOQOL)
instrument. Journal of Clinical Epidemiology, 53, 1-12.
https://doi.org.10.1016/S0895-4356(99)00123-7.
Boulman, N., Levy, Y., Lebia, R., Shachar, S., Linn, R., Zinder, O., & Blumefeld, Z.
(2004). Increased C-reaction protein levels in polycystic ovary: A marker of
cardiovascular disease. Journal of Clinical Endocrinology & Metabolism, 89,
2160-2165. 21282136. https://doi.org/10.1152/japplphysoi.00683.
Brakat, S., Lizneva, D., Mykhalchenko, K., Iman, A., Walker, W., Diamond, M. &
Aziza, R. (2017). Perspectives on Polycystic Ovary Syndrome research
97
underfunded. Journal of Clinical Endocrinology of Metabolism, 102(2), 4421 –
4427. https://doi.org/10.1210/jc.2017- 0415.
Brand, J. S., Vander, S., Onland-Moret, C. N., Sharp, S. J., Ong, K. K., Khaw, K. T.,
Ardanaz, E., Amiano, P., Boeing, H., Chirlaque, M. D., Chavel-Chapelon, F.
Crowe, F. L., de lauzon- Guillan, B., Duell, E. J., Fagherazzi, G., Franks, P. W., ,
Groop, L. C., Kaaks, R., Key, T.,…. & Overvad, K. (2013). Age at menopause,
reproductive life span and type 2 diabetes risk: Results from the EPIC InterAct
Study. Diabetic Care, 36 (4), 1012-1019. https://doi.org/10.2337/dc12-1029.
Braun, V. & Clarke, V. (2006) Using thematic analysis in psychology. Qualitative
Research in Psychology, 3(2): 77–101.
Brennan, L., Teede, H., Skouteris, H., Linardon, J., Hill, B, & Moran, L. (2017). Lifestyle
and behavioral management of polycystic ovary syndrome. Journal of Women’s
Health, 26 (8), 836-849. https://doi.org/1089/jwh.2016.5792
Bromberger, J. T. & Epperson, Neill (2018). Depression During and After the
Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants
of Disease. Obstetric Gynecology Clinics of North America, 45(4),663-678.
Bromberger, J. T., Schott, L., Kravitz, H. M. & Joffe, H. (2015). Risk factors for major
depression during midlife among a community sample of women with and
without prior major depression: Are they the same or different? Psychological
Medicine, 45 (8), 1653 – 1664. https://doi.org/10.1017/S0033291714002773.
Bromberger, J. T., & Epperson, C. N. (2018). Depression During and After the
Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants
98
of Disease. Obstetrics and gynecology clinics of North America, 45(4), 663–678.
https://doi.org/10.1016/j.ogc.2018.07.007.
Brower, M., Brennan, K., Pall, M., & Azziz, R. (2013). The severity of menstrual
dysfunction as a prediction of insulin resistance in PCOS. Journal of Clinical
Endocrinology and Metabolism, 98 (13), E1967-E1971.
Brutocao, C., Zaiem, F., Alsawas, M., Morrow, A. S., Murad, M. H., & Javed, A. (2018)
Psychiatric disorders in women with polycystic ovary syndrome: a systematic
review and meta-analysis. Endocrine, 62, 318–325.
https://doi.org/10.1007/s12020-018-1692-3
Carmina, E. (2014) Polycystic ovary syndrome: Metabolic consequences of long-term
management. Scandinavian Journal of Clinical Laboratory Investigation
Supplement, 74, 244: 23 – 26, discussion 26.
https://doi.org./10.3109/00365513.2014.936676.
Carmina, E., Campagna, A. M., & Lobo, R. A. (2012). 20-year follow-up of young
women with Polycystic Ovary Syndrome. Obstetrics & Gynecology, 119 (2 pt1),
263-269.
Carmina E., Bucchier,, Manueto, P., Rinig, G., Ferin, M., & Lobo, R. A. (2009).
Circulating levels of adipose products and differences in fat distribution in the
ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertility
and Sterility, 4 (supl 1), 1332 – 135.
Carmina, E., Chu, M. C., Moran, C., Tortorieu, D., Vardhana, P., Tena, G., Preciado, R.,
& Lobo, R. (2008). Subcutaneous and omental fat expressions of adiponectin and
99
leptin in women with polycystic ovary syndrome. Fertility, 89 (3), 642 – 648.
http://doi.org/10.1016/j.fernstert.2007.03.085.
Carmina, E., Legro, R. S., Stamets, K., Lowell, J., & Lobo, R. A. (2003). Difference in
body weight between American and Italian women with polycystic ovary
syndrome: Influence of diet. Human Reproduction, 18 (11) 2289-2293.
Carmina, E., Koyama, T., Chang, I., Stanczyk, F. Z., Lobo, R. A. (1992). Difference in
body weight between American and Italian women with polycystic ovary
syndrome: Influence of diet. Human Reproduction, 167 (6), 1807 – 1812.
Carvalho, M. J., Subtil, S., Rodrigues, Â., Oliveira, J., & Figueiredo-Dias, M. (2019).
Controversial association between polycystic ovary syndrome and breast cancer.
European Journal of Obstetrics & Gynecology and Reproductive Biology, 243,
125-132. https://doi.org10.1016/j.ejogrb.2019.10.011..
Castello-Branco, C. & Naumova, I. (2020). Quality of life and sexual in function in
women with polycystic ovary syndrome: a comprehensive review. Gynecological
Endocrinology, 36 (2), 96-103.https://doi.org10.1080/09513590.2019.1670788.
Celik, Ö. and Kose, M. F. (2021). An overview of polycystic ovary syndrome in aging
women. Journal of Turkish-German Gynecological Association, 22: 326-33.
http://do1.10.4274/jtgga.galenos.2021.2021.0077.Centers for Disease Control and
Prevention (2017). PCOS and diabetes, heart disease and
strokehttps://www.cdc.gov/diabetes/library/spotlights/pcos.html.
Chan, C. C., Koo, M. W., Ng, E. H., Tang, O. S., Yeung, W. S., & Ho, P. C. (2006).
Effects of Chinese green tea on weight, and hormonal and biochemical profiles in
100
obese patients with polycystic ovary syndrome- a randomized placebo-controlled
trial. Journal of the Society for Gynecologic Investigation, 13(1), 63-68.
Chaudhari, A. P., Mazumdar, K., & Mehta, P. D. (2018). Anxiety, depression, and quality
of life in women with polycystic ovarian syndrome. Indian journal of
psychological medicine, 40(3), 239-246.
Chau, T. T., Teede, H. J., H., B., Loxton, D., & Joham, A. E. (2019) Increased prevalence
of eating disorders, low self-esteem, and psychological distress in women with
polycystic ovary syndrome: a community-based cohort study. Fertility and
Sterility, 112 (2), 353-361.
Chazenbalk, G., Trivax, B., Yildiz, B. O., Bertolotto, C., Mathar, R., Hemeidi, S. &
Riccardo, A. (2010). Regulation of adiponectin secretion by adipocytes in
polycystic ovary syndrome: Role of tumor necrosis factor-analysis. Journal of
Clinical Endocrinology & Metabolism, 95 (2), 934 -942.
Chedraui, P., & Pérez-López, F. R. (2019). Metabolic syndrome during female midlife:
what are the risks? Climacteric, 22(2), 127-132.
https://doi.org/10.1080/13697137.218.156166.
Chen, M. H., Su, T. P., Chang, W. H., Chen, T. J., & Bai, Y. M. (2013). Systematic
menopausal transitioning increasing the risk of new-onset depressive disorder in
later life: A nationwide prospective cohort study in Taiwan. Public Library of
Science One, 8 (3), https://doi.org/101371/journal.pone.0059899.
Chiesa, A. & Serretti, A. (2009) Mindfulness-based stress reduction for stress
management in healthy people: a review and meta-analysis. Journal of Alternative
101
& Complementary Medicine,15, 593-600.
Christian, R. C., Dumesic, D. A., Behrenbeck, T., Oberg, A. L., Sheedy, P. F., Fitzpatrick
L. (2003). Prevalence and predictors of coronary artery calcification in women
with polycystic ovary syndrome. Journal of Clinical Endocrinology &
Metabolism, 88 (6) 2562-2568.
Cinar, N., Kizilanoglu, M. C., Harmanci, A., Bozdag, G., Demir, B., & Yildiz, B. O.
(2011). Depression, anxiety and cardiometabolic risk in Polycystic Ovary
Syndrome. Human Reproduction, 26 (12), 3339 – 3345.
Clarke, V., & Braun, V. (2018). Using thematic analysis in counselling and psychotherapy
research: A critical reflection.” Counselling and Psychotherapy Research 18, (2),
107-110.
Comijs, H. C., Nieuwesteeg, J., Kak, R., van Marwijk, H., van der Mast, Naarding, P.,
Onde-Voshaar, R., Verhaakm P., de Waal, M., & Stek, M. L. (2015). The twoyear
course of late life depression: Results from the Netherlands study of depression.
Bio Med Central Psychiatry, 15 (20), 1 – 9.
Comim, F. V., Wippel, C. S., Langer, F. W., Carvalhjo, J. M., Moresco, R. N., & Premaor,
M. O. (2017). High prevalence of clinical cardiovascular comorbidities in post –
menopausal women with self-reported premenopausal hirsutism and oligo-
menorrhea. Dermatoendocrinology, 22 (1), 1356517.
https://doi.org/1080/1938/980.2171356517.
Cooney, L., Lee, I., Sammel, M. D., Dokras, A. (2017). High prevalence of moderate and
severe depressive and anxiety symptoms in polycystic ovary syndrome: a
102
systematic review and meta-analysis. Human Reproduction, 32 (5), 1075 – 1091.
https://doi.org/humrep/dex044.
Connelly, L., Pittman, M. (2016). Trustworthiness in Qualitative Research, Medsurg
Nursing, 25(6), 435 – 436.
Creswell, J. W. (2013a). Qualitative inquiry and research design (3rd ed). In Qualitative
inquiry and research design: Choosing among five approaches, pp (82). Los
Angeles, CA: Sage Publications Inc.
Creswell, J. W. (2013b). Qualitative inquiry and research design: Choosing among five
approaches (3rd ed.), Los Angeles, CA: Sage Publications Inc.
Creswell, J. (2014). Research design: Qualitative, quantitative, and mixed methods
approaches (4th ed). SAGE Publications.
Cronin, L., Guyatt, G., Griffith, E., Wong, R., Azziz, W., Futterweit, D., Cook, D., &
Dunaif, A. (1998). Development of a Health-Related Quality-of-Life
Questionnaire (PCOSQ) for Women with Polycystic Ovary Syndrome (PCOS).
Journal of Clinical Endocrinology and Metabolism, 83(6), 1976-1987.
Daley, A. MacArthur C. McManus R., Stokes-Lampard, Wilson, S., Roalfe, A, & Mutrie,
N. (2006). Factors associated with the use of complementary medicine and
nonpharmacological interventions in symptomatic menopausal women.
Climacteric, 9, 336-346. www.https//doi.10.1080/13697130600864074.
Davis, A., Christiansen, A., Horowitz, J. F., Klein, S., Hellerstein, M. K. & Ostlund, R. E.
(2000). Effect of pinitol treatment on insulin action in subjects with insulin
103
resistance. Diabetes Care, 23 (7), 1000 – 1005.
www.https://doi.org/10.2337/diacare.23.7.1000.
Dapas, M., Lin, F. T., Nadkarni, G. N., Sisk, R., Legro, R. S., Urbanek, M., Hayes, G., &
Dunaif, A. (2020). Distinct subtypes of polycystic ovary syndrome with novel
genetic associations: An unsupervised, phenotypic clustering analysis. Public
Library of Science Medicine, 17(6), e1003132.
https://doi.org/10.1371/journal.pmed.1003132
Deakin, H., & Wakefield, K. (2013) Skype interviewing: Reflections of two PhD
researchers. Qualitative Research. Epub ahead of print 24 May. https://doi.org/
10.1177/1468794113488126.
de Lima Nunes, R., Dos Santos, I. K., Cobucci, R. N., Pichini, G. S., Soares, G. M., de
Oliveira Maranhão, T. M., & Dantas, P. M. S. (2019). Lifestyle interventions and
quality of life for women with polycystic ovary syndrome: A systematic review
and meta-analysis protocol. Medicine, 98(50).
https://doi.org/10.1097/MD.0000000000018323.
de Medeiros, S. F., Yamamoto, M. M. W., de Medeiros, M. A. S., Barbosa, B. B., Soares,
J. M., & Baracat, E. C. (2020). Changes in clinical and biochemical characteristics of
polycystic ovary syndrome with advancing age. Endocrine connections, 9(2), 74-89.
http://doi.org/10.1530/EC-19-0496. de Lignieres, B. (1992). Oral micronized
progesterone. Clinical Therapeutics, 21(1), 41-
60. www.https//doi.org.10.1016/s0149-2918(00)88267-3.
Dennerstein, L., Smith, A. M., Morse C., Burger, H., Green, A., Hopper, J., & Ryan, M.
104
(1993) Menopausal symptoms in Australian women. The Medical Journal of
Australia,159, 232-236.
Deswal, R., Narwal, V., Dang, Amita, & Pundir, C. S.(2020) The Prevalence of
Polycystic Ovary Syndrome: A Brief Systematic Review, Journal of Human
Reproductive Science, 13(4): 261–271. doi: 10.4103/jhrs.JHRS_95_18.
Diamanti-Kandarakis, E. & Dunaif, A. (2012). Insulin resistance and polycystic ovary
syndrome Revisited: An update on mechanisms and implications. Endocrine
Review, 33(6), 981 – 1031. https://doi.org/10.1210/er.2011-1034.
Dokras, A., Stener-Victorin, E., Yildiz, B. O., Li, R., Ottey, S., Shah, D., Epperson, N., &
Teede, H. (2018). Androgen Excess-Polycystic Ovary Syndrome Society: position
statement on depression, anxiety, quality of life, and eating disorders in polycystic
ovary syndrome. Fertility and sterility, 109(5), 888-899.
https://doi.org/10.1016/j.fertnstert.2018.01.038.
Dokras, A., Sarwer, D. B., Allison, K. C., Miliman, L., Kris-Etherton, P. M., Kunnelman,
A. R., Sarwer, D. B., Allison, K. C., & Legro, R. S. (2016). Weight loss and
lowering androgens predict improvements in health-related quality of life in
women with PCOS. Journal of Clinical Endocrinology and Metabolism. 101(8)
2966-2974. https://doi.org/10.1210/c.201-1896.
Dokras, A., Clifton, S., Futterweit, W., & Wild, R. (2013). Increase prevalence of anxiety
symptoms in women with Polycystic Ovary Syndrome: A systematic review and
metal analysis. Fertility and Sterility, 97 (1), 225 – 230.ec.
105
Dokras, A., Clifton, S., Futterweit, A., & Wild, R. (2011). Increased risk for abnormal
depression scores in women with Polycystic Ovary Syndrome: A systematic
review and meta- analysis. Obstetric Gynecology, 117, (1) 145 – 152).
Doretto, L., Mari, F. C., & Chaves, A. C. (2020). Polycystic Ovary Syndrome and
Psychotic Disorder. Frontiers in Psychiatry, 11, 543.
https://doi.org/10.3389/fpsyt.2020.00543
Douglas, C. C., Moran, L., Noakes M, Grower, B. A., Darnell, B. E., Ovalle, F., Oster, R.
& Azziz, R. (2006). Role of diet in the treatment of polycystic ovary syndrome.
Fertility and Sterility, 85(3), 679-688.
Dumesic, D. A., Oberfield, S. E., & Legro, R. S. (2015). Scientific statement on the
diagnostic criteria. Epidemology, pathophysiology and molecular genetic of
polycystic ovary syndrome. Endocrine Review, 36 (5), 487 -525.
https://doi.org/10.1210/er.2015-1018.
Ehrmann, D. A, (2005). Polycystic ovary syndrome. New England Journal of Medicine,
352 (12), 1223 – 1236.
Elsenbruch S., Benson S., Hahn S., Tan S., Mann K., Pleger K., Kimmig, R., Janssen, &
O. E. (2006). Determinants of emotional distress in women with polycystic ovary
syndrome. Human Reproduction, 21, 1092–1099.
https://doi.org/10.1093/humrep/dei409.
Emeksiz, H. C., Bideci, A., Nalbantoğlu, B., Nalbantoğlu, A., Celik, C., Yulaf, Y.,
Camurdan, M. O. & Cinaz, P. (2018). Anxiety and depression states of
106
adolescents with polycystic ovary syndrome. Turkish journal of medical sciences,
48(3), 531-536.
Enjezab, B., Eftekhar, M., & Ghandiri-Amari, A. (2017). Associate between severity of
depression and clinical – biochemical markers of polycystic ovary syndrome.
Electronic Physician, 9 (11), 5820 – 5825. https://doi:10.19082/5820.
Escobar -Morreale, H. F., Carmina, E., & DeWailly, D. (2012). Epidemology diagnosis
and management of hirsutism Consensus Statement by Androgen Express
guideline. Human Reproduction Update, 18 (2) 146 – 170.
Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, etiology,
diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270.
Ezeh, U., Pall, M., Mather, R., Dey, D., Berman, D., Chen, I. Y., Dumesic, D. A., &
Azziz, R. (2013). Effects of endogenous androgens and abdominal fat distribution
on interrelationship between insulin and non-insulin mediated glucose uptake in
females. Journal of Clinical Endocrinology Metabolism, 98 (4), 1541- 1548.
Ezeh, U., Chen, I. Y., Chen, Y. H., & Azziz, R. (2020). Adipocyte Insulin Resistance in
PCOS: Relationship With GLUT-4 Expression and Whole-Body Glucose
Disposal and β-Cell Function. The Journal of Clinical Endocrinology &
Metabolism, 10 (7), e2408-e2420.
Fact Sheet: General facts on women and job-based health available at
www.http:doi.gov/ebsa/newsroom/fshlt5.accessedjuly22,2016.
Fauser, B. C., Tariatzis, B. C., Rebar, R. W., Legro, R., Balen, Lobo, R., A., Camina, E.,
Chang, J., Yildiz, B., Laven, J. S., Boivin, J., Petraglia, F., Wijeyaratne, C. N.,
107
Norman, R. J., Dunaif, A., Franks, S., Wild, R. A., & Barnhart, K., (2012).
Consensus on women’s health aspect of polycystic ovary syndrome (PCOS). The
Amsterdam ESHRE/ASRM sponsored 3rd PCOS Consensus Workshop.
,97(1):28-38 e25. https://doi.org/10.1016/j.fertnstert.2011.09.204
Fourier, A., Fabris, A., Mesrine, S., Boutron-Rualt, M. C., Benrino, F. & ClavelChapelon,
F. (2008). Use of different post-menopausal hormone receptor defined invasive
breast cancer, Journal of Clinical Oncology, 26 (8), 1260-1268.
www.https//doi.10./200/jco.2007.
Freedman, R. R. (2005). Hot flashes: behavioral treatments, mechanisms, and relation to
sleep. American Journal of Medicine, 118, 124-130
Freeman, E. W., Sammel, M. D., Boorman, D. W., & Zhang, R. (2014). The longitudinal
pattern of depressive symptoms around natural menopause. Journal of the
American Medical Association, 71 (1), 36 – 43.
https://doi.org/10.100/jamapsychiatry, 2013.2819.
Fulghesu, A. M., Campbell, M., & Muyzj, G. & Lanzone, A. (2002). N-Acetyl- cysteine
treatment improves insulin sensitivity in women with polycystic ovary syndrome.
Fertility & Sterility, 77 (6), 1128-1135. http://doi.org/10.1014/s0015-
0282(02)03133-3.
Galletly, C., Morran, L., Noakes, M., Clifton, P., Tomlinson, L., & Norman, R. (2007).
Psychological benefits of high-protein, low-carbohydrate diet in obese women
with polycystic ovary syndrome- A pilot study. Appetite, 49 (3), 590-593.
108
Ganapathy, T., & Al Furaikh, S. S. (2018). Health-related quality of life among
menopausal women. Archives of Medicine and Health Sciences, 6(1), 16.
http://doi.org.10.4103/amhs.amhs12217.
Gholami, A., Aragh, M. I., Shamsabad, F., Bayat, M., Dabirkhani, F., Mansori, K.,
Moradi, K., & Rajabi, A., (2016). Application of World Health Organization Quality of
Life instrument, Short Form (WHOQOL-BREF) to patients with cataracts. Epidemology
Health, 38, e206005.
https://doi.org/10.4178/3pih.e2016005.
Gilbert, E. W., Tay, C. T., Hiam, D. S., Teede, H. J., & Moran, L. J. (2018).
Comorbidities and complications of polycystic ovary syndrome: An overview of
systematic reviews. Clinical Endocrinology, 89(6), 683-699.
Glintborg, D., Rubin, K. H., Nybo, M., Abrahamsen, B., & Andersen, M. (2018)
Cardiovascular disease in a nationwide population of Danish women with
polycystic ovary syndrome, Cardiovascular Diabetology, 17 (37).
https://doi.org/10.1186/s12933-018-0680-5.
Goa, I., & Zhoa, F. L. (2012) Statin is a reasonable treatment for patient with polycystic
ovary syndrome: A meta-analysis of randomized controlled trials. Experimental
Clinical Endocrinology Diabetes, 120 (6) 367 – 375.
https://doi.org10.1055/s0032-1304619.
Gobbens, R. J. J., & Remmens, R. (2019). The effects of sociodemographic factors on
quality of life among people age 50 years or older are not equivocal: Comparing
109
SF-12, WHOQOL-BREF and WHOOLD-OLD. Clinical Interventions in Aging.
4, 231-239.
Goodman, N. F., Gobin, R. H., Futtrweit, W., Guterwelt, J. S., Legro, R. S., & Carmina,
E. (2015). American Association of clinical endocrinology, American College of
Endocrirnolgy, and androgens excess and pcos society disease state Clinical
review: Guide to bet practices in evaluation and treatment of polycystic
syndrome-part 1. Endocrinology Practice, 2 (11), 1291-1300.
https://doi.org/10.4158/EP15148.DSC.
González, F., Considine, R. V., Abdelhadi, O. A., & Acton, A. J. (2020). Inflammation
triggered by saturated fat ingestion is linked to insulin resistance and
hyperandrogenism in polycystic ovary syndrome. The Journal of Clinical
Endocrinology & Metabolism, 105(6), e2152-e2167.
Gordon, J. L. Rubinow, D. R., Eisenlohr-Moul, T. A., Lesserman, J. & Girdler, S. S.
(2016). Estradiol variability, stressful life events and the emergence depressive
symptomology during menopause. Menopause, 23 (3), 257 – 266.
https://doi.org/10.1097/GME.00000000000528.
Gottschau, M., Kajer, S. K., Jensen, A., & Mellenenkjaeb, L. (2005). Risk of cancer
among women with Polycystic Ovary Syndrome. A Danish Cohort Study.
Gynecological Oncology, 136 (1), 99 -103.
https://doi.org/10.1016/j.pgyno.201411012.
110
Gnawali, A., Patel, V., Cuello-Ramirez, A., Alkaabi, A., Noor, M. Rashid, M.Y. , Henin,
S. &, ..Mostafa, J. A. (2021). Why are Women with Polycystic Ovary Syndrome
at Increased Risk of Depression? Exploring the Etiological Maze. Cureus,
13(2):e13489. https://doi: 10.7759/cureus.13489.
Grant P. (2010). Spearmint herbal tea has significant anti-androgen effects in polycystic
ovarian syndrome. A randomized controlled trial. Phytotherapy Research, 24(2),
186–194.
Gu, Y., Zhou, G., Zhou, G., Wu, O., Ma, C., Zhang, Y., Ding, J., and Hua, K. (2022).
Life Modifications and PCOS: Old Story But New Tales. Frontiers in
Endocrinology, 13;13:808898.https://doi: 10.3389/fendo.2022.808898
Gupta, G., & Kumari, R. (2021). Quality of life among menopausal women. Indian
Journal of Scientific Research, 11(2), 25-32
Gurka, M. J., Vishnu, A., Santen, R., & DeBoer, M. D. (2016). Progression of metabolic
syndrome severity during menopause. American Heart Association, 5 (18),
e003609. https://doi.org/10.1161/jaha.1161.003609.
Guyatt, G., Weaver, B., Cronin, L., Dooley, J. A., & Azziz, R., (2004). Health-related
quality of life in women with Polycystic Ovary Syndrome, self-administered
questionnaire was validated. Journal of Clinical Epidemology, 57 (12), 1279 –
1287.
Guest, G., Bunce, A., & Johnson, L, (2006). How many interviews are enough? An
experiment with data saturation and variability. Field Methods, 18 (1), 59–82,
https://doi.org//10.1177/1525822X05279903.
111
Hadjiconstantinou, M., Mani, H., Patel, N., Levy, M., Davies, Khunti, K., & Stone, M.
(2017). Understanding and supporting women with polycystic ovary syndrome: A
qualitative study in an ethnically diverse U. K. sample. Endocrine Connections, 6
(5), 323 – 330. https://doi.org/10.1530/ec-17-0053.
Hahn S., Tan S., Elsenbruch, S., Quadbeck B., Herrmann B. L., Mann K., & Janssen, O.
E. (2005). Clinical and biochemical characterization of women with polycystic
ovary syndrome in North Rhine-Westphalia. Hormone Metabolic Research 37,
438–444. https://doi.org/10.1055/s-2005-870236
Haigh, E. A., Bogucki, O. E., Sigmon, S. T., & Blazer, D. G. (2018). Depression among
older adults: a 20-year update on five common myths and misconceptions. The
American Journal of Geriatric Psychiatry, 26(1), 107-122.
Halberg, N., Henriksen, M., Soderhomin, N., Stalknecht, B., Ploug, T., Schjerlong, P., &
Flemming, D. (2005). Effects of fasting and refeeding on insulin action in healthy
men. Journal of Applied Physiology, 6 ,2128-2136.
https://doi.org/10.1152/japplphysoi.00683.
Hallajzadeh, J., Karamzad, M., Almasi-Hashiani, Janat, A., Ayubi, E., Pakzad, R., &
Sulliman, M. J. (2018). Metabolic syndrome and its components among women
with polycystic ovary syndrome: a systematic review and meta-analysis. Journal
of Cardiovascular and Thoracic Research, 10(2), 56-69.
https://doi.org/10.15171/jcvtr.2018.10.
112
Hart, R., Doherty & D. A. (2015). The potential implications of a PCOS diagnosis on a
woman’s long-term health using data linkage. Journal of Clinical Endocrinology
& Metabolism, 100, 911–919. https://doi.org.10.1210/jc.2014-3886.
Hasin, D., S., Goodwin., R., D., Stinson, F. S., & Grant, B. F. (2005). Epidemology of
major depression disorder: Results from the National Epidemology Survey on
alcoholism and related conditions. Archives of General Psychiatry, 10, 1097 –
1106.
Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., Jung,
J,, Zang, H., & Grant, B. F. (2016). Prevalence and correlates of DSM-5 cannabis
use disorder, 2012-2013: findings from the National Epidemiologic Survey on
Alcohol and Related Conditions–III. American Journal of Psychiatry, 173(6),
588-599.
Haugen, R. P., & Glintborg, D. (2013). Overweight in polycystic ovary syndrome: An
update on evidenced-based advice in diet, exercise and metformin use for weight
loss. Minerva Endocrinology, 38 (1), 59 -76.
Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G. & Daoud, G. (2016). Polycystic ovary
syndrome: An updated overview. Frontiers in Physiology, 7 (124), 1 – 15.
https://doi.org/10.3389/fphys.2016.00124.
Helvaci, N. & Bulent, O. Y. (2020). Polycystic ovary syndrome and aging: Health
implications after menopause. Maturitas, 139, 12-19.
https://doi.org/10.1016/jmaturitas.2020.05.013.
Henson, M. and Kulkarni, J. (2022). Hormonal Agents for the Treatment of Depression
113
Associated with the Menopause. Drugs and Aging, 39:607–618.
https://doi.org/10.1007/s40266-022-00962
Helvaci, N., and Yildiz, B. O. Yildiz (2022). The impact of ageing and menopause in
women with polycystic ovary syndrome. Clinical Endocrinology, 97(3), 371 –
382. https://doi.org/10.1111/cen.14558.
Hickey M., Schoenaker, D. A., Joffe H., Mishra G. D. (2016). Depressive symptoms
across the menopause transition: findings from a large population-based cohort
study. Menopause, 23:1287–1293.
Hildreth, K. L., Ozemek, C., Kohrt, W. M. Blatchford, Patrick, J., & Moreau, K. L.
(2018). Vascular dysfunction across the stages of the menopause transition is associated
with menopausal symptoms and quality of life. Menopause. 25(9), 1011-1019.
https://doi.org/10.1097/GME.0000000000001112.
Himelein M. J., Thatcher, S. S. (2006). Depression and body image among women with
polycystic ovary syndrome. Journal of Health Psychology, 11, 613–625.
http://doi.org/ 10.1177/13591053060650.
Hollinrake, E., Abreu, A., Maifeld, M., Van Voorhis, B. J., & Dokkras, A. (2007).
Increased risk of depressive disorders in women with polycystic ovary syndrome.
Fertility & Sterility, 87 (6), 1369-1376.
https://doi.org/10.1016/j.fertnstert.2006.11.39.
Huber-Bucholz, M. M., Carey, D. G. & Norman, R. J. (1999). Restoration of reproductive
potential by lifestyle modification in obese polycystic ovary syndrome: Role of
insulin sensitivity and luteinizing hormones. Journal of
114
Clinical Endocrinology and Metabolism, 84, 1470-1474.
Hung, J. H., Hu, L., Tsai, S. J., Yang, A. C., Huang, M. W., Chen, P. M., Wang, S. I., Lu,
T., & Shen, C. C. (2014). Risk of psychiatric disorders following PCOS: A
nationwide population cohort study. Public Library of Science (One), 9 (5), 1-6.
https://doi:10.1371/journal pone.0097041.
Hungar, A. L., Kanijikar, A. P., & Londonkar, R. L. (2018). Polycystic ovary syndrome:
A mini review. Open Access Journal of Psychology,
3(1):00148.http://medwinpublishers.com/OAJG/PAKG/6000148.pdf
Hunter M. S. (1993). Predictors of menopausal symptoms: psychosocial aspects.
Baillière’s Clinical Endocrinology and Metabolism,7, 33-45.
Hvidtfeldt, U. A., Gunter, M. J., Lange, T., Chlebowskki, R. T., Lane, D., Farhat, G. N.,
Freiberg, M. S., Keiding, N., Lee, J. S., Prentice, R., Tjonneland, A,, Vitolins, M.
Z., Wasserheil-Smoller, S., Strickler, H. D., & Rod, N. J. (2012). Qualifying
mediating effects of endrogenous obesity, alcohol consumption and insulin inn
the relation between obesity, alcohol consumption and breast cancer. Cancer and
Epidemology Biomarkers & Prevention, 21 (7), 1203 – 1212.
Hywood, A. (2004). Phytotherapy for polycystic ovary syndrome. Townsend Lett,
Doctors Patients, 256, 28-34
Innes, K. E., Selfe, T. K., & Taylor, A. G. (2008). Menopause, the metabolic syndrome,
and mind-body therapies. Menopause,15, 1005-1013.
115
Innes, K. E., Vincent, H. K. &Taylor A. G. (2007) Chronic stress and insulin
resistancerelated indices of cardiovascular disease risk. Part 2: A potential role for
mindbody therapies. Alternative Therapies in Health & Medicine, 13(15), 44-51.
Iuorno, M. J., Jakobowicz, D. J., Ballargeon, J. P., Dillon, P., Gunn, R. D., Allan, G. &
Nestler, J. E. (2002). Effects of d-chiro-inositol in lean women with polycystic
ovary syndrome. Endocrine Practice, 8 (6), 417-423.
https://doi.org/10.4158/ep.8.6.417.
Janghorban, R., Roudsari, R. & Taghipour, A. (2014) Skype interviewing: The new
generation of online synchronous interview in qualitative research. International
Journal of Qualitative Studies on Health and Well-being.
https://doi.org/10.3402/qhw.v9.24152.
Jelodar G., Masoomi S., Rahmanifar F. (2018) Hydroalcoholic extract of flaxseed
improves polycystic ovary syndrome in a rat model. Iran Journal of Basic
Medical Science, 21(6), 645–50.
Jenabi, E., Shobeni, F. Hazaveher, S. M. M., & Roshanael, G. (2015). Assessment of
questionnaire measuring quality of life inn menopausal women: A systematic
review. Oman Medical Journal, 30(3), 151-156.
Jin, P., & Xie, Y. (2018). Treatment strategies for women with polycystic ovary
syndrome. Gynecological Endocrinology, 34(4), 272-277.
https://doi.org/10.1080/09513590.2017.139.95841.
Joham, A. E., Piltonen, T., Lajan, M. E., Kiconco, S., and Tay, C. T. (2022). Challenges
in diagnosis and understanding of natural history of polycystic ovary syndrome.
116
Clinical Endocrinology, 97(2), 165–173. https://doi,org/ 10.1111/cen.14757.
Jones G. L., Hall J. M., Balen A. H., & Ledger, W. L. (2008). Health-related quality of
life measurement in women with polycystic ovary syndrome: a systematic review.
Human ReproductionUpdate,14(1),1525. https://doi:10.1093/humupd/dmm030.
Kakoly, N. S., Moran, L. J., Teede, H. J., & Joham, A. E. (2019). Cardiometabolic risks in
PCOS: a review of the current state of knowledge. Expert Review of
Endocrinology & Metabolism, 14 (1), 23
33.https//doi.org/10.1080/17446651.2019.1556094
Kessler, R., & Mroczek, D. (1992). An Update of the Development of Mental Health
Screening Scales for the US National Health Interview Study, [memo dated
12/22/92], Ann Arbor (MI): Survey Research Center of the Institute for Social
Research, University of Michigan.
Kelly, C. C., Lyall, H., Petrie, J. R., Gould, G. W., Connell, J. M. & Sattar, N. (2001).
Low grade chronic inflammation in women with polycystic ovary syndrome.
Journal of Clinical Endocrinology, 86 (6), 2453-2458.
Kiddy, D. S., Hamilton - Fairlex, D., Bush, A., Short, F., Antaoky, V., Reed, M. J. &
Franks, S. (1992). Improvement in endocrine and ovarian function during dietary
treatment of obese women with polycystic ovary syndrome. Clinical
Endocrinology, 36, 105-106.
Kilic-okman, T., & Kucuk, M., & Steine, N. (2004). N- Acetylcy Treatment for PCOS.
International Journal of Gynecology & Obstetrics, 85 (3), 296 – 297.
https://doi.org/10.1016./j.igo.2004.03.002
117
Kim, A., Chiu A, Barone, M. K., Avino, D., Wang, F., Coleman, C. I. & Phung, O. J.
(2011). Green tea catechins decrease total and low-density lipoprotein cholesterol:
A systematic review and meta-analysis. Journal of the American Dietetic
Association, 111(11), 1720-1729.
Kitzinger, C., and Willmott, J. (2002) ‘The thief of womanhood’: Women’s experience of
polycystic ovarian syndrome. Social Science and Medicine, 54, 349–361.
Kluzek, S., Hass Rubin, K., Sanchez-Santos, M., O’Hanlon, M. S., Anderson, M.
Glintborg, D., and Abrahamsen, B. (2021). Accelerated osteoarthritis in women
with polycystic ovary syndrome: a prospective nationwide registry-based cohort
study. Arthritis Research & Therapy, 23:225. https://doi.org/10.1186/s13075-
02102604-w.
Kolhe, J. V., Chhippa, A. S., Butani, S., Chavda, V., and Patel, S. S. (2022). PCOS and
Depression: Common Links and Potential Targets. PCOS and Depression:
Common Links and Potential Targets. Reproductive Science, 29(11):3106-3123.
https://doi 10.1007/s43032-021-00765-2.
Kolivand, M., Keramat, A., & Khosravi, A. (2017). The Effect of Herbal Teas on
Management of Polycystic Ovary Syndrome: A Systematic Review. Journal of
Midwifery & Reproductive Health, 5 (4). 1098-1106.
https://d01.org/10.22038/MRH.2017.9368.
Koo, M. W. & Cho, C. H. (2004). Pharmacological effects of Green tea on the
gastrointestinal system. European Journal of Pharmacology, 500(1), 177-185. Kuan-Tu,
Lu, Yu-Cheng, H., Kuo-Chung, l., and Yu-Ting, S. (2022). Evaluation of
118
Bodily Pain Associated with Polycystic Ovary Syndrome: A Review of
HealthRelated Quality of Life and Potential Risk Factors. Biomedicines, 10 (12):
3197.
https://doi.org 10.3390/biomedicines10123197
Kujanpää, L., Arffman, R., Vaaramo, F., Rossi, H. R., Laitinen, J., Morin-Papunen, L.,
Tapanainen, J.,Ala-Mursula, L., and Pillonen, T. T. (2022). Women with
polycystic ovary syndrome have poorer work ability and higher disability
retirement rate at midlife: a Northern Finland Birth Cohort 1966 study. European
Journal of Endocrinology, 187(3): 479–488. https://doi.org 10.1530/EJE-22-0027.
Kurzer, M. S. (2002). Hormonal effects of soy in premenopausal women and men.
Journal of Nutrition, 132, 570S-573S. https://doi.org/10.1093/jn/132.3.570S
Kuramoto A. M. (2006). Therapeutic benefits of Tai Chi exercise: research review.
Wisconsin Medical Journal,105, 42-46.
Kushir, V. A., Halevy, N., Barad, D. H., Albertini, D. F. & Gleicher, N. (2015). Relative
importance of AMH androgen changes with aging among non-obese women with
polycystic ovary syndrome. Journal of Ovarian Research, 8 (45).
https://doi.org/10.1186/s/3048-075
Kraut, R., Olson J., Banaji M., Bruckman, A., Cohen, A., & Couper, M. (2004)
Psychological research online: Report of Board of Scientific Affairs’ Advisory
Group on the conduct of research on the internet. American Psychologist, 59 (2):
105–117. https://doi.org/10.1037/0003-066x.59.2.105.
119
Larkin, M & Thompson, A (2012). Interpretative phenomenological analysis. In A
Thompson & D Harper (eds), Qualitative research methods in mental health and
psychotherapy: a guide for students and practitioners. John Wiley & Sons,
Oxford, pp. 99-116. https://doi.10.1002/9781119973249.
LeBlanc. E. S., Kapphahn, K., Hedlin, H., Desa, M., Parikh, N., Lui, S., Parker, D. R.,
Anderson, M., Aroda, V., Sullivan, S., Wood, N.F, Waring, M. E., Lewis,
C.,Steifinack, M. (2018). Reproductive history and risk of type 2 diabetes mellitus
in postmenopausal women: Findings from the women’s health initiative.
Menopause, 24 (1), 64 -72. https://doi.org/10.1079/GME.000000000000714.
Lee, M. S., Pittler, M. H., Guo, R., & Ernst, E. (2007). Qigong for hypertension: a
systematic review of randomized clinical trials. Journal of Hypertension, 25,
1525-1532
Legro, R. S. (2017). Evaluation and treatment of polycystic ovary syndrome. http://ncbi.n
lm,nih,govbooks.NBk278959.
Lenart-Lipnska, M., Matyjaszek, B., Wozniakowska, E., Solski, J., Tarach, J. S., &
Paszkowski, T. 2014). Polycystic ovary syndrome: Clinical implications in
menopause. Przeglad Menopauzalyny, 13 (6), 348 – 35.
https//doi/10.5114/pm.2014.47988.
Liddy, C., Blazkho, V. & Mill, K. (2014). Challenges of self-management when living
with multiple chronic conditions: Systematic review of the qualitative literature.
Canada Family Physician, 60 (12). 1123 – 1133.
120
Lim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012). Overweight, obesity, and
central polycystic ovary syndrome: A systematic review and meta-analysis.
Human Reproduction Update, 18 (6), 618 – 637.
https://doi.org/10.1111/obr.12762.
Lim, S. S., Kakoly, N. S., Tan, J. W. J., Fitzgerald, G., Bahri Khomami, M., Joham, A.
E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., Ranasinha, Teede,
H.J., & Moran, L. J. (2019). Metabolic syndrome in polycystic ovary syndrome: a
systematic review, meta‐analysis and meta‐regression. Obesity Reviews, 20(2),
339-352.
Lin, A. W., Kazemi, M., Jarrett, B. Y., Vanden-Brink, H., Hoeger, K. M., Spandofer, S.
D., and Lujan, M.E. (2019). Dietary and Physical Activity Behaviors in Women
with Polycystic Ovary Syndrome per the New International Evidence-Based
Guideline. Nutrients, 11(2711), https://doi.org :10.3390/nu11112711.
Lincoln, Y.S. & Guba, E. G. (1985). Naturalistic Inquiry. Newbury Park, CA: Sage
Publications.
Lindberg D.A. (2005). Integrative review of research related to meditation, spirituality,
and the elderly. Geriatric Nursing, 26, 372-377
Li, Y., Li Y., Yu Ng, E. H., Stener-Victorin, E., Hou, L., Wu, T., Han, F., & Wu, X. (2011).
Polycystic ovary syndrome is associated with negatively variable impacts on
domains of health-related quality of life: evidence from a meta-analysis.
Fertility & Sterility, 96, 452–458. https://doi.org/10.1016/j.fertnstert.2011.05.072
121
Lizneva, D., Kirubakaran, R., Mykhalchenko, K., Suturina, L., Chernukha, G., Diamond,
M. P., & Azziz, R. (2016b). Phenotypes and body mass in women with polycystic
ovary syndrome identified in referral versus unselected populations: systematic
review and meta-analysis. Fertility and Sterility, 106 (6), 1510-1520.
Lizneva, D., Sutrinal, L., Walker, W., Brakata, S., Gavrilova-Jordon, L., & Azziz, R.
(2016a). Criteria prevalence of polycystic ovary syndrome. Fertility and Sterility.
106 (1), 6 – 15.
Lo, J. C., Feigenbaum, S. L., Yang, J., Pressman, A. R., Selby, J. V., & Go, A. S. (2006)
Epidemology and adverse cardiovascular risk profile of diagnosed polycystic
ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 91 (4), 1357-
1363.
Long, V. D., Mattson, M. I. (2014). Fasting: Molecular Mechanisms and Clinical
Applications. Cell Metabolism, 19 (2), 181-192.
https://doi.org.10.1014/s.cmet.2013.12.008.
Lu, K. T., Ho, Y. C., Chang, C. L., Lan, K. C., Wu, C. C., & Su, Y. T. (2022). Evaluation
of bodily pain associated with polycystic ovary syndrome: A review of
healthrelated quality of life and potential risk factors. Biomedicines, 10(12), 3197.
Lucas, S. R. (2014). Beyond the existence proof: Ontological conditions, epistemological
implication, and in-depth interview research, Quality and Quantity,48:387- 408.
https://doi.org/10.1007/s1135012-9775-3.
Lucidi, R. S., Thyer, A. C., Easton, C. A., Holden, A. E., Schenken, R. S. & Brzyski, R.
122
G. (2005). Effects of chromium supplementation on insulin resistance and ovarian
and menstrual circlicity in women with polycystic ovary syndrome. Fertility &
Sterility, 84 (6), 1755-1756. https//doi.org/10.1016/j.fertnstert.2005.0b.028
Lugue-Ramirez, M., Alpanis, M., Sanchon, R., Fernandez-Duran, E., Ortiz-Florez, A. E.,
& Escobar-Morraele, H. E. (2015). Referral bias in female functional
hyperandrogenism and polycystic ovary syndrome. European Journal of
Endocrinology, 173 (5), 603 – 610.
Lujan, M. E., Chizen, D. R., & Pierson, R. (2008). Diagnostic criteria for Polycystic
Ovary syndrome: Pitfalls and controversy. Journal of Obstetric Gynecology of
Canada, 30, (8), 671 – 679.
Magnus, E. (2016). The phenomenological method in qualitative psychology and
psychiatry. International Journal of Qualitative Studies on Health and Wellbeing,
11:30682. https://doi.org/10.3402/qhw.v11.30682.
Mahalingaiah, S., & Diamanti – Kancharakis, E. (2014). Targets to treat metabolism
syndrome in polycystic ovary syndrome. Expert Opinion Therapy Targets, 19
(11), 1561- 1574. https://doi.org/10.1517/1472/222.1101067.
Maki, K. C., Reeves M. S., Farmer, M., Yasunaga, K., Matsuo N., Katsuragi, Y.,
Komikado, I. T., Wilder, D., Jones, F., Blumberg, J. B., & Cartwright, Y. (2009).
Green tea catechin consumption enhances exercise-induced abdominal fat loss in
overweight and obese adults. The Journal of Nutrition, 139(2), 264-270.
Maki, P. M., Kornstein, S. G., Joffe, H., Bromberger, J. T., Freeman, E. W., Athappilly,
G., Bobo, W. V., Rubin, L., Koleva, H., Hristina, K., Cohen, L. & Soares, C. N.
123
(2018). Guidelines for the evaluation and treatment of perimenopausal depression:
summary and recommendations. Menopause, 25(10), 1069-1085.
http://doi.org/10.1097/GME.0000000000001174.
Marsh, W. K., Bromberger, J. T., Crawford, S. L., Leung, K., Kravitz, A., Randolph, J. F.,
Joffe, H., & Soares, C. N. (2017). Lifelong estradoil exposure and risk of
depressive symptoms during the transition to menopause and post-menopause.
Menopause, 24(12), 1351-1359. https://doi.org/10. 1097/GME.000 000000000.
Mansoon, M., Norstrom, K., Holte, J., Ladin-Wilhelmsen, K., Daugren, E., & Landen, M.
(2011). Sexuality and psychosocial well-being in women with Polycystic Ovary
Syndrome compared to healthy controls. European Journal of Obstetric
Gynecology and Reproduction, 155 (2), 161 – 165.
Martin, M. L., Halling, K., Eek, D., Krohe, M., & Poty, N. (2017). Understanding
Polycystic ovary syndrome from the patient perspective: A concept elicitation
patient interview. Health Quality Life Outcomes, 15 (162), 1 – 10.
https://doi.org/1186/s12955-017-0736-3.
Mason, M. (2010). Sample Size and Saturation in PhD Studies Using Qualitative
Interviews [63 paragraphs]. Forum Qualitative Sozialforschung / Forum:
Qualitative Social Research, 11 (3), Art. 8,
www.http://nbnresolving.de/urn:nbn:de:0114-fqs100387
Masood, A., Rashid, S., Musarrat, R., & Mazahir, S. (2016). Depression, anxiety,
psychological distress, and quality of life in menopausal women. Pakistan
124
Journal of Women’s Studies: Alame-Niswan, 23(1), 77-89.
https://doi.orgmayoclinic.org/diseases-conditions/pcos/symptoms-
causes/syc20353439.
Meaz, C. N. B., Shaw, L. J., Azziz, R., Stanczyk, F., Z, Sopko, G. Braimstein, G. D., &
Kelsey, S. F. (2016). Cardiovascular disease and 10 year morality in post-
menopausal women with clinical features of polycystic ovary syndrome. Journal
of Women’s Health, 25(9), 875 -881. https://doi.org/10/1089/jwh.2015.5441.
Mehban, M., Jelodar, G., & Rahmanifar, F. (2020). A combination of spearmint and
flaxseed extract improved endocrine and histomorphology of ovary in experiment
PCOS. Journal of Ovarian Research, 13(32). www.https//doi:10.1186/s13048020-
00633-8.
Merriam, S. B., & Tisdell, E. J. (2015). Qualitative research: A guide to design and
implementation (4th ed.). San Francisco, CA: John Wiley & Sons.
Milewicz, A. (2013) Reimbursement of metformin for polycystic ovary syndrome.
Endokrynologia Polska, 64(5):409-414.
Moghadam, Z. B., Fereidooni, B., Saffari, M., & Montazeri, A. (2018). Measures of
health-related quality of life in PCOS women: a systematic review. International
Journal of Women’s Health, 10, 397. https:// doi.org/10.2147/IJWH.S165794
Mohsin, M., Khan, W. & Aziz, B. (2018) Polycystic ovary syndrome: an ailment with
unknown etiology. Journal of Rehman Medical Institute, 4 (3), 1-2.
Monteleone, P., Mascagni, G., Giannini, A., Genazzani, A. R., & Simoncini, T. (2018).
Symptoms of menopause—global prevalence, physiology and implications.
125
Nature Reviews Endocrinology, 14(4), 199.
https://doi.org/10.1038/nrendo.2017.180.
Morales, A.J., Laughlin, G. A., Butzow, T., Maheshawa, N., Bauman, G., &Yen, S. S.
(1996). Insulin, somatotropic, luteinizing hormones axes in lean and obese women
with (PCOS) polycystic ovary syndrome. Common and distinct features.
Journal of Clinical Endocrinology and Metabolism, 81 (8), 2854 – 2864.
Moran, L. J., Misso, M. I., Wild, R. A., & Norman, R. J. (2010). Impaired glucose
tolerance, type 2 diabetes and metabolic syndrome: A systematic review and
meta-analysis. Human Reproduction Update, 16 (4), 347 -363
Morrow, S. L. (2005). Quality and trustworthiness in qualitative research in counseling
psychology. Journal of Counseling Psychology, 52(2), 250-260.
Moulana M. (2020). Persistent risk: psychological comorbidity in polycystic ovary
syndrome. Endocrinology & Metabolism International Journal, 8(6):139-141.
https://do1.org: 10.15406/emij.2020.08.002972020).
Moustakas, C. (1994). Phenomenological research methods. Thousand Oaks, CA: Sage.
Muka, T., Asllanaj, E., Avazverdi, N., Jaspers, L., Stringa, J., Milic, J., Ligthart, S., Ikram,
M., Laven, J. S., Kavous, M,, Dehghan, A., &.Frano, O. (2017). Age at natural
menopause and risk of Type II diabetes: A prospective cohort study.
Diabetelogia, 60 (10), 1951-1960. https://doi.org/1007/s00125-017-4346-8.
National Institutes of Health (2017) Evidenced-based methodology workshop on
polycysticsyndrome.https://www.nichd.nih.gov/health/topics/pcos/conditioninfo./
reatments
126
National Institute of Mental Health. (2017). Prevalence of Major Depressive Episode
Among Adults.
https://www.nimh.nih..gov/health/statistics/major.depression.shtml.
Nazarpour, S., Simbar, M., Ramezani Tehrani, F., & Alavi -Majd, H. (2018). Quality of
life and sexual function in postmenopausal women. Journal of Women & Aging,
30(4), 299-309.
Naz, M. S. G., Tehrani, F. R., Maid, H. A., Ahmadi, F., Ozgoli, G., Fakari, F. R., &
Ghasemi, V. (2019). The prevalence of polycystic ovary syndrome in adolescents:
A systematic review and meta-analysis. International Journal of Reproductive
Biomedine,17(8): 533–542.doi:https:// 10.18502/ijrmv17i8.4818
NIH Publication, No. 01– 4584, Bethesda, MD: US Department of Health and Human
Services National Institute of Health, 2001.Nestler, J. E., Jakubowicz, D. J.,
Reamer, P., Gunn, L. D., & Allen, G. (1999). Ovulaltory and metabolism of
Dchiro-inositol in the polycystic ovary syndrome. New England Journal of
Medicine, 340 (17), 1314-1320. https://doi.10.1056/NEJM199904293401703.
Newton, K., Buist, D., Keenan N., Anderson L., & LaCroix A. (2002). Use of alternative
therapies for menopause symptoms: results of a population-based survey.
Obstetrics and Gynecology, 100, 18-25.
Neven, A. C. H., Laven, J., Teede, H. J., & Boyle, J. A. (2018, January). A summary on
polycystic ovary syndrome: diagnostic criteria, prevalence, clinical
manifestations, and management according to the latest international guidelines.
127
Seminars in Reproductive Medicine, 36 (01), 5-12. https://doi.org/ 10.1055/s0038-
1668085. Thieme Medical Publishers.
North American Menopause Society. The 2012 hormone therapy position statement of
The North American Menopause Society, Menopause, 19 (3), 257-271.
https://doi.org/1097/gme.0b013e31824b970.
Nowak, D. A., Snyder D. C., Brown, A. J., & Demark-Wahnefried W. (2007) The effect
of flaxseed supplementation on hormonal levels associated with polycystic
ovarian syndrome: a case study. Current Topopics Nutraceutical Research 5(4)
177.
Oner, G., & Muderris, I. I. (2013). Efficacy of mega 3 in the treatment of polycystic
ovary syndrome. Journal of Obstetrics, 33 (3), 289-291.
Ozkan, S., Erkan, S. A., & Zencir, M. (2005). Women’s quality of life in the menopause
and post-menopausal period. Quality of Life Research, 14, 1795-1801.
https://doi.org/10.1007/s111-005-5692-4.
Palomba, S., Santagni, S., Falbo, & La Sala, G. B. (2015). Complications and challenges
associated with polycystic ovarian syndrome: Current perspective. International
Journal of Women’s Health, 7, 745 – 763.
Panico, A., Messinal, G., Gelsy, A. L., Cacciapuoti, M., Mosctelli, F., Esposito, & T.
Lupoli, (2017). Quality of life in overweight (obese) and normal weight women
with polycystic ovary syndrome. Patient Preference and Adherence, 2017 (11),
423 – 429. https://doi.org/10.2196/jmir.s417.
128
Park, S. C., Lee, Y. L., Lee, D. W., Hahn, S. W., Park, S. H., Kim, Y. H., Choi, J. S., &
Kwon, Y. J. (2017). Screening for depressive disorder in elderly patients with
chronic physical disease using the patient health questionnaire-9. Psychiatry
Investigation, 14 (3), 306 313. https://doi.org.10.4306/PI.2017.14.3.306.
Pasquali, R., Casimari, F., & Vicennati, V. (1997). Weight control and its beneficial effect
on fertility in women with obesity and polycystic ovary syndrome. Human
Reproduction, 17 (suppl.), 82-87. https://doi.org/10.1093/humrep/12suppl_1.82.
Pastore, L. M., Patrie, J. T., Morris, W. L., Dalal, P., & Bray, M. J. (2011). Depression
symptoms body dissatisfaction association among polycystic ovary syndrome
women. Journal of Psychosomatic Research, 71(4), 270 – 276.
https://doi.org/10.1016/j.jpsychores.2011.02.005.
Patel, S. (2018). Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle
endocrinopathy. The Journal of Steroid Biochemistry and Molecular Biology,
182, 27-36. https://doi.org/10.1016/j-jsbms-216.04.008
Patil, C. N., Racusen, L. C., & Reckelhoff, J. F. (2017). Consequences of advanced aging
on renal function in chronic hyperandrogenimic female rats: Implications for
aging women with PCOS. Physiology Reports, 5 (20) pii:e13461. https://doi.org/
10.14814/phy2.13461.
Patton, M. Q. (2002). Qualitative research and evaluation methods (3rd ed.). Thousand
Oaks, CA: Sage Publications, Inc.
Pietkiewicz, I., and Smith, J.A., A Practical Guide to Using Interpretative
129
Phenomenological Analysis in Qualitative Research Psychology. Psychological
Journal, 20(1), 7- 14.
Polit, D., & Beck, T. C. (2008) Nursing research: Generating and assessing evidence for
nursing practice (8th ed.). Philadelphia, Pa.: Lippincott Williams and Wilkins.
PolycysticSyndrome.Factsheet.https://womenshealth.gov/files/documentsents/iipc
os-factsheet.pdf
Praissman, S. (2008). Mindfulness-based stress reduction: a literature review and
clinician’s guide. Journal of the American Academy of Nurse Practitioners, 20,
212-216.
Quinn, M., Shinka, K., Pasch, I., Kuzmich, I., Cedars, M., & Huddleston, A. (2014).
Prevalence of androgenic alopecia in patient with polycystic ovary syndrome and
characterization of associated chemical and biochemical features. Fertility and
Sterility, 10 (4), 1129-1134.
Rafraf, M., Mohammadi, E., Asghari-Jafarabad, M., & Farzadi, L. (2011). Omega-3 fatty
acids improve glucose metabolism without effects on obesity values and serum
vistfatin levels in women with polycystic ovary syndrome. Journal of American
College of Nutrition, 31 (5), 361-368.
https://doi.org/10.1080/07315724.2012.10720443.
Randeva, H. S., Tan, B. K, Weickert, M. O., Lehnert, H., Kostantinos, L., Nestler, J. E.,&
Suttar, N. (2012). Cardiometabolic aspects of the polycystic ovary syndrome.
EndocrineReview, 33(5), 812 – 841. https://doi.org/101210/er20121001.
130
Rathnayake, N., Janaka, L., Gayan, A. & Sarath, L. (2019). Prevalence and Severity of
menopausal symptoms and the quality of life in middle-aged women: A study
from Sri Lanka. Nursing Research and Practice, ID 2081507, 1-9.
https://doi.org/10.1155/2019/2081507
Ring, M. (2017). Women’s Health: Polycystic Ovarian Syndrome, Menopause, and
Osteoporosis. Primary Care, 44(2), 377-398,
https://doi.org/1016/.pop2017.02.012.
Romualdi, D., Constantini, B., & Compagna, G. (2007). Is there a role for soy
isoflavones in the therapeutic approach to polycystic ovary? Results from a Pilot
study. Fertility & Sterility, 90 (5), 1826-1833.
Rosenfield, R. L., & Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary
syndrome (PCOS): The hypothesis of PCOS as functional ovarian
hyperandrogenism revisited. Endocrine Review, 37 (5), 467 -520.
Rosenfield, R. L. (2020). Perspectives on the international recommendations for the
diagnosis and treatment of polycystic ovary syndrome in adolescence. Journal of
Pediatric and Adolescent Gynecology, 33(5), 445-447.
https://doi.org/10.1016/j.jpag.2020.06.017
Rotterdam ESHRE/ASRM consensus diagnostic criteria and long-term health risk related
to polycystic ovary syndrome (PCOS) (2004) Human Reproduction, 19 (1), 41 –
47.
131
Rotterdam ESHRE/ASRM. Sponsored PCOS consensus workshop group revised 2003
consensus on diagnostic criteria and long-term health risk related to polycystic
ovary syndrome (2004). Fertility and Sterility, 81 (1) 19 – 22.
Rumaisa, R., Mir, S., Ozaifa, K., Ali, T., Ara, R., Anium, M., Fiza, A., and Badger, G. N.
(2022) Polycystic ovarian syndrome-current pharmacotherapy and clinical
implications. Journal Obstetrics Gynecology,61(1):40-50.https://doi:
10.1016/j.tjog.2021.11.009.
Rzonca, E., Bien, A., Wdowiak, A., Szymanski, A. & Iwanowicz-Palus, G. (2018).
Determinants of quality of life and satisfaction with life in women with polycystic
ovary syndrome. International Journal of Environmental Research and Public
Health, 15 (376), 1-12. https://doi:10.3390/ijerph15020376
Shahid, R., Mahnoor, L. U. H, Awan, A. A., Iqbal, M. J., Saeed, I. (2022). Diet and
lifestyle modifications for effective management of polycystic ovarian syndrome
(PCOS). Journal of Food Biochemistry, 46(7) e14117.https://doi.org/
10.1111/jfbc.14117.
Salpeter, S, R, Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2018). Meta-Analysis:
Metformin treatment in persons at risk for diabetes mellitus. American Journal of
Medicine, 121 (2), 149 -157.e2.
Sanchez, N. (2014). A life course perspective on polycystic ovary syndrome.
International Journal of Women’s Health, 6, 115 – 122.
https://doi.org/10.2147/IJWH.S55748.
132
Sanchez, N. & Jones, H. (2016). “Less than a wife.” A study of polycystic ovary
syndrome in teen women’s digital magazines. Journal of Medical Internet Research, 28
(6), 1- 33. https://doi.org/10.2196/jmir.5417.
Sanchez, N. (2018). Suitability of the National Health Care Surveys to examine
Behavioral Health Services associated with polycystic ovary syndrome. Journal
of Behavioral Health Services Research, 45 (2), 252 – 268.
https://doi.org/10.1007/s11414-016-9543-6.
Sangeeta S. (2012). Metformin and pioglitazone in polycystic ovarian syndrome: a
comparative study. The Journal of Obstetrics and Gynecology of India,62(5), 551-
556.
Sarfati, J., Moraillon-Bougerolle, M., and Christin-Maitre, S. (2022) Hyperandrogenism
in postmenopausal women: ovarian origin or adrenal origin? Hyperandrogenism
after menopause: Ovarian or adrenal origin. Gynecology Obstetrics Fertility &
Senology,50(10), 675 -681. https://doi.org/10.1016/j.gofs.2022.05.002
Sayyah-Melli, M., Alizadeh, M., Pourafkary, N., Ouladsahemadarek, E., Jafari-Sniberi,
M., Abbassi, J., & Kazemi-Shishvan, M. (2015). Psychological factors associated
with polycystic ovary syndrome: A case control. Journal of Caring Science, 4 (3),
225 – 231.
Scaruffi, E., Gambiner, A., Stefania, C., Turra, J., Vettor, J., & Mioni, R. (2014).
Personality and psychiatric disorder in women affected by polycystic ovary
syndrome. Frontiers in Endocrinology, 5 (158), 1 – 8.
https://doi.org/10.3389fendo.2014.00185.
133
Scaruffi, E., Franzoi, I. G., Civilotti, C., Guglielmucci, F., La Marca, L., Tomelini, M.,
Veglia, F. & Granieri, A. (2019). Body image, personality profiles and alexithymia in
patients with polycystic ovary syndrome (PCOS). Journal of
Psychosomatic Obstetrics & Gynecology, 40(4), 294-303.
https://doi.org/10.10800167482x.2018.1530120.
Schildkraut, J. M., Schwingl, P. J., Bastos, E., Evanoff, A., Hughes, C. (1996). Epithelial
ovarian cancer risk among women with polycystic ovary syndrome. Obstetrics &
Gynecology, 88 (4, pt. 1), 554-559.
Schmidt, J., Dehlgren, E., Brannstorm, M, & Landin-Wilhelmsen, K. (2012). Body
composition, bone mineral and fractures in late post – menopausal women with
PCOS- A long term follow-up study. Clinical Endocrinology, 77, (2), 207 – 214.
https://doi.org/10.111/j./1365-2265.212.04376x.
Shah, D. and Rasool, S. (2021). Polycystic Ovary Syndrome (PCOS) Transition at
Menopause. Midlife Health, 12(1): 30–32.
https://doi.org/10.4103/jmh.jmh_37_21.
Shahid, R., Ul-Haq, L., Aziz-Awan, M., Iqbal, M.H., Munir, H. and Saeed, I. (2022). Diet
and lifestyle modifications for effective management of polycystic ovarian
syndrome (PCOS). Journal of Food Biochemistry, 46(7), e14117. http://doi.org/
10.1111/jfbc.14117.
Sharmeen, S., Nomani, H., Taub, E., Carlson, H., and Yao, Q. (2021) Polycystic ovary
syndrome (PCOS) causes anovulation and hyperandrogenism. Hormonal
imbalance is known to contribute to systemic autoimmune diseases. Clinical
134
Rheumatology, 40(12):4837-4843. https://doi.ors/ 10.1007/s10067-021-05850-0
Shoberi, F. & Jenabi, E. (2016). The association between polycystic ovary syndrome and
breast cancer: A meta-analysis. Obstetrics Gynecology Science, 59 (5), 367 – 372.
Shroff, R., Syrop, C. H., Davis, W. & Van Voorhis, R. J. (2007). Risk of metabolic
complications in the new PCOS phenotypes based on Rotterdam criteria. Fertility
and Sterility, 88 (5). 1389-1395.
Sirmans, S. M., & Pate, K. A. (2014). Epidemology diagnosis and management of
polycystic ovary syndrome. Clinical Epidemology, 6, 1 – 13.
https://doi.org/10.2147/ CLEP.s307559.
Smith, J. A. (2011). Evaluating the contribution of interpretative phenomenological
analysis: A reply to the commentaries and further development of criteria. Health
Psychology Review, 5(1), 55-61. https://doi.org/10.1080/17437199.2010.541743
Smith, J.A., Flower, P., & Larkin, M. (2009). Interpretative Phenomenological Analysis:
Theory, Method and Research. Qualitative Research in Psychology. London:
Sage.
Smith, J. (2004). Reflecting on the development of interpretative phenomenological
analysis and its contribution to qualitative research in psychology. Qualitative
Research in Psychology, 1:39-54. https://doi.org/10.1191/1478088704qp004oa.
Sternfeld, B., Colvin, A., Stewart, A., Appelhans, B. M., Cauley, J. A., Dugan, S. A., El
Khoudary , S . R., Greendale, G. A., & Karvonen-Gutierrez, C. (2020).
Understanding Racial/Ethnic Disparities in Physical Performance in Midlife
Women: Findings From SWAN (Study of Women’s Health Across the Nation).
135
The Journals of Gerontology: Series B, 75(9), 1961-1971.
https://doi.org/10.1093/geronb/gbz103
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J.
V., & Saten, R. J. (2015). Treatment of symptoms of menopause: An endocrine
society clinical practice guideline. The Journal of Clinical Endocrinology &
Metabolism, 100, (11), 3975- https://doi.org/10.1210/jc.2015-222236
Sturgeon, S. R., Heersink, J. L., Volpe S. L., Bertone-Johnson E. R., Puleo, E., Stanczyk,
F. Z., Sabelawski, S., Wähälä, K., Kurzer, M. S., & Bigelow C. (2008). Effect of
dietary flaxseed on serum levels of estrogens and androgens in postmenopausal
women. Nutrician & Cancer, 60(5), 612–620.
Suárez, L., Tay, B., & Abdullah, F. (2018). Psychometric properties of the World Health
Organization WHOQOL-BREF quality of life assessment in Singapore. Quality of
Life Research, 27(11), 2945-2952.
Sudhaa, S., Mahajan, N. (2021). Polycystic Ovarian Syndrome and Menopause in Forty
Plus Women. Journal of Midlife Health, 12(1) 3–7. https://doi.org/
10.4103/jmh.jmh_8_21
Sulaiman, A. H. M., Al – Farsi, Y. M., Al-Khaduri, M. M., Waly, M. I., Saleh, J., &
AlAdawi, S. (2017). Psychological burden among women with polycystic ovarian
syndrome in Oman: A case-control. International Journal of Women’s Health, 9,
897- 904.
Szczuko, M., Kikut, J., Szczuko, U., Szydlowska, I., Nawrocka-Rutkowsaka, J., Zietek,
M., Verbanac, D. and Saso, L. (2021). Nutrition Strategy and Life Style in
136
Polycystic Ovary Syndrome, Narrative Review, 1813(7) 2452.
https://doi.org/10.3390/nu13072452.
Taghavi, S. A., Bazarganipour, F., & Hugh-Jones, S. (2015). Health-related quality of life
in Iranian women with Polycystic Ovary Syndrome: A qualitative study. BMC
Women’s Health, 15(111), 1-8.
Teede, H. J., Misso M. L., Deeks A. A., Moran L. J., Stuckey B. G., Wong J. L., Norman,
R. J., & Costello, M. F. (2011). Assessment and management of polycystic ovary
syndrome: Summary of an evidence-based guideline. Medical Journal of
Australia, 195, S65–S112. http://doi.org/10.5694/mja11.10915.
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T.,
& Norman, R. J. (2018). Recommendations from the international evidence-based
guideline for the assessment and management of polycystic ovary syndrome.
Human reproduction, 33(9), 1602-1618.
Toosy, S., Sodi, R., & Papachan, J. N. (2018). Lean polycystic ovary syndrome: An
endocrine – based practical approach. Journal of Diabetes & Metabolic Disorder,
17, 277 – 285. http://doi.org/10.1007/s40207-018-0371-5.
Torchen, Laura, C. (2017) Cardiometabolic risk in PCOS more than a reproductive
disorder. Current Diabetic Report, 17,12, 137. https//doi.org/10.1007/s11892017-
0956-2.
Torres Fernandez, E. D., Adams, K. V., Syed, M., Maranon, R. O., Romero, D. G., &
Yanes Cardozo, L. L. (2018). Long-lasting androgen-induced cardiometabolic
effects in polycystic ovary syndrome. Journal of the Endocrine Society, 2(8), 949-
137
964. https://doi.org/10.12/js.2018-0031.
Vicary, S., Young, A., & Hicks, S. (2017). A reflective journal as learning process and
contribution to quality and validity in interpretative phenomenological analysis.
Qualitative Social Work, 16(4), 550-565.
Visser, J. A. (2020). The importance of metabolic dysfunction in polycystic ovary
syndrome. Nature Reviews Endocrinology, 1-2. WHOQOL Group (1995). The
World Health Organization Quality of Life Assessment (WHOQOL): Position
paper from the World Health Organization. Social Science & Medicine,
41(10),1403–9.
Walters, R. K., Polimanti, R., Johnson, E. C., McClintick, J. N., Adams, M. J., Adkins,
A. M., Ailey, F., Silviu-Fazil, B., Batzler, A., Bertelsen, S., Biernacka, J. M.,
Bigdeli, T. M., Chen L. C., Clark, T. K., Chou, Y.L.,, Degenhardt, F., Docherty,
A. R., Edwards, A. C., Fontanllias, P.,...& Agrawal, A.(2018) Transancestral
GWAS of alcohol dependence reveals common genetic underpinnings with
psychiatric disorders. Nature neuroscience, 21(12), 1656-1669.
https://doi.org/10.1038/s41593-018-0275-1
Wild, R.A., Carmina, E., Diamanti-Kandara, E., Dorkras, A., Escobar-Morreale, H. F.,
Futterweit, W., Lobo, R., Norman, R. J., Talbitt, E., & Dumesic, D. A. (2010).
Assessment of cardiovascular risk and prevention of cardiovascular disease in
women with a consensus statement by the Androgen Excess and Polycystic Ovary
syndrome (AE-PCOS) Society. The Journal of Clinical Endocrinology &
Metabolism, 95 (5), 2038-2049.
138
Williams S, Sheffield D. & Knibb, R. (2014) A snapshot of the lives of women with
polycystic ovary syndrome: A photovoice investigation. Journal of Health
Psychology, 21(6), 1170 -1182. https://doi.org/10.1177/1359105314547941.
Winkler, P., Horacek, Weissova, A., Sustr, M. & Bronovsky, M. (2015). Physical
comorbidities in depression co-occurring with anxiety: A cross-sectional study in
the Czech primary care system. International Journal of Environmental Research
and Public Health, 12 (12), 15728 – 15738.
https://doi.org/10.3390/Ijerph121215015.
Winnie, C. L., & Florence, W. M. (2020). Menopausal- specific quality of life among
women in Hong Kong. GSTF Journal of Nursing and Health Care (JNHC), 5(1).
https://doi.org/10.5176/2345-7198_5.1.25.
Worthen, M. G. F. (2014). An invitation to use craigslist ads to recruit respondents from
stigmatized groups for qualitative interviews. Qualitative Research,14(3) 371–
383. https://doi.org/10.1177/146879411348179.
Xing, L., Xu, J., Wei, Y., Chen, Y, Zhuang, H., Wei, J., Tang, W., Yu, S, Zhang, J., Yin, G.,
Wang, R., Zhoa, R. and Qin, D. (2022) Depression in polycystic ovary syndrome:
Focusing on pathogenesis a treatment. Frontiers in Psychiatry: Mini Review, 1 -
10. https://doi.org/10.3389/fpsyt.2022.1001484.
Zhao, X., Zhong, J., Mo, Y., Chen, X., Chen, Y., & Yang, D. (2010). Association of
biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese
women with polycystic ovary syndrome. International Journal of Gynecology &
Obstetrics, 108(2), 148-151. https://do1.org/10.1016./j.jigo.2009.09.021.
139
Zheng, Y., Zhou, Y., Hu, J., Hua, Q., & Tao, M. (2017). Prediction of risk of depression
symptoms in menopausal women based on hot flash and sweating symptoms: A multicenter
study. Clinical Interventions in Aging, 12, 1993 – 2001.
https://doi.org/10.2147/Cias148688.
Zore, T., Joshi, N. V., Lizneva, D., & Azziz, R. (2017). Polycystic ovarian syndrome:
long-term health consequences. Seminars in Reproductive Medicine, 35 (3) 271-
281. Theme Medical Publishers multicenter study. Clinical Interventions in
Aging, 12, 1993 – 2001. https://doi.org/10.2147/Cias148688
Zhu , T., Cui , J. and Goodarzi, M. O. (2021) Polycystic Ovary Syndrome and Risk of
Type 2 Diabetes, Coronary Heart Disease, and Stroke. Diabetes, 70(2):627-637.
https://doi.org/10.10.2337/db20-0800.
Abdel-Gadier, A., Oyawoye, O. O., & Chander, B. P. (2009). Coexistence of polycystic
ovaries and uterine fibroids and their combined effect on the uterine artery blood
flow in relations to age and parity. Journal of Reproductive Medicine, 54 (6), 347
-352.
Acmaz, G. Albayrak, E. Acmaz, B., Baser, M., Soyak, M. A., Zararsiz, G., &
Ipekmuderis, I. (2013). Level of anxiety and, depression, self-esteem, social
anxiety and quality of life among the women with polycystic ovary syndrome.
Scientific World Journal, 2013, 1-v7. https://doi.org/10.1155/2013/851815
Anagnostis, P., Tarlatzis, B. C., & Kauffman, R. P. (2018). Polycystic ovarian syndrome:
Long-term metabolic consequences. Metabolism, 86, 33-43.
https://doi.org/10.1016/j.metabol.2017.09.016
140
Al-Jefout, M., Alnawaiseh, N., & Al-Qtaitat, A. (2017). Insulin resistance and obesity
among infertile women with different polycystic ovary syndrome phenotypes.
Scientific Reports, 7(1), 1-9. https://doi.org/10.1038/s4198-017-05717y
Akdoğan, M., Tamer, M. N., Cüre E, Cüre, M. C., Köroğlu, B. K., & Delibaş, N. (2007).
Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women
with hirsutism. Phytotherapy Research, 21(5), 444–451.
https://doi.org/10.1002/ptr.2074
Akilen, R., Tsiami, A., Devendraa, D., & Robinson, N. (2012). Cinnamon in glycemic
control: Systemic review and meta-analysis. Clinical Nutrition, 31 (5), 607 -615.
Albahar, A. (2015). A look at the epidemiology of PCOS and economic cost to healthcare
Polycystic Ovary Syndrome Conference. Endocrinology & Metabolic Syndrome,
4(4), pg.51. https://dx.doio.org//10.4172/2161-1017-c1.011
Anderson, S. A., Barry, J. A., Hardiman, P. J. (2014). Risk of coronary heart disease and
risk of stroke in women: A systematic review and meta-analysis. International
Journal of Cardiology, 176(2), 486 - 487
https://doi.org/10.1016/j.ijcard.2014.06.079
Amin, F. N., Tehrani, F. R., Simbar, M., Montazen, A., & Thamtan, R. A. M. (2014). The
experience of women affected by polycystic ovary syndrome: A qualitative study
from Iran. International Journal of Endocrinology and Metabolism, 12(2),
e13612. https://d01.org/10.5812/Item/13612.
141
Amiri, F. N., Tehrani, F. R., Simbar, M., Ali, R., Thamtan, M. & Shiva, N. (2014). Female
gender scheme is disturbed by polycystic ovary syndrome: A qualitative study
from Iran. Iran Red Crescent Medical Journal, 16 (2), e12423.
https://do1.org/10.52812/ircmj.1234.
Antoun, C., Zhang, C., Conrad, F. G., and Schober, M. F. (2016). Comparisons of online
recruitment strategies for convenience samples: Craiglist,Google AdWords,
Facebook and Amazon Mechanical Turk. Fields Methods, 28 (3), 231 – 246.
https://doi.10.11771525822X15603149
Appian, D., Schreiner, P. J., & Folsom, A. R. (2016). Association of age at menopause
with incident of heart failure: A prospective cohort study and meta-analysis.
Journal of American Heart Association, 5(8) e003709.
http://doi.org/10.61/jaka.116.003769.
Apridonidze, T., Essahm P., Iuorna, M. J., & Nestor, J. E. (2005). Prevalence and
characteristics of the metabolic syndrome in women with polycystic ovary
syndrome. Journal of Clinical Endocrinology & Metabolism, 90 (4), 1929 - 1935.
https://doi.org/10.1210/jc.2004-1045.
Archibald, M. M., Ambagtsheer, R. C. Casey, M. G., and Lawless, M. (2019). Using
Zoom videoconferencing for qualitative data collection: Perceptions and
experiences of researchers and participants. International Journal of Qualitative
Methods, 18, https://doi.org/10.1177/1609406919874596.
Arentz, S., Abbott, J. A., Smith, C. A., Bennsoussan, A. (2014). Herbal medicine for the
management of polycystic ovary syndrome (PCOS) and associated
142
oligo/amenorrhea and hyperandrogenism: A review of the laboratory evidence for
effects with corroborative clinical findings. BMC Complement Alternative
Medicine, 14, 511 (2014). https://doi.org/10.1186/1472-6882-14-511
Arm, N., & Abdel-Rahim, H. E. (2015). The effect of chromium supplementations on
polycystic ovary syndrome in adolescents. Journal of Pediatric Adolescent
Gynecology, 28(2), 112–118. https://doi.org/10j-pag.2014.05.005
Asp, M., Lindqvist, D., Fernström, J., Ambrus, L., Tuninger, E., Reis, M., & Westrin, Å.
(2020). Recognition of personality disorder and anxiety disorder comorbidity in
patients treated for depression in secondary psychiatric care. PloS One, 15(1),
e0227364. https://d01.org/10.1371/journal.pone.0227364
Ataabadi, M. S., Alaee S., Bagheri, M. J. & Bahmanpoor, S. (2017). Role of essential oil
of Mentha Spicata (spearmint) in addressing reverse hormonal and
folliculogenesis disturbances in a polycystic ovarian syndrome in a rat model.
Advanced Pharmacy Bulletin, 7(4), 651–654.
https://doi.org/10.15171/apb.2017.078.
Audette, J. F., Jin Y. S., Newcomer, R., Stein L., Duncan G. & Frontera, & W. R. (2006).
Tai Chi versus brisk walking in elderly women. Age & Ageing, 35, 388-393.
Avery, J., Ottey, S., Morman, R., Cree-Green, M., & Gibson-Helm, M. (2020). Polycystic
Ovary Syndrome support groups and their role in awareness, advocacy and peer-
support: a systematic search and narrative review. Current Opinion in
Endocrine and Metabolic Research, 12, 98 -104.
https://doi.org/10.1016/j.coemr.2020.04.008
143
Azizia, B. J., & Hardiman, P. J. (2014) Risk of endometrial, ovarian, and breast cancer in
women with polycystic ovary syndrome: A systematic review and meta-analysis.
Human Reproduction, 20 (5), 748-758.
Azziz, R., Carmina E, Dewailly D., Diamanti-Kandarakis, E., Escobar-Morreale H. F.,
Futterweit, W., Janssen, O. E., Legro R. S., Norman, R. J., Taylor, A. E., &
Witchel, S. F. (2006). Position statement criteria for defining polycystic ovary
syndrome as predominantly hyperandrogenic syndrome: An Androgen Excess
guideline. Clinical Endocrinology Metabolic, 91(11):4237-4245.
Azziz, R. (2018). Polycystic ovary syndrome. Obstetrics & Gynecology, 132(2), 321-336.
https://doi.org/10.1097/AOG.0000000000002698.
Bakken, K., Fournier, A., Lund, E., Wasaseth, M., Dumeaux, V., Clavel-Chapelon, F.,
Fabre, A., Hemon, B., Rinaldi, S., Chajes, V., Slimani, N., Allen, N. E., Reeves,
G. K., Bingham, S., Khaw, K. T., Olsen, A., Tjonneland, A., Rodriquez, L.,
Sanchez, M. J.,...& Berrino, F. (2010) Menopausal hormone therapy and breast
cancer risk: Impact of different treatment: The European prospective investigation
into cancer and nutrition. International Journal of Cancer, 128 (1), 144-156.
Baldani, D. P., Skrgatic, L., & Ougouag, R. (2015). Polycystic ovary syndrome:
Important underrecognized cardiometabolic risk factor in reproductive age
women. International Journal of Endocrinology, 2015 (2015), 1- 17.
Barnard L., Ferriday D., Guenther N., Strauss B., Balen, A. H., & Dye, L. (2007). Quality
of life and psychological well-being in polycystic ovary syndrome. Human
Reproduction, 22, 2279–2286. https://doi.org/10.1093/humrep/dem108.
144
Barry, J. A., Azzizia, M. M., & Hardiman, P. J. (2014). Risk of endometrial, ovarian and
breast cancer in women with polycystic ovary cancer: A systematic review and
meta-analysis. Human Reproduction Update, 20 (5), 748 – 758.
Barrea, L., Muscogiuri, G., Pugliese, G., de Alterius, G., Colao, A., and
Savastrano, S. (2021). Metabolically Healthy Obesity (MHO) vs. Metabolically
Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with
EndocrineMetabolic Profile, Adherence to the Mediterranean Diet, and Body
Composition.
Nutrients, 2;13(11):3925. https://doi.10.3390/nu13113925.
Barry, J. A., Kuczmierczyk, A. R., & Hardiman, P. J. (2011) Anxiety and depression in
Polycystic Ovary Syndrome: A systematic review and meta-analysis. Human
Reproduction, 26 (9), 2442 – 2451.
Barthelmess, E. K. & Naz, R. K. (2014). Polycystic ovary syndrome: Current and future
perspectives. Frontiers Bioscience (Elite Ed.),6,104 -119.
Basirat, Z., Faramarzi, M., Esmaelzadeh, S., Abedi, S., Firooziai, M., Mahouti, B., &
Geraili, Z. (2019). Stress, depression, sexual function, and alexithymia in infertile
females with and without polycystic ovary syndrome: a case-control study.”
International Journal of Fertility & Sterility,13 (3), 203 – 208. doi:
10.22074/ijfs.2019.5703
Basu, A., Du, M., Sanchez, K., Leyva M. J., Betts, N. M., & Blevins S., Wu, M., Aston,
A., & Vons, T. J. (2011). Green tea minimally affects biomarkers of inflammation
obese subjects with metabolic syndrome. Nutrition, 27(2), 206-213.
145
Bazarganipur, F., Taghavi, S., Montazeri, A., Fazollah, A., Reza, C., & Khosravi, A.
(2015). The impact of reproductive medicine on health-related quality of life: A
systematic review and meta-analysis. Iran Journal of Reproductive Medicine, 13
(2), 61-70.
Behboodi -Moghagam, Z., Fereidooni, B., Moghadana, S., Mohsen, S. & Montazeir, A.
(2018). Measures of health-related quality of life in pcos women: A systematic
review. International Journal of Women’s Health, 10, 397-408.
Behboudi‐Gandevani, S., Amiri, M., Bidhendi Yarandi, R., Noroozzadeh, M.,
Farahmand, M., Rostami Dovom, M., & Ramezani Tehrani, F. (2018). The risk of
metabolic syndrome in polycystic ovary syndrome: A systematic review and
meta‐analysis. Clinical endocrinology, 88(2), 169-184.
https://d01.org/10.1111/cen.13477.
Bellever, J., Reodriquez – Tabemer, L., Reobeles, A., Munoz, E., Martinez, F., Landeras,
J., Garcia-Velasco, J., Fontes, J., Alvarez, M., Alvarez, C., & Acevedo, B. (2018).
Polycystic ovary syndrome throughout a woman’s life. Journal of Assisted
Reproduction Genetics, 35, 25 – 39. https://doi.org/10.1007/s10815-017-1047-7.
Bienenfeld, A., Azarchi, S., Sicco, K. L., Marchbein, S., Shapiro, J., & Nagler, A. R.
(2019). Androgens in women: Androgen-mediated skin disease and patient
evaluation. Journal of the American Academy of Dermatology, 80(6), 1497-1506.
https://doi.org/10.1016/j.jaad.2018.08.06.2
Blay, S. L., Aguiar, J. V. A., & Passos, I. C. (2016). Polycystic ovary syndrome and
mental disorders: A systematic review and exploratory meta-analysis.
146
Neuropsychiatric Disease Treatment, 2016 (12), 2895 – 2903.
Bonadonna, R. (2003) Meditation’s impact on chronic illness. Holistic Nursing Practice,
17, 309-319.
Bonomi, A., Patrick, D., Bushnell, D., & Martin, M. (2000). Validation of the United
States’ version of the World Health Organization Quality of Life (WHOQOL)
instrument. Journal of Clinical Epidemiology, 53, 1-12.
https://doi.org.10.1016/S0895-4356(99)00123-7.
Boulman, N., Levy, Y., Lebia, R., Shachar, S., Linn, R., Zinder, O., & Blumefeld, Z.
(2004). Increased C-reaction protein levels in polycystic ovary: A marker of
cardiovascular disease. Journal of Clinical Endocrinology & Metabolism, 89,
2160-2165. 21282136. https://doi.org/10.1152/japplphysoi.00683.
Brakat, S., Lizneva, D., Mykhalchenko, K., Iman, A., Walker, W., Diamond, M. &
Aziza, R. (2017). Perspectives on Polycystic Ovary Syndrome research
underfunded. Journal of Clinical Endocrinology of Metabolism, 102(2), 4421 –
4427. https://doi.org/10.1210/jc.2017- 0415.
Brand, J. S., Vander, S., Onland-Moret, C. N., Sharp, S. J., Ong, K. K., Khaw, K. T.,
Ardanaz, E., Amiano, P., Boeing, H., Chirlaque, M. D., Chavel-Chapelon, F.
Crowe, F. L., de lauzon- Guillan, B., Duell, E. J., Fagherazzi, G., Franks, P. W., ,
Groop, L. C., Kaaks, R., Key, T.,…. & Overvad, K. (2013). Age at menopause,
reproductive life span and type 2 diabetes risk: Results from the EPIC InterAct
Study. Diabetic Care, 36 (4), 1012-1019. https://doi.org/10.2337/dc12-1029.
Braun, V. & Clarke, V. (2006) Using thematic analysis in psychology. Qualitative
147
Research in Psychology, 3(2): 77–101.
Brennan, L., Teede, H., Skouteris, H., Linardon, J., Hill, B, & Moran, L. (2017). Lifestyle
and behavioral management of polycystic ovary syndrome. Journal of Women’s
Health, 26 (8), 836-849. https://doi.org/1089/jwh.2016.5792
Bromberger, J. T. & Epperson, Neill (2018). Depression During and After the
Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants
of Disease. Obstetric Gynecology Clinics of North America, 45(4),663-678.
Bromberger, J. T., Schott, L., Kravitz, H. M. & Joffe, H. (2015). Risk factors for major
depression during midlife among a community sample of women with and
without prior major depression: Are they the same or different? Psychological
Medicine, 45 (8), 1653 – 1664. https://doi.org/10.1017/S0033291714002773.
Bromberger, J. T., & Epperson, C. N. (2018). Depression During and After the
Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants
of Disease. Obstetrics and gynecology clinics of North America, 45(4), 663–678.
https://doi.org/10.1016/j.ogc.2018.07.007.
Brower, M., Brennan, K., Pall, M., & Azziz, R. (2013). The severity of menstrual
dysfunction as a prediction of insulin resistance in PCOS. Journal of Clinical
Endocrinology and Metabolism, 98 (13), E1967-E1971.
Brutocao, C., Zaiem, F., Alsawas, M., Morrow, A. S., Murad, M. H., & Javed, A. (2018)
Psychiatric disorders in women with polycystic ovary syndrome: a systematic
review and meta-analysis. Endocrine, 62, 318–325.
https://doi.org/10.1007/s12020-018-1692-3
148
Carmina, E. (2014) Polycystic ovary syndrome: Metabolic consequences of long-term
management. Scandinavian Journal of Clinical Laboratory Investigation
Supplement, 74, 244: 23 – 26, discussion 26.
https://doi.org./10.3109/00365513.2014.936676.
Carmina, E., Campagna, A. M., & Lobo, R. A. (2012). 20-year follow-up of young
women with Polycystic Ovary Syndrome. Obstetrics & Gynecology, 119 (2 pt1),
263-269.
Carmina E., Bucchier,, Manueto, P., Rinig, G., Ferin, M., & Lobo, R. A. (2009).
Circulating levels of adipose products and differences in fat distribution in the
ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertility
and Sterility, 4 (supl 1), 1332 – 135.
Carmina, E., Chu, M. C., Moran, C., Tortorieu, D., Vardhana, P., Tena, G., Preciado, R.,
& Lobo, R. (2008). Subcutaneous and omental fat expressions of adiponectin and
leptin in women with polycystic ovary syndrome. Fertility, 89 (3), 642 – 648.
http://doi.org/10.1016/j.fernstert.2007.03.085.
Carmina, E., Legro, R. S., Stamets, K., Lowell, J., & Lobo, R. A. (2003). Difference in
body weight between American and Italian women with polycystic ovary
syndrome: Influence of diet. Human Reproduction, 18 (11) 2289-2293.
Carmina, E., Koyama, T., Chang, I., Stanczyk, F. Z., Lobo, R. A. (1992). Difference in
body weight between American and Italian women with polycystic ovary
syndrome: Influence of diet. Human Reproduction, 167 (6), 1807 – 1812.
Carvalho, M. J., Subtil, S., Rodrigues, Â., Oliveira, J., & Figueiredo-Dias, M. (2019).
149
Controversial association between polycystic ovary syndrome and breast cancer.
European Journal of Obstetrics & Gynecology and Reproductive Biology, 243,
125-132. https://doi.org10.1016/j.ejogrb.2019.10.011..
Castello-Branco, C. & Naumova, I. (2020). Quality of life and sexual in function in
women with polycystic ovary syndrome: a comprehensive review. Gynecological
Endocrinology, 36 (2), 96-103.https://doi.org10.1080/09513590.2019.1670788.
Celik, Ö. and Kose, M. F. (2021). An overview of polycystic ovary syndrome in aging
women. Journal of Turkish-German Gynecological Association, 22: 326-33.
http://do1.10.4274/jtgga.galenos.2021.2021.0077.Centers for Disease Control and
Prevention (2017). PCOS and diabetes, heart disease and
strokehttps://www.cdc.gov/diabetes/library/spotlights/pcos.html.
Chan, C. C., Koo, M. W., Ng, E. H., Tang, O. S., Yeung, W. S., & Ho, P. C. (2006).
Effects of Chinese green tea on weight, and hormonal and biochemical profiles in
obese patients with polycystic ovary syndrome- a randomized placebo-controlled
trial. Journal of the Society for Gynecologic Investigation, 13(1), 63-68.
Chaudhari, A. P., Mazumdar, K., & Mehta, P. D. (2018). Anxiety, depression, and quality
of life in women with polycystic ovarian syndrome. Indian journal of
psychological medicine, 40(3), 239-246.
Chau, T. T., Teede, H. J., H., B., Loxton, D., & Joham, A. E. (2019) Increased prevalence
of eating disorders, low self-esteem, and psychological distress in women with
polycystic ovary syndrome: a community-based cohort study. Fertility and
Sterility, 112 (2), 353-361.
150
Chazenbalk, G., Trivax, B., Yildiz, B. O., Bertolotto, C., Mathar, R., Hemeidi, S. &
Riccardo, A. (2010). Regulation of adiponectin secretion by adipocytes in
polycystic ovary syndrome: Role of tumor necrosis factor-analysis. Journal of
Clinical Endocrinology & Metabolism, 95 (2), 934 -942.
Chedraui, P., & Pérez-López, F. R. (2019). Metabolic syndrome during female midlife:
what are the risks? Climacteric, 22(2), 127-132.
https://doi.org/10.1080/13697137.218.156166.
Chen, M. H., Su, T. P., Chang, W. H., Chen, T. J., & Bai, Y. M. (2013). Systematic
menopausal transitioning increasing the risk of new-onset depressive disorder in
later life: A nationwide prospective cohort study in Taiwan. Public Library of
Science One, 8 (3), https://doi.org/101371/journal.pone.0059899.
Chiesa, A. & Serretti, A. (2009) Mindfulness-based stress reduction for stress
management in healthy people: a review and meta-analysis. Journal of Alternative
& Complementary Medicine,15, 593-600.
Christian, R. C., Dumesic, D. A., Behrenbeck, T., Oberg, A. L., Sheedy, P. F., Fitzpatrick
L. (2003). Prevalence and predictors of coronary artery calcification in women
with polycystic ovary syndrome. Journal of Clinical Endocrinology &
Metabolism, 88 (6) 2562-2568.
Cinar, N., Kizilanoglu, M. C., Harmanci, A., Bozdag, G., Demir, B., & Yildiz, B. O.
(2011). Depression, anxiety and cardiometabolic risk in Polycystic Ovary
Syndrome. Human Reproduction, 26 (12), 3339 – 3345.
151
Clarke, V., & Braun, V. (2018). Using thematic analysis in counselling and psychotherapy
research: A critical reflection.” Counselling and Psychotherapy Research 18, (2),
107-110.
Comijs, H. C., Nieuwesteeg, J., Kak, R., van Marwijk, H., van der Mast, Naarding, P.,
Onde-Voshaar, R., Verhaakm P., de Waal, M., & Stek, M. L. (2015). The twoyear
course of late life depression: Results from the Netherlands study of depression.
Bio Med Central Psychiatry, 15 (20), 1 – 9.
Comim, F. V., Wippel, C. S., Langer, F. W., Carvalhjo, J. M., Moresco, R. N., & Premaor,
M. O. (2017). High prevalence of clinical cardiovascular comorbidities in post –
menopausal women with self-reported premenopausal hirsutism and oligo-
menorrhea. Dermatoendocrinology, 22 (1), 1356517.
https://doi.org/1080/1938/980.2171356517.
Cooney, L., Lee, I., Sammel, M. D., Dokras, A. (2017). High prevalence of moderate and
severe depressive and anxiety symptoms in polycystic ovary syndrome: a
systematic review and meta-analysis. Human Reproduction, 32 (5), 1075 – 1091.
https://doi.org/humrep/dex044.
Connelly, L., Pittman, M. (2016). Trustworthiness in Qualitative Research, Medsurg
Nursing, 25(6), 435 – 436.
Creswell, J. W. (2013a). Qualitative inquiry and research design (3rd ed). In Qualitative
inquiry and research design: Choosing among five approaches, pp (82). Los
Angeles, CA: Sage Publications Inc.
152
Creswell, J. W. (2013b). Qualitative inquiry and research design: Choosing among five
approaches (3rd ed.), Los Angeles, CA: Sage Publications Inc.
Creswell, J. (2014). Research design: Qualitative, quantitative, and mixed methods
approaches (4th ed). SAGE Publications.
Cronin, L., Guyatt, G., Griffith, E., Wong, R., Azziz, W., Futterweit, D., Cook, D., &
Dunaif, A. (1998). Development of a Health-Related Quality-of-Life
Questionnaire (PCOSQ) for Women with Polycystic Ovary Syndrome (PCOS).
Journal of Clinical Endocrinology and Metabolism, 83(6), 1976-1987.
Daley, A. MacArthur C. McManus R., Stokes-Lampard, Wilson, S., Roalfe, A, & Mutrie,
N. (2006). Factors associated with the use of complementary medicine and
nonpharmacological interventions in symptomatic menopausal women.
Climacteric, 9, 336-346. www.https//doi.10.1080/13697130600864074.
Davis, A., Christiansen, A., Horowitz, J. F., Klein, S., Hellerstein, M. K. & Ostlund, R. E.
(2000). Effect of pinitol treatment on insulin action in subjects with insulin
resistance. Diabetes Care, 23 (7), 1000 – 1005.
www.https://doi.org/10.2337/diacare.23.7.1000.
Dapas, M., Lin, F. T., Nadkarni, G. N., Sisk, R., Legro, R. S., Urbanek, M., Hayes, G., &
Dunaif, A. (2020). Distinct subtypes of polycystic ovary syndrome with novel
genetic associations: An unsupervised, phenotypic clustering analysis. Public
Library of Science Medicine, 17(6), e1003132.
https://doi.org/10.1371/journal.pmed.1003132
153
Deakin, H., & Wakefield, K. (2013) Skype interviewing: Reflections of two PhD
researchers. Qualitative Research. Epub ahead of print 24 May. https://doi.org/
10.1177/1468794113488126.
de Lima Nunes, R., Dos Santos, I. K., Cobucci, R. N., Pichini, G. S., Soares, G. M., de
Oliveira Maranhão, T. M., & Dantas, P. M. S. (2019). Lifestyle interventions and
quality of life for women with polycystic ovary syndrome: A systematic review
and meta-analysis protocol. Medicine, 98(50).
https://doi.org/10.1097/MD.0000000000018323.
de Medeiros, S. F., Yamamoto, M. M. W., de Medeiros, M. A. S., Barbosa, B. B., Soares,
J. M., & Baracat, E. C. (2020). Changes in clinical and biochemical characteristics of
polycystic ovary syndrome with advancing age. Endocrine connections, 9(2), 74-89.
http://doi.org/10.1530/EC-19-0496. de Lignieres, B. (1992). Oral micronized
progesterone. Clinical Therapeutics, 21(1), 41-
60. www.https//doi.org.10.1016/s0149-2918(00)88267-3.
Dennerstein, L., Smith, A. M., Morse C., Burger, H., Green, A., Hopper, J., & Ryan, M.
(1993) Menopausal symptoms in Australian women. The Medical Journal of
Australia,159, 232-236.
Deswal, R., Narwal, V., Dang, Amita, & Pundir, C. S.(2020) The Prevalence of
Polycystic Ovary Syndrome: A Brief Systematic Review, Journal of Human
Reproductive Science, 13(4): 261–271. doi: 10.4103/jhrs.JHRS_95_18.
Diamanti-Kandarakis, E. & Dunaif, A. (2012). Insulin resistance and polycystic ovary
syndrome Revisited: An update on mechanisms and implications. Endocrine
154
Review, 33(6), 981 – 1031. https://doi.org/10.1210/er.2011-1034.
Dokras, A., Stener-Victorin, E., Yildiz, B. O., Li, R., Ottey, S., Shah, D., Epperson, N., &
Teede, H. (2018). Androgen Excess-Polycystic Ovary Syndrome Society: position
statement on depression, anxiety, quality of life, and eating disorders in polycystic
ovary syndrome. Fertility and sterility, 109(5), 888-899.
https://doi.org/10.1016/j.fertnstert.2018.01.038.
Dokras, A., Sarwer, D. B., Allison, K. C., Miliman, L., Kris-Etherton, P. M., Kunnelman,
A. R., Sarwer, D. B., Allison, K. C., & Legro, R. S. (2016). Weight loss and
lowering androgens predict improvements in health-related quality of life in
women with PCOS. Journal of Clinical Endocrinology and Metabolism. 101(8)
2966-2974. https://doi.org/10.1210/c.201-1896.
Dokras, A., Clifton, S., Futterweit, W., & Wild, R. (2013). Increase prevalence of anxiety
symptoms in women with Polycystic Ovary Syndrome: A systematic review and
metal analysis. Fertility and Sterility, 97 (1), 225 – 230.ec.
Dokras, A., Clifton, S., Futterweit, A., & Wild, R. (2011). Increased risk for abnormal
depression scores in women with Polycystic Ovary Syndrome: A systematic
review and meta- analysis. Obstetric Gynecology, 117, (1) 145 – 152).
Doretto, L., Mari, F. C., & Chaves, A. C. (2020). Polycystic Ovary Syndrome and
Psychotic Disorder. Frontiers in Psychiatry, 11, 543.
https://doi.org/10.3389/fpsyt.2020.00543
Douglas, C. C., Moran, L., Noakes M, Grower, B. A., Darnell, B. E., Ovalle, F., Oster, R.
& Azziz, R. (2006). Role of diet in the treatment of polycystic ovary syndrome.
155
Fertility and Sterility, 85(3), 679-688.
Dumesic, D. A., Oberfield, S. E., & Legro, R. S. (2015). Scientific statement on the
diagnostic criteria. Epidemology, pathophysiology and molecular genetic of
polycystic ovary syndrome. Endocrine Review, 36 (5), 487 -525.
https://doi.org/10.1210/er.2015-1018.
Ehrmann, D. A, (2005). Polycystic ovary syndrome. New England Journal of Medicine,
352 (12), 1223 – 1236.
Elsenbruch S., Benson S., Hahn S., Tan S., Mann K., Pleger K., Kimmig, R., Janssen, &
O. E. (2006). Determinants of emotional distress in women with polycystic ovary
syndrome. Human Reproduction, 21, 1092–1099.
https://doi.org/10.1093/humrep/dei409.
Emeksiz, H. C., Bideci, A., Nalbantoğlu, B., Nalbantoğlu, A., Celik, C., Yulaf, Y.,
Camurdan, M. O. & Cinaz, P. (2018). Anxiety and depression states of
adolescents with polycystic ovary syndrome. Turkish journal of medical sciences,
48(3), 531-536.
Enjezab, B., Eftekhar, M., & Ghandiri-Amari, A. (2017). Associate between severity of
depression and clinical – biochemical markers of polycystic ovary syndrome.
Electronic Physician, 9 (11), 5820 – 5825. https://doi:10.19082/5820.
Escobar -Morreale, H. F., Carmina, E., & DeWailly, D. (2012). Epidemology diagnosis
and management of hirsutism Consensus Statement by Androgen Express
guideline. Human Reproduction Update, 18 (2) 146 – 170.
156
Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, etiology,
diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270.
Ezeh, U., Pall, M., Mather, R., Dey, D., Berman, D., Chen, I. Y., Dumesic, D. A., &
Azziz, R. (2013). Effects of endogenous androgens and abdominal fat distribution
on interrelationship between insulin and non-insulin mediated glucose uptake in
females. Journal of Clinical Endocrinology Metabolism, 98 (4), 1541- 1548.
Ezeh, U., Chen, I. Y., Chen, Y. H., & Azziz, R. (2020). Adipocyte Insulin Resistance in
PCOS: Relationship With GLUT-4 Expression and Whole-Body Glucose
Disposal and β-Cell Function. The Journal of Clinical Endocrinology &
Metabolism, 10 (7), e2408-e2420.
Fact Sheet: General facts on women and job-based health available at
www.http:doi.gov/ebsa/newsroom/fshlt5.accessedjuly22,2016.
Fauser, B. C., Tariatzis, B. C., Rebar, R. W., Legro, R., Balen, Lobo, R., A., Camina, E.,
Chang, J., Yildiz, B., Laven, J. S., Boivin, J., Petraglia, F., Wijeyaratne, C. N.,
Norman, R. J., Dunaif, A., Franks, S., Wild, R. A., & Barnhart, K., (2012).
Consensus on women’s health aspect of polycystic ovary syndrome (PCOS). The
Amsterdam ESHRE/ASRM sponsored 3rd PCOS Consensus Workshop.
,97(1):28-38 e25. https://doi.org/10.1016/j.fertnstert.2011.09.204
Fourier, A., Fabris, A., Mesrine, S., Boutron-Rualt, M. C., Benrino, F. & ClavelChapelon,
F. (2008). Use of different post-menopausal hormone receptor defined invasive
breast cancer, Journal of Clinical Oncology, 26 (8), 1260-1268.
www.https//doi.10./200/jco.2007.
157
Freedman, R. R. (2005). Hot flashes: behavioral treatments, mechanisms, and relation to
sleep. American Journal of Medicine, 118, 124-130
Freeman, E. W., Sammel, M. D., Boorman, D. W., & Zhang, R. (2014). The longitudinal
pattern of depressive symptoms around natural menopause. Journal of the
American Medical Association, 71 (1), 36 – 43.
https://doi.org/10.100/jamapsychiatry, 2013.2819.
Fulghesu, A. M., Campbell, M., & Muyzj, G. & Lanzone, A. (2002). N-Acetyl- cysteine
treatment improves insulin sensitivity in women with polycystic ovary syndrome.
Fertility & Sterility, 77 (6), 1128-1135. http://doi.org/10.1014/s0015-
0282(02)03133-3.
Galletly, C., Morran, L., Noakes, M., Clifton, P., Tomlinson, L., & Norman, R. (2007).
Psychological benefits of high-protein, low-carbohydrate diet in obese women
with polycystic ovary syndrome- A pilot study. Appetite, 49 (3), 590-593.
Ganapathy, T., & Al Furaikh, S. S. (2018). Health-related quality of life among
menopausal women. Archives of Medicine and Health Sciences, 6(1), 16.
http://doi.org.10.4103/amhs.amhs12217.
Gholami, A., Aragh, M. I., Shamsabad, F., Bayat, M., Dabirkhani, F., Mansori, K.,
Moradi, K., & Rajabi, A., (2016). Application of World Health Organization Quality of
Life instrument, Short Form (WHOQOL-BREF) to patients with cataracts. Epidemology
Health, 38, e206005.
https://doi.org/10.4178/3pih.e2016005.
Gilbert, E. W., Tay, C. T., Hiam, D. S., Teede, H. J., & Moran, L. J. (2018).
158
Comorbidities and complications of polycystic ovary syndrome: An overview of
systematic reviews. Clinical Endocrinology, 89(6), 683-699.
Glintborg, D., Rubin, K. H., Nybo, M., Abrahamsen, B., & Andersen, M. (2018)
Cardiovascular disease in a nationwide population of Danish women with
polycystic ovary syndrome, Cardiovascular Diabetology, 17 (37).
https://doi.org/10.1186/s12933-018-0680-5.
Goa, I., & Zhoa, F. L. (2012) Statin is a reasonable treatment for patient with polycystic
ovary syndrome: A meta-analysis of randomized controlled trials. Experimental
Clinical Endocrinology Diabetes, 120 (6) 367 – 375.
https://doi.org10.1055/s0032-1304619.
Gobbens, R. J. J., & Remmens, R. (2019). The effects of sociodemographic factors on
quality of life among people age 50 years or older are not equivocal: Comparing
SF-12, WHOQOL-BREF and WHOOLD-OLD. Clinical Interventions in Aging.
4, 231-239.
Goodman, N. F., Gobin, R. H., Futtrweit, W., Guterwelt, J. S., Legro, R. S., & Carmina,
E. (2015). American Association of clinical endocrinology, American College of
Endocrirnolgy, and androgens excess and pcos society disease state Clinical
review: Guide to bet practices in evaluation and treatment of polycystic
syndrome-part 1. Endocrinology Practice, 2 (11), 1291-1300.
https://doi.org/10.4158/EP15148.DSC.
González, F., Considine, R. V., Abdelhadi, O. A., & Acton, A. J. (2020). Inflammation
triggered by saturated fat ingestion is linked to insulin resistance and
159
hyperandrogenism in polycystic ovary syndrome. The Journal of Clinical
Endocrinology & Metabolism, 105(6), e2152-e2167.
Gordon, J. L. Rubinow, D. R., Eisenlohr-Moul, T. A., Lesserman, J. & Girdler, S. S.
(2016). Estradiol variability, stressful life events and the emergence depressive
symptomology during menopause. Menopause, 23 (3), 257 – 266.
https://doi.org/10.1097/GME.00000000000528.
Gottschau, M., Kajer, S. K., Jensen, A., & Mellenenkjaeb, L. (2005). Risk of cancer
among women with Polycystic Ovary Syndrome. A Danish Cohort Study.
Gynecological Oncology, 136 (1), 99 -103.
https://doi.org/10.1016/j.pgyno.201411012.
Gnawali, A., Patel, V., Cuello-Ramirez, A., Alkaabi, A., Noor, M. Rashid, M.Y. , Henin,
S. &, ..Mostafa, J. A. (2021). Why are Women with Polycystic Ovary Syndrome
at Increased Risk of Depression? Exploring the Etiological Maze. Cureus,
13(2):e13489. https://doi: 10.7759/cureus.13489.
Grant P. (2010). Spearmint herbal tea has significant anti-androgen effects in polycystic
ovarian syndrome. A randomized controlled trial. Phytotherapy Research, 24(2),
186–194.
Gu, Y., Zhou, G., Zhou, G., Wu, O., Ma, C., Zhang, Y., Ding, J., and Hua, K. (2022).
Life Modifications and PCOS: Old Story But New Tales. Frontiers in
Endocrinology, 13;13:808898.https://doi: 10.3389/fendo.2022.808898
Gupta, G., & Kumari, R. (2021). Quality of life among menopausal women. Indian
Journal of Scientific Research, 11(2), 25-32
160
Gurka, M. J., Vishnu, A., Santen, R., & DeBoer, M. D. (2016). Progression of metabolic
syndrome severity during menopause. American Heart Association, 5 (18),
e003609. https://doi.org/10.1161/jaha.1161.003609.
Guyatt, G., Weaver, B., Cronin, L., Dooley, J. A., & Azziz, R., (2004). Health-related
quality of life in women with Polycystic Ovary Syndrome, self-administered
questionnaire was validated. Journal of Clinical Epidemology, 57 (12), 1279 –
1287.
Guest, G., Bunce, A., & Johnson, L, (2006). How many interviews are enough? An
experiment with data saturation and variability. Field Methods, 18 (1), 59–82,
https://doi.org//10.1177/1525822X05279903.
Hadjiconstantinou, M., Mani, H., Patel, N., Levy, M., Davies, Khunti, K., & Stone, M.
(2017). Understanding and supporting women with polycystic ovary syndrome: A
qualitative study in an ethnically diverse U. K. sample. Endocrine Connections, 6
(5), 323 – 330. https://doi.org/10.1530/ec-17-0053.
Hahn S., Tan S., Elsenbruch, S., Quadbeck B., Herrmann B. L., Mann K., & Janssen, O.
E. (2005). Clinical and biochemical characterization of women with polycystic
ovary syndrome in North Rhine-Westphalia. Hormone Metabolic Research 37,
438–444. https://doi.org/10.1055/s-2005-870236
Haigh, E. A., Bogucki, O. E., Sigmon, S. T., & Blazer, D. G. (2018). Depression among
older adults: a 20-year update on five common myths and misconceptions. The
American Journal of Geriatric Psychiatry, 26(1), 107-122.
161
Halberg, N., Henriksen, M., Soderhomin, N., Stalknecht, B., Ploug, T., Schjerlong, P., &
Flemming, D. (2005). Effects of fasting and refeeding on insulin action in healthy
men. Journal of Applied Physiology, 6 ,2128-2136.
https://doi.org/10.1152/japplphysoi.00683.
Hallajzadeh, J., Karamzad, M., Almasi-Hashiani, Janat, A., Ayubi, E., Pakzad, R., &
Sulliman, M. J. (2018). Metabolic syndrome and its components among women
with polycystic ovary syndrome: a systematic review and meta-analysis. Journal
of Cardiovascular and Thoracic Research, 10(2), 56-69.
https://doi.org/10.15171/jcvtr.2018.10.
Hart, R., Doherty & D. A. (2015). The potential implications of a PCOS diagnosis on a
woman’s long-term health using data linkage. Journal of Clinical Endocrinology
& Metabolism, 100, 911–919. https://doi.org.10.1210/jc.2014-3886.
Hasin, D., S., Goodwin., R., D., Stinson, F. S., & Grant, B. F. (2005). Epidemology of
major depression disorder: Results from the National Epidemology Survey on
alcoholism and related conditions. Archives of General Psychiatry, 10, 1097 –
1106.
Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., Jung,
J,, Zang, H., & Grant, B. F. (2016). Prevalence and correlates of DSM-5 cannabis
use disorder, 2012-2013: findings from the National Epidemiologic Survey on
Alcohol and Related Conditions–III. American Journal of Psychiatry, 173(6),
588-599.
162
Haugen, R. P., & Glintborg, D. (2013). Overweight in polycystic ovary syndrome: An
update on evidenced-based advice in diet, exercise and metformin use for weight
loss. Minerva Endocrinology, 38 (1), 59 -76.
Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G. & Daoud, G. (2016). Polycystic ovary
syndrome: An updated overview. Frontiers in Physiology, 7 (124), 1 – 15.
https://doi.org/10.3389/fphys.2016.00124.
Helvaci, N. & Bulent, O. Y. (2020). Polycystic ovary syndrome and aging: Health
implications after menopause. Maturitas, 139, 12-19.
https://doi.org/10.1016/jmaturitas.2020.05.013.
Henson, M. and Kulkarni, J. (2022). Hormonal Agents for the Treatment of Depression
Associated with the Menopause. Drugs and Aging, 39:607–618.
https://doi.org/10.1007/s40266-022-00962
Helvaci, N., and Yildiz, B. O. Yildiz (2022). The impact of ageing and menopause in
women with polycystic ovary syndrome. Clinical Endocrinology, 97(3), 371 –
382. https://doi.org/10.1111/cen.14558.
Hickey M., Schoenaker, D. A., Joffe H., Mishra G. D. (2016). Depressive symptoms
across the menopause transition: findings from a large population-based cohort
study. Menopause, 23:1287–1293.
Hildreth, K. L., Ozemek, C., Kohrt, W. M. Blatchford, Patrick, J., & Moreau, K. L.
(2018). Vascular dysfunction across the stages of the menopause transition is associated
with menopausal symptoms and quality of life. Menopause. 25(9), 1011-1019.
https://doi.org/10.1097/GME.0000000000001112.
163
Himelein M. J., Thatcher, S. S. (2006). Depression and body image among women with
polycystic ovary syndrome. Journal of Health Psychology, 11, 613–625.
http://doi.org/ 10.1177/13591053060650.
Hollinrake, E., Abreu, A., Maifeld, M., Van Voorhis, B. J., & Dokkras, A. (2007).
Increased risk of depressive disorders in women with polycystic ovary syndrome.
Fertility & Sterility, 87 (6), 1369-1376.
https://doi.org/10.1016/j.fertnstert.2006.11.39.
Huber-Bucholz, M. M., Carey, D. G. & Norman, R. J. (1999). Restoration of reproductive
potential by lifestyle modification in obese polycystic ovary syndrome: Role of
insulin sensitivity and luteinizing hormones. Journal of
Clinical Endocrinology and Metabolism, 84, 1470-1474.
Hung, J. H., Hu, L., Tsai, S. J., Yang, A. C., Huang, M. W., Chen, P. M., Wang, S. I., Lu,
T., & Shen, C. C. (2014). Risk of psychiatric disorders following PCOS: A
nationwide population cohort study. Public Library of Science (One), 9 (5), 1-6.
https://doi:10.1371/journal pone.0097041.
Hungar, A. L., Kanijikar, A. P., & Londonkar, R. L. (2018). Polycystic ovary syndrome:
A mini review. Open Access Journal of Psychology,
3(1):00148.http://medwinpublishers.com/OAJG/PAKG/6000148.pdf
Hunter M. S. (1993). Predictors of menopausal symptoms: psychosocial aspects.
Baillière’s Clinical Endocrinology and Metabolism,7, 33-45.
Hvidtfeldt, U. A., Gunter, M. J., Lange, T., Chlebowskki, R. T., Lane, D., Farhat, G. N.,
164
Freiberg, M. S., Keiding, N., Lee, J. S., Prentice, R., Tjonneland, A,, Vitolins, M.
Z., Wasserheil-Smoller, S., Strickler, H. D., & Rod, N. J. (2012). Qualifying
mediating effects of endrogenous obesity, alcohol consumption and insulin inn
the relation between obesity, alcohol consumption and breast cancer. Cancer and
Epidemology Biomarkers & Prevention, 21 (7), 1203 – 1212.
Hywood, A. (2004). Phytotherapy for polycystic ovary syndrome. Townsend Lett,
Doctors Patients, 256, 28-34
Innes, K. E., Selfe, T. K., & Taylor, A. G. (2008). Menopause, the metabolic syndrome,
and mind-body therapies. Menopause,15, 1005-1013.
Innes, K. E., Vincent, H. K. &Taylor A. G. (2007) Chronic stress and insulin
resistancerelated indices of cardiovascular disease risk. Part 2: A potential role for
mindbody therapies. Alternative Therapies in Health & Medicine, 13(15), 44-51.
Iuorno, M. J., Jakobowicz, D. J., Ballargeon, J. P., Dillon, P., Gunn, R. D., Allan, G. &
Nestler, J. E. (2002). Effects of d-chiro-inositol in lean women with polycystic
ovary syndrome. Endocrine Practice, 8 (6), 417-423.
https://doi.org/10.4158/ep.8.6.417.
Janghorban, R., Roudsari, R. & Taghipour, A. (2014) Skype interviewing: The new
generation of online synchronous interview in qualitative research. International
Journal of Qualitative Studies on Health and Well-being.
https://doi.org/10.3402/qhw.v9.24152.
165
Jelodar G., Masoomi S., Rahmanifar F. (2018) Hydroalcoholic extract of flaxseed
improves polycystic ovary syndrome in a rat model. Iran Journal of Basic
Medical Science, 21(6), 645–50.
Jenabi, E., Shobeni, F. Hazaveher, S. M. M., & Roshanael, G. (2015). Assessment of
questionnaire measuring quality of life inn menopausal women: A systematic
review. Oman Medical Journal, 30(3), 151-156.
Jin, P., & Xie, Y. (2018). Treatment strategies for women with polycystic ovary
syndrome. Gynecological Endocrinology, 34(4), 272-277.
https://doi.org/10.1080/09513590.2017.139.95841.
Joham, A. E., Piltonen, T., Lajan, M. E., Kiconco, S., and Tay, C. T. (2022). Challenges
in diagnosis and understanding of natural history of polycystic ovary syndrome.
Clinical Endocrinology, 97(2), 165–173. https://doi,org/ 10.1111/cen.14757.
Jones G. L., Hall J. M., Balen A. H., & Ledger, W. L. (2008). Health-related quality of
life measurement in women with polycystic ovary syndrome: a systematic review.
Human ReproductionUpdate,14(1),1525. https://doi:10.1093/humupd/dmm030.
Kakoly, N. S., Moran, L. J., Teede, H. J., & Joham, A. E. (2019). Cardiometabolic risks in
PCOS: a review of the current state of knowledge. Expert Review of
Endocrinology & Metabolism, 14 (1), 23
33.https//doi.org/10.1080/17446651.2019.1556094
Kessler, R., & Mroczek, D. (1992). An Update of the Development of Mental Health
Screening Scales for the US National Health Interview Study, [memo dated
166
12/22/92], Ann Arbor (MI): Survey Research Center of the Institute for Social
Research, University of Michigan.
Kelly, C. C., Lyall, H., Petrie, J. R., Gould, G. W., Connell, J. M. & Sattar, N. (2001).
Low grade chronic inflammation in women with polycystic ovary syndrome.
Journal of Clinical Endocrinology, 86 (6), 2453-2458.
Kiddy, D. S., Hamilton - Fairlex, D., Bush, A., Short, F., Antaoky, V., Reed, M. J. &
Franks, S. (1992). Improvement in endocrine and ovarian function during dietary
treatment of obese women with polycystic ovary syndrome. Clinical
Endocrinology, 36, 105-106.
Kilic-okman, T., & Kucuk, M., & Steine, N. (2004). N- Acetylcy Treatment for PCOS.
International Journal of Gynecology & Obstetrics, 85 (3), 296 – 297.
https://doi.org/10.1016./j.igo.2004.03.002
Kim, A., Chiu A, Barone, M. K., Avino, D., Wang, F., Coleman, C. I. & Phung, O. J.
(2011). Green tea catechins decrease total and low-density lipoprotein cholesterol:
A systematic review and meta-analysis. Journal of the American Dietetic
Association, 111(11), 1720-1729.
Kitzinger, C., and Willmott, J. (2002) ‘The thief of womanhood’: Women’s experience of
polycystic ovarian syndrome. Social Science and Medicine, 54, 349–361.
Kluzek, S., Hass Rubin, K., Sanchez-Santos, M., O’Hanlon, M. S., Anderson, M.
Glintborg, D., and Abrahamsen, B. (2021). Accelerated osteoarthritis in women
with polycystic ovary syndrome: a prospective nationwide registry-based cohort
167
study. Arthritis Research & Therapy, 23:225. https://doi.org/10.1186/s13075-
02102604-w.
Kolhe, J. V., Chhippa, A. S., Butani, S., Chavda, V., and Patel, S. S. (2022). PCOS and
Depression: Common Links and Potential Targets. PCOS and Depression:
Common Links and Potential Targets. Reproductive Science, 29(11):3106-3123.
https://doi 10.1007/s43032-021-00765-2.
Kolivand, M., Keramat, A., & Khosravi, A. (2017). The Effect of Herbal Teas on
Management of Polycystic Ovary Syndrome: A Systematic Review. Journal of
Midwifery & Reproductive Health, 5 (4). 1098-1106.
https://d01.org/10.22038/MRH.2017.9368.
Koo, M. W. & Cho, C. H. (2004). Pharmacological effects of Green tea on the
gastrointestinal system. European Journal of Pharmacology, 500(1), 177-185. Kuan-Tu,
Lu, Yu-Cheng, H., Kuo-Chung, l., and Yu-Ting, S. (2022). Evaluation of
Bodily Pain Associated with Polycystic Ovary Syndrome: A Review of
HealthRelated Quality of Life and Potential Risk Factors. Biomedicines, 10 (12):
3197.
https://doi.org 10.3390/biomedicines10123197
Kujanpää, L., Arffman, R., Vaaramo, F., Rossi, H. R., Laitinen, J., Morin-Papunen, L.,
Tapanainen, J.,Ala-Mursula, L., and Pillonen, T. T. (2022). Women with
polycystic ovary syndrome have poorer work ability and higher disability
retirement rate at midlife: a Northern Finland Birth Cohort 1966 study. European
Journal of Endocrinology, 187(3): 479–488. https://doi.org 10.1530/EJE-22-0027.
168
Kurzer, M. S. (2002). Hormonal effects of soy in premenopausal women and men.
Journal of Nutrition, 132, 570S-573S. https://doi.org/10.1093/jn/132.3.570S
Kuramoto A. M. (2006). Therapeutic benefits of Tai Chi exercise: research review.
Wisconsin Medical Journal,105, 42-46.
Kushir, V. A., Halevy, N., Barad, D. H., Albertini, D. F. & Gleicher, N. (2015). Relative
importance of AMH androgen changes with aging among non-obese women with
polycystic ovary syndrome. Journal of Ovarian Research, 8 (45).
https://doi.org/10.1186/s/3048-075
Kraut, R., Olson J., Banaji M., Bruckman, A., Cohen, A., & Couper, M. (2004)
Psychological research online: Report of Board of Scientific Affairs’ Advisory
Group on the conduct of research on the internet. American Psychologist, 59 (2):
105–117. https://doi.org/10.1037/0003-066x.59.2.105.
Larkin, M & Thompson, A (2012). Interpretative phenomenological analysis. In A
Thompson & D Harper (eds), Qualitative research methods in mental health and
psychotherapy: a guide for students and practitioners. John Wiley & Sons,
Oxford, pp. 99-116. https://doi.10.1002/9781119973249.
LeBlanc. E. S., Kapphahn, K., Hedlin, H., Desa, M., Parikh, N., Lui, S., Parker, D. R.,
Anderson, M., Aroda, V., Sullivan, S., Wood, N.F, Waring, M. E., Lewis,
C.,Steifinack, M. (2018). Reproductive history and risk of type 2 diabetes mellitus
in postmenopausal women: Findings from the women’s health initiative.
Menopause, 24 (1), 64 -72. https://doi.org/10.1079/GME.000000000000714.
169
Lee, M. S., Pittler, M. H., Guo, R., & Ernst, E. (2007). Qigong for hypertension: a
systematic review of randomized clinical trials. Journal of Hypertension, 25,
1525-1532
Legro, R. S. (2017). Evaluation and treatment of polycystic ovary syndrome. http://ncbi.n
lm,nih,govbooks.NBk278959.
Lenart-Lipnska, M., Matyjaszek, B., Wozniakowska, E., Solski, J., Tarach, J. S., &
Paszkowski, T. 2014). Polycystic ovary syndrome: Clinical implications in
menopause. Przeglad Menopauzalyny, 13 (6), 348 – 35.
https//doi/10.5114/pm.2014.47988.
Liddy, C., Blazkho, V. & Mill, K. (2014). Challenges of self-management when living
with multiple chronic conditions: Systematic review of the qualitative literature.
Canada Family Physician, 60 (12). 1123 – 1133.
Lim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012). Overweight, obesity, and
central polycystic ovary syndrome: A systematic review and meta-analysis.
Human Reproduction Update, 18 (6), 618 – 637.
https://doi.org/10.1111/obr.12762.
Lim, S. S., Kakoly, N. S., Tan, J. W. J., Fitzgerald, G., Bahri Khomami, M., Joham, A.
E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., Ranasinha, Teede,
H.J., & Moran, L. J. (2019). Metabolic syndrome in polycystic ovary syndrome: a
systematic review, meta‐analysis and meta‐regression. Obesity Reviews, 20(2),
339-352.
170
Lin, A. W., Kazemi, M., Jarrett, B. Y., Vanden-Brink, H., Hoeger, K. M., Spandofer, S.
D., and Lujan, M.E. (2019). Dietary and Physical Activity Behaviors in Women
with Polycystic Ovary Syndrome per the New International Evidence-Based
Guideline. Nutrients, 11(2711), https://doi.org :10.3390/nu11112711.
Lincoln, Y.S. & Guba, E. G. (1985). Naturalistic Inquiry. Newbury Park, CA: Sage
Publications.
Lindberg D.A. (2005). Integrative review of research related to meditation, spirituality,
and the elderly. Geriatric Nursing, 26, 372-377
Li, Y., Li Y., Yu Ng, E. H., Stener-Victorin, E., Hou, L., Wu, T., Han, F., & Wu, X. (2011).
Polycystic ovary syndrome is associated with negatively variable impacts on
domains of health-related quality of life: evidence from a meta-analysis.
Fertility & Sterility, 96, 452–458. https://doi.org/10.1016/j.fertnstert.2011.05.072
Lizneva, D., Kirubakaran, R., Mykhalchenko, K., Suturina, L., Chernukha, G., Diamond,
M. P., & Azziz, R. (2016b). Phenotypes and body mass in women with polycystic
ovary syndrome identified in referral versus unselected populations: systematic
review and meta-analysis. Fertility and Sterility, 106 (6), 1510-1520.
Lizneva, D., Sutrinal, L., Walker, W., Brakata, S., Gavrilova-Jordon, L., & Azziz, R.
(2016a). Criteria prevalence of polycystic ovary syndrome. Fertility and Sterility.
106 (1), 6 – 15.
Lo, J. C., Feigenbaum, S. L., Yang, J., Pressman, A. R., Selby, J. V., & Go, A. S. (2006)
Epidemology and adverse cardiovascular risk profile of diagnosed polycystic
ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 91 (4), 1357-
171
1363.
Long, V. D., Mattson, M. I. (2014). Fasting: Molecular Mechanisms and Clinical
Applications. Cell Metabolism, 19 (2), 181-192.
https://doi.org.10.1014/s.cmet.2013.12.008.
Lu, K. T., Ho, Y. C., Chang, C. L., Lan, K. C., Wu, C. C., & Su, Y. T. (2022). Evaluation
of bodily pain associated with polycystic ovary syndrome: A review of
healthrelated quality of life and potential risk factors. Biomedicines, 10(12), 3197.
Lucas, S. R. (2014). Beyond the existence proof: Ontological conditions, epistemological
implication, and in-depth interview research, Quality and Quantity,48:387- 408.
https://doi.org/10.1007/s1135012-9775-3.
Lucidi, R. S., Thyer, A. C., Easton, C. A., Holden, A. E., Schenken, R. S. & Brzyski, R.
G. (2005). Effects of chromium supplementation on insulin resistance and ovarian
and menstrual circlicity in women with polycystic ovary syndrome. Fertility &
Sterility, 84 (6), 1755-1756. https//doi.org/10.1016/j.fertnstert.2005.0b.028
Lugue-Ramirez, M., Alpanis, M., Sanchon, R., Fernandez-Duran, E., Ortiz-Florez, A. E.,
& Escobar-Morraele, H. E. (2015). Referral bias in female functional
hyperandrogenism and polycystic ovary syndrome. European Journal of
Endocrinology, 173 (5), 603 – 610.
Lujan, M. E., Chizen, D. R., & Pierson, R. (2008). Diagnostic criteria for Polycystic
Ovary syndrome: Pitfalls and controversy. Journal of Obstetric Gynecology of
Canada, 30, (8), 671 – 679.
172
Magnus, E. (2016). The phenomenological method in qualitative psychology and
psychiatry. International Journal of Qualitative Studies on Health and Wellbeing,
11:30682. https://doi.org/10.3402/qhw.v11.30682.
Mahalingaiah, S., & Diamanti – Kancharakis, E. (2014). Targets to treat metabolism
syndrome in polycystic ovary syndrome. Expert Opinion Therapy Targets, 19
(11), 1561- 1574. https://doi.org/10.1517/1472/222.1101067.
Maki, K. C., Reeves M. S., Farmer, M., Yasunaga, K., Matsuo N., Katsuragi, Y.,
Komikado, I. T., Wilder, D., Jones, F., Blumberg, J. B., & Cartwright, Y. (2009).
Green tea catechin consumption enhances exercise-induced abdominal fat loss in
overweight and obese adults. The Journal of Nutrition, 139(2), 264-270.
Maki, P. M., Kornstein, S. G., Joffe, H., Bromberger, J. T., Freeman, E. W., Athappilly,
G., Bobo, W. V., Rubin, L., Koleva, H., Hristina, K., Cohen, L. & Soares, C. N.
(2018). Guidelines for the evaluation and treatment of perimenopausal depression:
summary and recommendations. Menopause, 25(10), 1069-1085.
http://doi.org/10.1097/GME.0000000000001174.
Marsh, W. K., Bromberger, J. T., Crawford, S. L., Leung, K., Kravitz, A., Randolph, J. F.,
Joffe, H., & Soares, C. N. (2017). Lifelong estradoil exposure and risk of
depressive symptoms during the transition to menopause and post-menopause.
Menopause, 24(12), 1351-1359. https://doi.org/10. 1097/GME.000 000000000.
Mansoon, M., Norstrom, K., Holte, J., Ladin-Wilhelmsen, K., Daugren, E., & Landen, M.
(2011). Sexuality and psychosocial well-being in women with Polycystic Ovary
173
Syndrome compared to healthy controls. European Journal of Obstetric
Gynecology and Reproduction, 155 (2), 161 – 165.
Martin, M. L., Halling, K., Eek, D., Krohe, M., & Poty, N. (2017). Understanding
Polycystic ovary syndrome from the patient perspective: A concept elicitation
patient interview. Health Quality Life Outcomes, 15 (162), 1 – 10.
https://doi.org/1186/s12955-017-0736-3.
Mason, M. (2010). Sample Size and Saturation in PhD Studies Using Qualitative
Interviews [63 paragraphs]. Forum Qualitative Sozialforschung / Forum:
Qualitative Social Research, 11 (3), Art. 8,
www.http://nbnresolving.de/urn:nbn:de:0114-fqs100387
Masood, A., Rashid, S., Musarrat, R., & Mazahir, S. (2016). Depression, anxiety,
psychological distress, and quality of life in menopausal women. Pakistan
Journal of Women’s Studies: Alame-Niswan, 23(1), 77-89.
https://doi.orgmayoclinic.org/diseases-conditions/pcos/symptoms-
causes/syc20353439.
Meaz, C. N. B., Shaw, L. J., Azziz, R., Stanczyk, F., Z, Sopko, G. Braimstein, G. D., &
Kelsey, S. F. (2016). Cardiovascular disease and 10 year morality in post-
menopausal women with clinical features of polycystic ovary syndrome. Journal
of Women’s Health, 25(9), 875 -881. https://doi.org/10/1089/jwh.2015.5441.
Mehban, M., Jelodar, G., & Rahmanifar, F. (2020). A combination of spearmint and
flaxseed extract improved endocrine and histomorphology of ovary in experiment
174
PCOS. Journal of Ovarian Research, 13(32). www.https//doi:10.1186/s13048020-
00633-8.
Merriam, S. B., & Tisdell, E. J. (2015). Qualitative research: A guide to design and
implementation (4th ed.). San Francisco, CA: John Wiley & Sons.
Milewicz, A. (2013) Reimbursement of metformin for polycystic ovary syndrome.
Endokrynologia Polska, 64(5):409-414.
Moghadam, Z. B., Fereidooni, B., Saffari, M., & Montazeri, A. (2018). Measures of
health-related quality of life in PCOS women: a systematic review. International
Journal of Women’s Health, 10, 397. https:// doi.org/10.2147/IJWH.S165794
Mohsin, M., Khan, W. & Aziz, B. (2018) Polycystic ovary syndrome: an ailment with
unknown etiology. Journal of Rehman Medical Institute, 4 (3), 1-2.
Monteleone, P., Mascagni, G., Giannini, A., Genazzani, A. R., & Simoncini, T. (2018).
Symptoms of menopause—global prevalence, physiology and implications.
Nature Reviews Endocrinology, 14(4), 199.
https://doi.org/10.1038/nrendo.2017.180.
Morales, A.J., Laughlin, G. A., Butzow, T., Maheshawa, N., Bauman, G., &Yen, S. S.
(1996). Insulin, somatotropic, luteinizing hormones axes in lean and obese women
with (PCOS) polycystic ovary syndrome. Common and distinct features.
Journal of Clinical Endocrinology and Metabolism, 81 (8), 2854 – 2864.
Moran, L. J., Misso, M. I., Wild, R. A., & Norman, R. J. (2010). Impaired glucose
tolerance, type 2 diabetes and metabolic syndrome: A systematic review and
meta-analysis. Human Reproduction Update, 16 (4), 347 -363
175
Morrow, S. L. (2005). Quality and trustworthiness in qualitative research in counseling
psychology. Journal of Counseling Psychology, 52(2), 250-260.
Moulana M. (2020). Persistent risk: psychological comorbidity in polycystic ovary
syndrome. Endocrinology & Metabolism International Journal, 8(6):139-141.
https://do1.org: 10.15406/emij.2020.08.002972020).
Moustakas, C. (1994). Phenomenological research methods. Thousand Oaks, CA: Sage.
Muka, T., Asllanaj, E., Avazverdi, N., Jaspers, L., Stringa, J., Milic, J., Ligthart, S., Ikram,
M., Laven, J. S., Kavous, M,, Dehghan, A., &.Frano, O. (2017). Age at natural
menopause and risk of Type II diabetes: A prospective cohort study.
Diabetelogia, 60 (10), 1951-1960. https://doi.org/1007/s00125-017-4346-8.
National Institutes of Health (2017) Evidenced-based methodology workshop on
polycysticsyndrome.https://www.nichd.nih.gov/health/topics/pcos/conditioninfo./
reatments
National Institute of Mental Health. (2017). Prevalence of Major Depressive Episode
Among Adults.
https://www.nimh.nih..gov/health/statistics/major.depression.shtml.
Nazarpour, S., Simbar, M., Ramezani Tehrani, F., & Alavi -Majd, H. (2018). Quality of
life and sexual function in postmenopausal women. Journal of Women & Aging,
30(4), 299-309.
Naz, M. S. G., Tehrani, F. R., Maid, H. A., Ahmadi, F., Ozgoli, G., Fakari, F. R., &
Ghasemi, V. (2019). The prevalence of polycystic ovary syndrome in adolescents:
A systematic review and meta-analysis. International Journal of Reproductive
176
Biomedine,17(8): 533–542.doi:https:// 10.18502/ijrmv17i8.4818
NIH Publication, No. 01– 4584, Bethesda, MD: US Department of Health and Human
Services National Institute of Health, 2001.Nestler, J. E., Jakubowicz, D. J.,
Reamer, P., Gunn, L. D., & Allen, G. (1999). Ovulaltory and metabolism of
Dchiro-inositol in the polycystic ovary syndrome. New England Journal of
Medicine, 340 (17), 1314-1320. https://doi.10.1056/NEJM199904293401703.
Newton, K., Buist, D., Keenan N., Anderson L., & LaCroix A. (2002). Use of alternative
therapies for menopause symptoms: results of a population-based survey.
Obstetrics and Gynecology, 100, 18-25.
Neven, A. C. H., Laven, J., Teede, H. J., & Boyle, J. A. (2018, January). A summary on
polycystic ovary syndrome: diagnostic criteria, prevalence, clinical
manifestations, and management according to the latest international guidelines.
Seminars in Reproductive Medicine, 36 (01), 5-12. https://doi.org/ 10.1055/s0038-
1668085. Thieme Medical Publishers.
North American Menopause Society. The 2012 hormone therapy position statement of
The North American Menopause Society, Menopause, 19 (3), 257-271.
https://doi.org/1097/gme.0b013e31824b970.
Nowak, D. A., Snyder D. C., Brown, A. J., & Demark-Wahnefried W. (2007) The effect
of flaxseed supplementation on hormonal levels associated with polycystic
ovarian syndrome: a case study. Current Topopics Nutraceutical Research 5(4)
177.
177
Oner, G., & Muderris, I. I. (2013). Efficacy of mega 3 in the treatment of polycystic
ovary syndrome. Journal of Obstetrics, 33 (3), 289-291.
Ozkan, S., Erkan, S. A., & Zencir, M. (2005). Women’s quality of life in the menopause
and post-menopausal period. Quality of Life Research, 14, 1795-1801.
https://doi.org/10.1007/s111-005-5692-4.
Palomba, S., Santagni, S., Falbo, & La Sala, G. B. (2015). Complications and challenges
associated with polycystic ovarian syndrome: Current perspective. International
Journal of Women’s Health, 7, 745 – 763.
Panico, A., Messinal, G., Gelsy, A. L., Cacciapuoti, M., Mosctelli, F., Esposito, & T.
Lupoli, (2017). Quality of life in overweight (obese) and normal weight women
with polycystic ovary syndrome. Patient Preference and Adherence, 2017 (11),
423 – 429. https://doi.org/10.2196/jmir.s417.
Park, S. C., Lee, Y. L., Lee, D. W., Hahn, S. W., Park, S. H., Kim, Y. H., Choi, J. S., &
Kwon, Y. J. (2017). Screening for depressive disorder in elderly patients with
chronic physical disease using the patient health questionnaire-9. Psychiatry
Investigation, 14 (3), 306 313. https://doi.org.10.4306/PI.2017.14.3.306.
Pasquali, R., Casimari, F., & Vicennati, V. (1997). Weight control and its beneficial effect
on fertility in women with obesity and polycystic ovary syndrome. Human
Reproduction, 17 (suppl.), 82-87. https://doi.org/10.1093/humrep/12suppl_1.82.
Pastore, L. M., Patrie, J. T., Morris, W. L., Dalal, P., & Bray, M. J. (2011). Depression
symptoms body dissatisfaction association among polycystic ovary syndrome
women. Journal of Psychosomatic Research, 71(4), 270 – 276.
178
https://doi.org/10.1016/j.jpsychores.2011.02.005.
Patel, S. (2018). Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle
endocrinopathy. The Journal of Steroid Biochemistry and Molecular Biology,
182, 27-36. https://doi.org/10.1016/j-jsbms-216.04.008
Patil, C. N., Racusen, L. C., & Reckelhoff, J. F. (2017). Consequences of advanced aging
on renal function in chronic hyperandrogenimic female rats: Implications for
aging women with PCOS. Physiology Reports, 5 (20) pii:e13461. https://doi.org/
10.14814/phy2.13461.
Patton, M. Q. (2002). Qualitative research and evaluation methods (3rd ed.). Thousand
Oaks, CA: Sage Publications, Inc.
Pietkiewicz, I., and Smith, J.A., A Practical Guide to Using Interpretative
Phenomenological Analysis in Qualitative Research Psychology. Psychological
Journal, 20(1), 7- 14.
Polit, D., & Beck, T. C. (2008) Nursing research: Generating and assessing evidence for
nursing practice (8th ed.). Philadelphia, Pa.: Lippincott Williams and Wilkins.
PolycysticSyndrome.Factsheet.https://womenshealth.gov/files/documentsents/iipc
os-factsheet.pdf
Praissman, S. (2008). Mindfulness-based stress reduction: a literature review and
clinician’s guide. Journal of the American Academy of Nurse Practitioners, 20,
212-216.
Quinn, M., Shinka, K., Pasch, I., Kuzmich, I., Cedars, M., & Huddleston, A. (2014).
Prevalence of androgenic alopecia in patient with polycystic ovary syndrome and
179
characterization of associated chemical and biochemical features. Fertility and
Sterility, 10 (4), 1129-1134.
Rafraf, M., Mohammadi, E., Asghari-Jafarabad, M., & Farzadi, L. (2011). Omega-3 fatty
acids improve glucose metabolism without effects on obesity values and serum
vistfatin levels in women with polycystic ovary syndrome. Journal of American
College of Nutrition, 31 (5), 361-368.
https://doi.org/10.1080/07315724.2012.10720443.
Randeva, H. S., Tan, B. K, Weickert, M. O., Lehnert, H., Kostantinos, L., Nestler, J. E.,&
Suttar, N. (2012). Cardiometabolic aspects of the polycystic ovary syndrome.
EndocrineReview, 33(5), 812 – 841. https://doi.org/101210/er20121001.
Rathnayake, N., Janaka, L., Gayan, A. & Sarath, L. (2019). Prevalence and Severity of
menopausal symptoms and the quality of life in middle-aged women: A study
from Sri Lanka. Nursing Research and Practice, ID 2081507, 1-9.
https://doi.org/10.1155/2019/2081507
Ring, M. (2017). Women’s Health: Polycystic Ovarian Syndrome, Menopause, and
Osteoporosis. Primary Care, 44(2), 377-398,
https://doi.org/1016/.pop2017.02.012.
Romualdi, D., Constantini, B., & Compagna, G. (2007). Is there a role for soy
isoflavones in the therapeutic approach to polycystic ovary? Results from a Pilot
study. Fertility & Sterility, 90 (5), 1826-1833.
180
Rosenfield, R. L., & Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary
syndrome (PCOS): The hypothesis of PCOS as functional ovarian
hyperandrogenism revisited. Endocrine Review, 37 (5), 467 -520.
Rosenfield, R. L. (2020). Perspectives on the international recommendations for the
diagnosis and treatment of polycystic ovary syndrome in adolescence. Journal of
Pediatric and Adolescent Gynecology, 33(5), 445-447.
https://doi.org/10.1016/j.jpag.2020.06.017
Rotterdam ESHRE/ASRM consensus diagnostic criteria and long-term health risk related
to polycystic ovary syndrome (PCOS) (2004) Human Reproduction, 19 (1), 41 –
47.
Rotterdam ESHRE/ASRM. Sponsored PCOS consensus workshop group revised 2003
consensus on diagnostic criteria and long-term health risk related to polycystic
ovary syndrome (2004). Fertility and Sterility, 81 (1) 19 – 22.
Rumaisa, R., Mir, S., Ozaifa, K., Ali, T., Ara, R., Anium, M., Fiza, A., and Badger, G. N.
(2022) Polycystic ovarian syndrome-current pharmacotherapy and clinical
implications. Journal Obstetrics Gynecology,61(1):40-50.https://doi:
10.1016/j.tjog.2021.11.009.
Rzonca, E., Bien, A., Wdowiak, A., Szymanski, A. & Iwanowicz-Palus, G. (2018).
Determinants of quality of life and satisfaction with life in women with polycystic
ovary syndrome. International Journal of Environmental Research and Public
Health, 15 (376), 1-12. https://doi:10.3390/ijerph15020376
181
Shahid, R., Mahnoor, L. U. H, Awan, A. A., Iqbal, M. J., Saeed, I. (2022). Diet and
lifestyle modifications for effective management of polycystic ovarian syndrome
(PCOS). Journal of Food Biochemistry, 46(7) e14117.https://doi.org/
10.1111/jfbc.14117.
Salpeter, S, R, Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2018). Meta-Analysis:
Metformin treatment in persons at risk for diabetes mellitus. American Journal of
Medicine, 121 (2), 149 -157.e2.
Sanchez, N. (2014). A life course perspective on polycystic ovary syndrome.
International Journal of Women’s Health, 6, 115 – 122.
https://doi.org/10.2147/IJWH.S55748.
Sanchez, N. & Jones, H. (2016). “Less than a wife.” A study of polycystic ovary
syndrome in teen women’s digital magazines. Journal of Medical Internet Research, 28
(6), 1- 33. https://doi.org/10.2196/jmir.5417.
Sanchez, N. (2018). Suitability of the National Health Care Surveys to examine
Behavioral Health Services associated with polycystic ovary syndrome. Journal
of Behavioral Health Services Research, 45 (2), 252 – 268.
https://doi.org/10.1007/s11414-016-9543-6.
Sangeeta S. (2012). Metformin and pioglitazone in polycystic ovarian syndrome: a
comparative study. The Journal of Obstetrics and Gynecology of India,62(5), 551-
556.
182
Sarfati, J., Moraillon-Bougerolle, M., and Christin-Maitre, S. (2022) Hyperandrogenism
in postmenopausal women: ovarian origin or adrenal origin? Hyperandrogenism
after menopause: Ovarian or adrenal origin. Gynecology Obstetrics Fertility &
Senology,50(10), 675 -681. https://doi.org/10.1016/j.gofs.2022.05.002
Sayyah-Melli, M., Alizadeh, M., Pourafkary, N., Ouladsahemadarek, E., Jafari-Sniberi,
M., Abbassi, J., & Kazemi-Shishvan, M. (2015). Psychological factors associated
with polycystic ovary syndrome: A case control. Journal of Caring Science, 4 (3),
225 – 231.
Scaruffi, E., Gambiner, A., Stefania, C., Turra, J., Vettor, J., & Mioni, R. (2014).
Personality and psychiatric disorder in women affected by polycystic ovary
syndrome. Frontiers in Endocrinology, 5 (158), 1 – 8.
https://doi.org/10.3389fendo.2014.00185.
Scaruffi, E., Franzoi, I. G., Civilotti, C., Guglielmucci, F., La Marca, L., Tomelini, M.,
Veglia, F. & Granieri, A. (2019). Body image, personality profiles and alexithymia in
patients with polycystic ovary syndrome (PCOS). Journal of
Psychosomatic Obstetrics & Gynecology, 40(4), 294-303.
https://doi.org/10.10800167482x.2018.1530120.
Schildkraut, J. M., Schwingl, P. J., Bastos, E., Evanoff, A., Hughes, C. (1996). Epithelial
ovarian cancer risk among women with polycystic ovary syndrome. Obstetrics &
Gynecology, 88 (4, pt. 1), 554-559.
183
Schmidt, J., Dehlgren, E., Brannstorm, M, & Landin-Wilhelmsen, K. (2012). Body
composition, bone mineral and fractures in late post – menopausal women with
PCOS- A long term follow-up study. Clinical Endocrinology, 77, (2), 207 – 214.
https://doi.org/10.111/j./1365-2265.212.04376x.
Shah, D. and Rasool, S. (2021). Polycystic Ovary Syndrome (PCOS) Transition at
Menopause. Midlife Health, 12(1): 30–32.
https://doi.org/10.4103/jmh.jmh_37_21.
Shahid, R., Ul-Haq, L., Aziz-Awan, M., Iqbal, M.H., Munir, H. and Saeed, I. (2022). Diet
and lifestyle modifications for effective management of polycystic ovarian
syndrome (PCOS). Journal of Food Biochemistry, 46(7), e14117. http://doi.org/
10.1111/jfbc.14117.
Sharmeen, S., Nomani, H., Taub, E., Carlson, H., and Yao, Q. (2021) Polycystic ovary
syndrome (PCOS) causes anovulation and hyperandrogenism. Hormonal
imbalance is known to contribute to systemic autoimmune diseases. Clinical
Rheumatology, 40(12):4837-4843. https://doi.ors/ 10.1007/s10067-021-05850-0
Shoberi, F. & Jenabi, E. (2016). The association between polycystic ovary syndrome and
breast cancer: A meta-analysis. Obstetrics Gynecology Science, 59 (5), 367 – 372.
Shroff, R., Syrop, C. H., Davis, W. & Van Voorhis, R. J. (2007). Risk of metabolic
complications in the new PCOS phenotypes based on Rotterdam criteria. Fertility
and Sterility, 88 (5). 1389-1395.
Sirmans, S. M., & Pate, K. A. (2014). Epidemology diagnosis and management of
polycystic ovary syndrome. Clinical Epidemology, 6, 1 – 13.
184
https://doi.org/10.2147/ CLEP.s307559.
Smith, J. A. (2011). Evaluating the contribution of interpretative phenomenological
analysis: A reply to the commentaries and further development of criteria. Health
Psychology Review, 5(1), 55-61. https://doi.org/10.1080/17437199.2010.541743
Smith, J.A., Flower, P., & Larkin, M. (2009). Interpretative Phenomenological Analysis:
Theory, Method and Research. Qualitative Research in Psychology. London:
Sage.
Smith, J. (2004). Reflecting on the development of interpretative phenomenological
analysis and its contribution to qualitative research in psychology. Qualitative
Research in Psychology, 1:39-54. https://doi.org/10.1191/1478088704qp004oa.
Sternfeld, B., Colvin, A., Stewart, A., Appelhans, B. M., Cauley, J. A., Dugan, S. A., El
Khoudary , S . R., Greendale, G. A., & Karvonen-Gutierrez, C. (2020).
Understanding Racial/Ethnic Disparities in Physical Performance in Midlife
Women: Findings From SWAN (Study of Women’s Health Across the Nation).
The Journals of Gerontology: Series B, 75(9), 1961-1971.
https://doi.org/10.1093/geronb/gbz103
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J.
V., & Saten, R. J. (2015). Treatment of symptoms of menopause: An endocrine
society clinical practice guideline. The Journal of Clinical Endocrinology &
Metabolism, 100, (11), 3975- https://doi.org/10.1210/jc.2015-222236
Sturgeon, S. R., Heersink, J. L., Volpe S. L., Bertone-Johnson E. R., Puleo, E., Stanczyk,
F. Z., Sabelawski, S., Wähälä, K., Kurzer, M. S., & Bigelow C. (2008). Effect of
185
dietary flaxseed on serum levels of estrogens and androgens in postmenopausal
women. Nutrician & Cancer, 60(5), 612–620.
Suárez, L., Tay, B., & Abdullah, F. (2018). Psychometric properties of the World Health
Organization WHOQOL-BREF quality of life assessment in Singapore. Quality of
Life Research, 27(11), 2945-2952.
Sudhaa, S., Mahajan, N. (2021). Polycystic Ovarian Syndrome and Menopause in Forty
Plus Women. Journal of Midlife Health, 12(1) 3–7. https://doi.org/
10.4103/jmh.jmh_8_21
Sulaiman, A. H. M., Al – Farsi, Y. M., Al-Khaduri, M. M., Waly, M. I., Saleh, J., &
AlAdawi, S. (2017). Psychological burden among women with polycystic ovarian
syndrome in Oman: A case-control. International Journal of Women’s Health, 9,
897- 904.
Szczuko, M., Kikut, J., Szczuko, U., Szydlowska, I., Nawrocka-Rutkowsaka, J., Zietek,
M., Verbanac, D. and Saso, L. (2021). Nutrition Strategy and Life Style in
Polycystic Ovary Syndrome, Narrative Review, 1813(7) 2452.
https://doi.org/10.3390/nu13072452.
Taghavi, S. A., Bazarganipour, F., & Hugh-Jones, S. (2015). Health-related quality of life
in Iranian women with Polycystic Ovary Syndrome: A qualitative study. BMC
Women’s Health, 15(111), 1-8.
Teede, H. J., Misso M. L., Deeks A. A., Moran L. J., Stuckey B. G., Wong J. L., Norman,
R. J., & Costello, M. F. (2011). Assessment and management of polycystic ovary
syndrome: Summary of an evidence-based guideline. Medical Journal of
186
Australia, 195, S65–S112. http://doi.org/10.5694/mja11.10915.
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T.,
& Norman, R. J. (2018). Recommendations from the international evidence-based
guideline for the assessment and management of polycystic ovary syndrome.
Human reproduction, 33(9), 1602-1618.
Toosy, S., Sodi, R., & Papachan, J. N. (2018). Lean polycystic ovary syndrome: An
endocrine – based practical approach. Journal of Diabetes & Metabolic Disorder,
17, 277 – 285. http://doi.org/10.1007/s40207-018-0371-5.
Torchen, Laura, C. (2017) Cardiometabolic risk in PCOS more than a reproductive
disorder. Current Diabetic Report, 17,12, 137. https//doi.org/10.1007/s11892017-
0956-2.
Torres Fernandez, E. D., Adams, K. V., Syed, M., Maranon, R. O., Romero, D. G., &
Yanes Cardozo, L. L. (2018). Long-lasting androgen-induced cardiometabolic
effects in polycystic ovary syndrome. Journal of the Endocrine Society, 2(8), 949-
964. https://doi.org/10.12/js.2018-0031.
Vicary, S., Young, A., & Hicks, S. (2017). A reflective journal as learning process and
contribution to quality and validity in interpretative phenomenological analysis.
Qualitative Social Work, 16(4), 550-565.
Visser, J. A. (2020). The importance of metabolic dysfunction in polycystic ovary
syndrome. Nature Reviews Endocrinology, 1-2. WHOQOL Group (1995). The
World Health Organization Quality of Life Assessment (WHOQOL): Position
paper from the World Health Organization. Social Science & Medicine,
187
41(10),1403–9.
Walters, R. K., Polimanti, R., Johnson, E. C., McClintick, J. N., Adams, M. J., Adkins,
A. M., Ailey, F., Silviu-Fazil, B., Batzler, A., Bertelsen, S., Biernacka, J. M.,
Bigdeli, T. M., Chen L. C., Clark, T. K., Chou, Y.L.,, Degenhardt, F., Docherty,
A. R., Edwards, A. C., Fontanllias, P.,...& Agrawal, A.(2018) Transancestral
GWAS of alcohol dependence reveals common genetic underpinnings with
psychiatric disorders. Nature neuroscience, 21(12), 1656-1669.
https://doi.org/10.1038/s41593-018-0275-1
Wild, R.A., Carmina, E., Diamanti-Kandara, E., Dorkras, A., Escobar-Morreale, H. F.,
Futterweit, W., Lobo, R., Norman, R. J., Talbitt, E., & Dumesic, D. A. (2010).
Assessment of cardiovascular risk and prevention of cardiovascular disease in
women with a consensus statement by the Androgen Excess and Polycystic Ovary
syndrome (AE-PCOS) Society. The Journal of Clinical Endocrinology &
Metabolism, 95 (5), 2038-2049.
Williams S, Sheffield D. & Knibb, R. (2014) A snapshot of the lives of women with
polycystic ovary syndrome: A photovoice investigation. Journal of Health
Psychology, 21(6), 1170 -1182. https://doi.org/10.1177/1359105314547941.
Winkler, P., Horacek, Weissova, A., Sustr, M. & Bronovsky, M. (2015). Physical
comorbidities in depression co-occurring with anxiety: A cross-sectional study in
the Czech primary care system. International Journal of Environmental Research
and Public Health, 12 (12), 15728 – 15738.
https://doi.org/10.3390/Ijerph121215015.
188
Winnie, C. L., & Florence, W. M. (2020). Menopausal- specific quality of life among
women in Hong Kong. GSTF Journal of Nursing and Health Care (JNHC), 5(1).
https://doi.org/10.5176/2345-7198_5.1.25.
Worthen, M. G. F. (2014). An invitation to use craigslist ads to recruit respondents from
stigmatized groups for qualitative interviews. Qualitative Research,14(3) 371–
383. https://doi.org/10.1177/146879411348179.
Xing, L., Xu, J., Wei, Y., Chen, Y, Zhuang, H., Wei, J., Tang, W., Yu, S, Zhang, J., Yin, G.,
Wang, R., Zhoa, R. and Qin, D. (2022) Depression in polycystic ovary syndrome:
Focusing on pathogenesis a treatment. Frontiers in Psychiatry: Mini Review, 1 -
10. https://doi.org/10.3389/fpsyt.2022.1001484.
Zhao, X., Zhong, J., Mo, Y., Chen, X., Chen, Y., & Yang, D. (2010). Association of
biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese
women with polycystic ovary syndrome. International Journal of Gynecology &
Obstetrics, 108(2), 148-151. https://do1.org/10.1016./j.jigo.2009.09.021.
Zheng, Y., Zhou, Y., Hu, J., Hua, Q., & Tao, M. (2017). Prediction of risk of depression
symptoms in menopausal women based on hot flash and sweating symptoms: A multicenter
study. Clinical Interventions in Aging, 12, 1993 – 2001.
https://doi.org/10.2147/Cias148688.
Zore, T., Joshi, N. V., Lizneva, D., & Azziz, R. (2017). Polycystic ovarian syndrome:
long-term health consequences. Seminars in Reproductive Medicine, 35 (3) 271-
281. Theme Medical Publishers multicenter study. Clinical Interventions in
Aging, 12, 1993 – 2001. https://doi.org/10.2147/Cias148688